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CHAPTER I 
 
INTRODUCTION 
 
Abstract 
Diabetes mellitus affects approximately 150 million people worldwide. This 
disease is characterized by hyperglycemia resulting from dysfunctional pancreatic beta 
cells. Current treatments for diabetics are inadequate because they often do not prevent 
complications associated with the disease; therefore, considerable efforts are focused on 
derivation of beta cells from embryonic stem cells. Accomplishing this requires a precise 
understanding of beta cell development and the molecular control of beta cell expansion 
in vivo. We addressed these approaches in two ways: first, we analyzed the requirement 
for neural crest (NC) derivatives in regulating beta cell maturation and second, we 
determined that the transcription factor Foxd3 is required for beta cell mass expansion 
during pregnancy. 
The pancreas develops through a coordinated system of signals from both the 
endoderm and surrounding mesoderm. Little effort has been devoted to analyzing the role 
of ectodermally-derived NC that innervates the pancreas during embryogenesis. Our 
work illustrated that NC enters the pancreatic primordium around 10.25 dpc, shortly after 
pancreatic evagination from the foregut epithelium. Using a genetic ablation of NC 
derivatives in the pancreas, we showed, in agreement with published data, increased beta 
cell proliferation and insulin-positive area.  Additionally, our work illustrated a novel 
requirement for this lineage; NC derivatives are required for beta cell maturation.   
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Beta cell proliferation in adult mice is rare unless the mice are metabolically 
challenged, such as during pregnancy. Therefore, I chose to analyze the requirement for 
Foxd3 during pregnancy. Foxd3 is expressed in the pancreatic primordium beginning at 
10.5 dpc and is localized predominantly to beta cells after birth. Virgin mice carrying a 
pancreas-specific deletion of Foxd3 are euglycemic; however, during pregnancy these 
mice become glucose intolerant. Several genes required for cell proliferation are 
misregulated in the absence of Foxd3 resulting in decreased beta cell proliferation and 
beta cell mass during pregnancy. 
Together, my thesis research illustrated the requirement for NC derivatives in 
controlling beta cell maturation and demonstrated a novel role for Foxd3 in beta cell mass 
expansion during pregnancy. The findings from both studies can be applied to cell-based 
therapies to treat diabetics.  
 
Pancreas anatomy and function 
Pancreas anatomy and function: The pancreas is a glandular organ responsible for 
secreting hormones to regulate blood glucose levels and enzymes to aid digestion (Berne, 
1993). In humans, the head of the pancreas (ventral pancreas) is located adjacent to the 
duodenum while the tail of the pancreas (dorsal) is located adjacent to the stomach and 
spleen. The pancreas is connected to the duodenum by the ampulla of Vater, the location 
where the pancreatic duct connects to the common bile duct (Figure 1.1, reviewed in 
(Slack, 1995)).  
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Figure 1.1: Diagram of the human pancreas. The head of the pancreas (ventral pancreas) 
is attached to the duodenum at the Ampulla of Vater. The main pancreatic duct connects 
to the bile duct. The tail of the pancreas (dorsal pancreas) is adjacent to the stomach and 
spleen. This image was taken from (Slack, 1995). 
 
The endodermally-derived pancreas consists of 2 cell types: the exocrine pancreas 
that is responsible for secreting enzymes required for digestion and the endocrine 
pancreas that secretes hormones to regulate blood glucose levels (Figure 1.2, reviewed in 
(Slack, 1995)). Approximately 98 percent of the pancreatic mass is comprised of exocrine 
tissue consisting of acinar and ductal cells. The acinar cells produce enzymes including 
proteases, amylases, lipases, and nucleases that aid in digestion. These pancreatic 
enzymes are secreted by the acinar cells into the ducts as immature proteins in zymogen 
granules and eventually drain into the duodenum where they are activated (Bruno, 1995). 
Additionally, centroacinar cells adjacent to the pancreatic duct produce and secrete 
bicarbonate to neutralize acidic chyme located in the stomach while the goblet cells 
located within the ductal epithelium produce and secrete mucin (Berne, 1993; Grapin-
Botton, 2005).  
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This essential organ is conserved among all vertebrates, although the structure and 
organization of the pancreas is different in some fish. Additionally, while most 
invertebrates do not have a pancreas, some have endocrine cells similar to beta cells 
located in the gut or brain (reviewed in (Slack, 1995)).     
 
 
Figure 1.2: The acinar cells of the pancreas (A) which produce enzymes to aid in 
digestion and ductal cells (D) which facilitate draining of enzymes into the duodenum 
form the exocrine pancreas. The endocrine cells are located in the islets of Langerhans 
(I). Cell types within the pancreas can be distinguished histologically using hematoxylin 
and eosin staining. 
 
Pancreatic endocrine cells comprise approximately 2 percent of the entire 
pancreatic mass and are responsible for producing hormones that regulate blood glucose 
levels. The endocrine cells are organized into spherical microorgans called the islets of 
Langerhans consisting of 5 different endocrine cell types (Figure 1.3A reviewed in  
I
D
A
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Figure 1.3: Images of murine islets. A. In murine islets, beta cells (indicated by insulin 
immunofluorescence, green) are located at the core of the islets of Langerhans while 
other endocrine cell types are primarily located at the periphery of the islets. In this 
image, alpha cells (indicated by glucagon immunofluorescence, red) are located at the 
periphery of the islets. B. Islets are highly vascularized; many blood vessels (indicated by 
PECAM immunofluorescence, red) are detected in the islets (indicated by insulin 
immunofluorescence, green). Red arrows, PECAM-positive endothelial cells. 
 
(Edlund, 2002; Murtaugh and Melton, 2003)). The islets are highly vascularized 
mediating secretion of hormones into the blood flow (Figure 1.3B,(Lifson et al., 1985)). 
The most abundant islet cell type in most mammals, including rodents, primates, camels, 
bats, whales, and seals, is the beta cell (Steiner et al., 2010); beta cells are the only cell in 
the body capable of secreting insulin in response to blood glucose levels. When blood 
glucose levels are high insulin is secreted into the blood stimulating glucose uptake by 
peripheral tissues such as the liver, skeletal muscle, or adipose cells (Berne, 1993). The 
second most abundant cell type in the islets is the glucagon-producing alpha cell. 
Glucagon function opposes insulin; glucagon is secreted when blood sugar is low causing 
the liver to convert glycogen to glucose (Berne, 1993). The third most abundant cell type 
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in the islets is the somatostatin-producing delta cells that secrete somatostatin to inhibit 
secretion of both glucagon and insulin. The pancreatic polypeptide (PP) cells secrete PP 
to regulate endocrine and exocrine cell secretion (Lonovics et al., 1981). Finally, the least 
abundant endocrine cell is the ghrelin-producing epsilon cell. Epsilon cells are abundant 
in the islets during embryogenesis and in the adult under certain circumstances (Prado et 
al., 2004). While ghrelin secreted from the stomach is known to stimulate hunger, the 
function of ghrelin in the islets is less understood although some investigators suggest 
that ghrelin regulates proliferation and survival of beta cells (Prado et al., 2004; Sussel et 
al., 1998). Together, the endocrine cells in the pancreas function to precisely control 
blood glucose levels.   
Pancreatic dysfunction: Dysfunction of either the exocrine or endocrine pancreas results 
in serious clinical complications. Diabetes mellitus results from insufficient production of 
insulin to compensate for blood glucose levels. Approximately 25.8 million people in the 
United States, or 8.3 percent of the population, has diabetes and another 79 million are 
considered to be pre-diabetic resulting in an economic burden of 218 billion dollars per 
year (ADA, 2011). To properly control diabetes, treatments such as exogenous insulin 
injections are used to lower blood glucose levels. However, even slight hyperglycemia 
can result in secondary complications such as heart disease, stroke, high blood pressure, 
blindness, kidney disease, neuropathy, and amputation of extremities demonstrating the 
importance of precisely controlling the disease (Genuth, 2006).  
 There are three major classes of diabetes: type 1, type 2, and gestational diabetes 
(GDM). Type 1 diabetes, formerly called juvenile diabetes, is an autoimmune disorder 
that results in destruction of pancreatic beta cells (Devendra et al., 2004). Type 1 diabetes 
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is most commonly developed during childhood although patients can develop the disease 
at any age. The most common treatment for type 1 diabetic patients is exogenous insulin 
injections. Type 2 diabetes is characterized by insulin resistance followed by beta cell 
failure. In early stages of type 2 diabetes, patients can be treated with oral medication 
such as sulfonylurea drugs; however, late stage type 2 diabetic patients ultimately 
become dependent on exogenous insulin injections (Laybutt et al., 2007; Scheuner et al., 
2001; Scheuner et al., 2005). During pregnancy, peripheral tissues become insulin 
resistant and the beta cell population must expand to compensate for increased metabolic 
demand. GDM occurs in patients whose beta cells are unable to overcome the increased 
need for insulin due insulin resistance in peripheral tissues (Parsons et al., 1992).  
Normally, GDM patients are euglycemic following parturition; however, they have an 
increased risk of developing type 2 diabetes later in life (Bellamy et al., 2009).  
 In addition to diseases of the endocrine pancreas, dysfunction in the exocrine 
pancreas can result in severe clinical implications. Pancreatic cancer is the fourth most 
common cause of cancer related deaths (Hariharan et al., 2008). Additionally, patients 
diagnosed with pancreatic cancer have a very poor prognosis; only 6 percent of patients 
diagnosed with pancreatic cancer survive 5 years with a median survival from diagnosis 
of 6 to 10 months. The majority of pancreatic cancers (95 percent) are ductal 
adenocarcinomas; ductal adenocarcinomas occur as a result of pancreatic intraepithelial 
neoplasias that acquire an oncogenic mutation (ACS, 2005). Primary ductal 
adenocarcinomas are largely asymptomatic until they metastasize resulting in poor 
prognosis. A rarer form of pancreatic cancer is neuroendocrine tumors or tumors that 
originate from the islets. Because neuroendocrine tumors produce high concentrations of 
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hormones, patients may be more symptomatic than patients with ductal adenocarcinoma 
and seek treatment earlier resulting in a better prognosis (Ekeblad et al., 2008). 
Additionally, neuroendocrine tumors are often less aggressive than exocrine tumors 
resulting in a median survival from diagnosis of 38 to 104 months (Yao, 2007). In 
addition to tumors that arise from exocrine or endocrine cells, neuroblastomas are an 
incredibly rare form of pancreatic cancer that results from increased proliferation of NC 
derivatives that innervate the pancreas during embryogenesis (Vouriot et al., 1985). 
Neuroblastomas normally originate from sympathetic ganglia, however, in rare cases 
neuroblastomas can originate from another location within the body. In fact, a recent case 
study identified a primary neuroblastoma that originated from NC derivatives that 
innervated the pancreas of a 22 year old female patient and resulted in a fatal outcome 
(Abdou et al., 2011).  
 
Pancreas and beta cell development 
Overview of murine pancreas development: Pancreas development in the mouse begins at 
approximately 9.5 dpc and occurs by responding to a series of intrinsic factors and 
extrinsic signaling molecules. At 9.5 dpc, the dorsal foregut epithelium thickens and 
evaginates to form the presumptive dorsal pancreas. After the evagination of the dorsal 
pancreatic bud, the ventral foregut epithelium thickens and evaginates to form the ventral 
pancreatic bud at approximately 10.0 dpc (reviewed in (Pan and Wright, 2011)). 
Immature endocrine cells expressing glucagon and insulin can be detected at this time 
(Herrera, 2000). From around 9.5 dpc until around 12.5 dpc, the pancreatic epithelium 
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undergoes extreme proliferation and branching. The secondary transition, a wave of 
extensive differentiation of endocrine cells, occurs from 12.5 to 15.5 dpc (reviewed in 
(Slack, 1995)). During this period, the branching epithelium can be divided into 2 distinct 
domains: tip and trunk cells (reviewed in (Pan and Wright, 2011)). The cells located in 
the tip are multipotent progenitor cells that can give rise to endocrine, acinar, or duct cells 
while cells adjacent to the tips in the trunk are duct-endocrine bipotent progenitor cells 
(Zhou et al., 2007). The cells that remain at the tip of the branches will form the acinar 
cells. The endocrine cells produced during the secondary transition will mature and form 
the glucose-responsive endocrine cells in the adult animal (Herrera, 2000). During late 
embryonic and early postnatal stages, the endocrine cells form clusters and delaminate 
from the ductal epithelium to form the mature islets of Langerhans (Rukstalis and 
Habener, 2007). 
Endoderm derivatives: The developing pancreatic endoderm is initially demarcated by 
three transcription factors that are critical for pancreas development: pancreatic and 
duodenal homeobox 1 (Pdx1), pancreatic transcription factor 1a (Ptf1a), and motor 
neuron and pancreas homeobox 1 (Mnx1, formerly called Hb9). In fact, a deletion in any 
of these factors is catastrophic for pancreas development; Pdx1 and/or Ptf1a null embryos 
are largely lacking a functional pancreas with only a small dorsal pancreatic rudiment 
present at 9.5 dpc while Mnx1 null embryos lack a dorsal pancreas (Harrison et al., 1999; 
Jonsson et al., 1994; Kawaguchi et al., 2002; Krapp et al., 1998; Offield et al., 1996; 
Stoffers et al., 1997b). Conversely, a deletion of Gata4, a transcription factor expressed 
in the pancreatic endoderm results in the absence of the ventral pancreas while the dorsal 
pancreas develops normally (Watt et al., 2007). Additionally, the transcription factors 
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hepatocyte nuclear factor 1 homeobox beta (Hnf1beta) and SRY-box 9 (Sox9) expressed 
in the pancreas are critical for initial pancreas development; Hnf1beta null embryos do 
not form a ventral pancreas and dorsal pancreas development is arrested early while Sox9 
null embryos have smaller pancreata than control littermates (Haumaitre et al., 2005; 
Seymour et al., 2007). 
Following the initial specification and outgrowth of the pancreatic buds, the 
pancreas undergoes extensive proliferation and branching. At around 12.5 dpc, cells in 
the branching epithelium can be characterized as “tip” or “trunk” cells. The cells located 
at the “tip” of the branching epithelium are multipotent progenitor cells that express low 
levels of Ptf1a, Pdx1, Sox9, and Hnf4beta while maintaining high levels of Gata4.  Cells 
at the “tips” lose multipotency between 13.5 and 14.5 dpc, obtain a proacinar fate, and 
express high levels of Ptf1a and Gata4. Cells that are located within the “trunk” of the 
branching epithelium are bipotent progenitor cells that can give rise to ductal or 
endocrine cells. These bipotent progenitors express low levels of Pdx1 and high levels of 
Sox9 and Hnf1beta. The cells fated to become ductal cells maintain expression of Sox9 
and Hnf1beta while Pdx1 expression is decreased. Alternatively, the progenitors fated to 
become endocrine cells express high levels of the proendocrine factor Neurog3, NeuroD, 
and Islet1 (reviewed in (Pan and Wright, 2011)). Expression of all 3 factors is required 
for pancreatic endocrine cell development.  
A complicated network of transcription factors is required for specification of 
beta cells from the endocrine cell progenitors (Figure 1.4). Beta cell specification requires 
repressive activity of the transcription factor Nkx2.2 (Papizan et al., 2011; Sussel et al., 
1998; Wang et al., 2004). Nkx2.2 null mice develop diabetes due to arrested development of 
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the pancreatic beta cell (Sussel et al., 1998).  Additionally, cells fated to become beta cells 
express high levels of Pdx1 and the transcription factors v-maf musculoaponeurotic 
fibrosarcoma oncogene homolog A and B (MafA and MafB), paired box gene 4 (Pax4), 
and NeuroD. These early insulin-expressing cells are not fully mature or competent to 
secrete insulin in response to glucose concentration (Herrera, 2000). Towards the end of 
embryogenesis, the insulin-expressing cells undergo maturation and MafB expression 
decreases while MafA expression persists (Artner et al., 2010). Additionally, the cells 
maintain expression of Pdx1 and begin to express the glucose transporter Glut2, islet-
specific glucose-6-phosphatase catalytic subunit specific protein (IGRP), and glucokinase 
to mediate glucose stimulated insulin secretion (Aramata et al., 2005; Artner et al., 2007; 
Raum et al., 2006; Zhao et al., 2005). Much less is known about the transcriptional 
profiles of the other endocrine cell types; developing alpha cells express MafB and 
aristaless related homeobox (Arx), PP cells express Arx, and delta cells express Pdx1 
(Artner et al., 2006; Collombat et al., 2005; Collombat et al., 2003).  
Mesodermal contributions: The pancreas develops through a series of inductive and 
permissive signals from the surrounding mesoderm. Both prospective pancreatic buds are 
adjacent to mesoderm prior to pancreas induction; the prospective dorsal pancreas is 
adjacent to the notochord and the dorsal aorta while the prospective ventral pancreas is 
adjacent to the lateral plate mesoderm (reviewed in (Slack, 1995)). Prior to pancreas 
specification, FGF2 and activin-beta2 signaling from the notochord is required to 
suppress Shh within the dorsal foregut (Kim et al., 1997). Additionally, retinoic acid 
secreted from the paraxial mesoderm is required to establish the prospective dorsal 
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Figure 1.4: Schematic of gene regulatory networks required for pancreas and beta cell 
development.  Details are outlined in the text. Figure adapted from (Pan and Wright, 
2011). 
 
pancreatic bud (Martin et al., 2005; Molotkov et al., 2005). Slightly later, the dorsal aorta 
and the vitelline veins contact the foregut endoderm and induce Pdx1, Ptf1a, and insulin 
expression in the developing pancreas (Lammert et al., 2001, 2003). Fetal liver kinase 1 
(Flk1) null mice that lack endothelial cells do not induce Ptf1a expression in the dorsal 
pancreas (Yoshitomi and Zaret, 2004). Later in development, connective tissue growth 
factor (CTGF) secreted from endothelial cells results in decreased vascularization 
reducing beta cell mass expansion; mice carrying a Tie1-Cre allele to delete CTGF from 
the endothelial cells have decreased beta cell proliferation compared to littermate controls 
(Guney et al., 2011).The lateral plate mesoderm (LPM) provides instructive signals to the 
prospective ventral pancreas bud, although the signal secreted from the LPM remains 
elusive (Kumar et al., 2003).  
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 As the pancreatic buds grow, the pancreatic mesenchyme condenses around the 
branching epithelium. Several factors expressed within the pancreatic mesenchyme are 
essential for pancreas development. Pancreatic buds dissected from embryos at 11.5 dpc 
and cultured without pancreatic mesenchyme were unable to develop further (Golosow 
and Grobstein, 1962). Fibroblast growth factor (Fgf10) secreted by the pancreatic 
mesenchyme recognized by the Fgf receptor 2b (Fgfr2b) in the pancreatic epithelium is 
required for pancreas development; mice lacking either Fgf10 or Fgfr2b do not form a 
pancreas (Bhushan et al., 2001; Hart et al., 2003; Miralles et al., 1999). Similarly, bone 
morphogenetic protein (BMP) signaling from the mesenchyme and recognized by the 
Alk2/3 receptors in the pancreatic epithelium is required for pancreas development 
(Ahnfelt-Ronne et al., 2010). A null mutation of Islet1 results in loss of mesenchyme 
surrounding the dorsal pancreas resulting in loss of the dorsal exocrine pancreas. 
Additionally, there is a complete loss of islet cell differentiation (Ahlgren et al., 1997). 
Similarly, the cell adhesion molecule N-cadherin, which is expressed in the pancreatic 
mesenchyme but not pancreatic endoderm during early pancreas development, is required 
for dorsal pancreas outgrowth (Esni et al., 2001). Together, all of these data demonstrate 
that signals from the developing mesoderm are absolutely required for pancreas 
development and a complex network of intrinsic and extrinsic signals mediate pancreatic 
outgrowth and beta cell development. Additionally, my dissertation research 
demonstrates that the ectodermally-derived NC is a critical regulator of beta cell mass 
expansion and maturation (Plank et al., 2011b). 
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Establishing and maintaining pancreatic beta cell mass  
 An organism’s beta cell mass is obtained and maintained by a careful balance of 
beta cell proliferation, neogenesis, cell size, apoptosis, and atrophy (reviewed in 
(Ackermann and Gannon, 2007)). While beta cell mass increases significantly during 
embryogenesis and early postnatal periods in both humans and rodents, following 
adolescence (or weaning in the case of rodents), beta cell mass increases at a much 
slower rate than during early postnatal stages (Bonner-Weir, 2000; Bonner-Weir et al., 
2010; Bouwens and Rooman, 2005; Finegood et al., 1995).  In rodents, beta cell mass 
expansion is most commonly a result of increased beta cell proliferation (Dor et al., 2004; 
Teta et al., 2007). Beta cells undergo low levels of proliferation in young animals and as 
the animals age, beta cell proliferation becomes even more rare under basal physiological 
conditions (Desgraz and Herrera, 2009; Scaglia et al., 1997; Teta et al., 2007). However, 
in some instances of metabolic challenge such as obesity or pregnancy, beta cells regain 
the ability to proliferate (Butler et al., 2007; Rhodes, 2005; Teta et al., 2007; Zhang et al., 
2010). Another mechanism for increasing beta cell mass is beta cell neogenesis. Beta cell 
neogenesis is most robust during embryogenesis; however, it is unclear if beta cell 
neogenesis can occur in postnatal animals. Some studies indicate that beta cell neogenesis 
in rodents also occurs perinatally and up to approximately 2 to 3 weeks of age (Finegood 
et al., 1995).  In addition to beta cell proliferation and neogenesis, beta cell hypertrophy 
regulates beta cell mass in humans and rodents. While beta cell size does not usually 
change drastically, beta cells can increase in size to compensate for increases in body 
mass (Montanya et al., 2000; Park et al., 2008; Scaglia et al., 1997). To avoid decreasing 
an organism’s beta cell mass, negative regulators of beta cell mass expansion such as 
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apoptosis and atrophy are rarely observed in healthy animals, although a wave of 
apoptosis occurs in postnatal rats around 3 weeks of age (Scaglia et al., 1997).  Together 
these mechanisms tightly regulate beta cell mass in healthy animals. 
 Postnatal beta cell mass expansion is maintained by a complex system of 
transcription factors, cell cycle regulators, tumor suppressors, growth factors, and 
cytokines. Some of the key regulators of beta cell mass are highlighted in this section. 
Loss of one copy of Pdx1 results in decreased beta cell mass and increased beta cell 
apoptosis (Johnson et al., 2003). Similarly, a beta cell specific deletion of Pdx1 results in 
the loss of beta cell identity. Specifically, Pdx1 is required to regulate expression of Glut2 
which is essential for glucose stimulated insulin secretion (Ahlgren et al., 1998; Gannon 
et al., 2008). Importantly, the requirement for PDX1 is conserved in humans; a missense 
mutation of PDX1 results in mature onset diabetes of the young (MODY) (Stoffers et al., 
1997a).  
 Placental lactogen (PL) signaling also regulates beta cell mass expansion. Mice 
over expressing PL exhibit increased beta cell mass, proliferation and hypertrophy 
(Cozar-Castellano et al., 2006; Vasavada et al., 2000). Conversely, a null mutation of the 
PL receptor results in decreased beta cell mass (Freemark et al., 2002). The transcription 
factor Foxm1 functions downstream of PL signaling (Zhang et al., 2010), and it is a 
critical regulator of beta cell mass expansion (Ackermann-Misfeldt et al., 2008; Zhang et 
al., 2006; Zhang et al., 2010). Mice lacking Foxm1 in the pancreas have reduced beta cell 
mass by 6 weeks of age due to decreased proliferation and male mutant mice have overt 
diabetes by 9 weeks of age (Zhang et al., 2006). The S-phase kinase associated protein 2 
(Skp2) functions downstream of Foxm1; Skp2 null mice have decreased beta cell mass 
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and proliferation but increased beta cell size (Zhong et al., 2007). The cell cycle inhibitor 
Cdkn1b (p27
kip1
) functions downstream of Foxm1 and Skp2, and in the absence of 
Foxm1, Cdkn1b accumulates in beta cells (Zhang et al., 2006). A null mutation of 
Cdkn1b
 
results in increased beta cell proliferation and mass (Georgia and Bhushan, 2006) 
while ectopic expression of Cdkn1b
 
in the beta cell results in decreased beta cell 
proliferation and mass (Uchida et al., 2005).  
 Another growth factor implicated in beta cell mass expansion is platelet derived 
growth factor (PDGF). In rodents and humans, expression of PDGF receptor (PDGFr) in 
the islets decreases with age coincident with decreasing beta cell proliferation. A beta 
cell-specific deletion of PDGFr results in decreased beta cell proliferation and beta cell 
mass. Alternatively, over expression of human PDGFr-alpha in mouse beta cells results 
in increased beta call mass expansion and proliferation. Additionally, juvenile human 
islets cultured with PDGF-AA ligand showed increased beta cell proliferation (Chen et 
al., 2011). Together these data suggest that PDGF signaling is a potent regulator of beta 
cell proliferation in humans and rodents. The enhancer of zeste homolog 2 (Ezh2) is a 
downstream target of PDGF signaling (Chen et al., 2011). Ezh2 is the histone 
methyltransferase of the polycomb repressor complex 2 (PRC2) (Cao et al., 2002; van der 
Vlag and Otte, 1999). Similar to expression of PDGFr, expression of Ezh2 in the islets 
decreases upon aging (Chen et al., 2011). A beta cell specific mutation of Ezh2 results in 
glucose intolerance; in the absence of Ezh2, the cell cycle inhibitor Cdkn2a (p16
Ink4a
)
 
accumulates in the beta cell inhibiting proliferation and beta cell mass expansion (Chen et 
al., 2009a). A null mutation of Cdkn2a
 
results in increased beta cell proliferation while 
ectopic expression results in impaired beta cell proliferation (Krishnamurthy et al., 2006). 
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These data demonstrate that PDGF regulates beta cell proliferation upstream of Ezh2 and 
Cdkn2a.  
 Another regulator of beta cell mass expansion is the multiple endocrine neoplasia 
1 (Menin1) tumor suppressor gene. Menin1 promotes expression of the cell cycle 
inhibitors Cdkn2c and Cdkn1b (p18
Ink4c
 and p27
Kip1 
) (Milne et al., 2005). Mice that are 
heterozygous for Menin1 have increased beta cell proliferation and beta cell mass but 
develop islet tumors (Karnik et al., 2005). Similarly, a beta cell specific deletion of 
Menin1 results in increased beta cell mass and beta cell proliferation (Crabtree et al., 
2003). Conversely, ectopic expression of Menin1 in beta cells results in decreased beta 
cell mass (Karnik et al., 2007). A null mutation of Cdkn2c, a target of Menin1, results in 
increased beta cell mass (Pei et al., 2004), presumably through increased beta cell 
proliferation. Together, all of these data demonstrate that regulation of beta cell mass 
expansion and maintenance is a tightly regulated process requiring several gene 
regulatory networks to ensure the organism’s beta cells are sufficient to secrete insulin in 
response to blood glucose levels and prevent hyperglycemia A model based on date from 
the literature indicating a subset of factors required to establish and maintain beta cell 
mass is depicted in Figure 1.5. 
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Figure 1.5: Genes and pathways required for beta cell mass establishment and expansion. 
Positive regulators of beta cell mass/establishment are indicated in green while negative 
regulators are indicated in red. Some conserved factors, including Foxm1, Skp2, and 
Cdkn1b are utilized in all three scenarios. This implies similarities in regulating beta cell 
mass expansion and ultimately glucose homeostasis in multiple physiological contexts.  
  
The impact of metabolic challenge on beta cell mass expansion 
 During physiological states of increased insulin resistance, such as pregnancy and 
obesity, beta cell mass must expand to meet the increased metabolic demand. Failure to 
adequately increase beta cell mass results in diabetes: type 2 in the case of obesity and 
gestational diabetes (GDM) in the case of pregnancy. Because 70 percent of women who 
develop GDM go on to develop type 2 diabetes, it is likely that the factors contributing to 
GDM are conserved in the onset of type 2 diabetes (Rieck and Kaestner, 2010). 
Additionally, at the onset of type 1 diabetes, an autoimmune response destroys the 
majority of beta cells; however, the remaining beta cells proliferate in an attempt to 
compensate. Ultimately, this attempt will be unsuccessful and the majority of the beta 
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cell population (greater than 99 percent) will be lost (Meier et al., 2005). A model of 
factors required for beta cell mass expansion during periods of metabolic challenge are 
depicted in Figure 1.5. 
Pregnancy: During pregnancy, peripheral tissues become insulin resistant necessitating 
increased insulin production and secretion during this metabolically challenging time 
(Brelje et al., 1993; Parsons et al., 1992; Sorenson and Brelje, 1997). During rodent 
pregnancy, there is a 3 to 4 fold increase in beta cell mass through increased proliferation 
and hypertrophy (Brelje et al., 1993; Parsons et al., 1992; Rieck et al., 2009; Sorenson 
and Brelje, 1997). Specifically, this increase in proliferation peaks approximately two-
thirds of the way through gestation (Karnik et al., 2007; Rieck et al., 2009). Following 
parturition, the beta cell mass returns to normal through decreased proliferation, 
increased atrophy, and increased apoptosis (Scaglia et al., 1995). A schematic of beta cell 
mass dynamics during pregnancy is depicted in Figure 1.6.      
 Regulation of beta cell mass expansion during pregnancy occurs through 
coordination of several gene regulatory networks. Factors required for beta cell 
proliferation and beta cell survival are both critical for beta cell mass expansion. PL, 
prolactin, and growth hormone signaling positively regulate beta cell proliferation during 
pregnancy. Over expression of PL in beta cells results in increased beta cell proliferation 
and hypoglycemia (Vasavada et al., 2000). Alternatively, a null deletion of the prolactin 
receptor which mediates PL and prolactin signaling results in decreased beta cell mass 
and decreased insulin secretion (Freemark et al., 2002). The transcription factor Foxm1 
functions downstream of PL signaling and is required for beta cell mass expansion during 
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Figure 1.6: A schematic of beta cell mass dynamics during and following rodent 
pregnancy. The peak of beta cell proliferation and hypertrophy occurs approximately two 
thirds of the way through pregnancy (b,c) resulting in increased beta cell mass (a). 
Following parturition, a wave of apoptosis occurs (d) resulting in the beta cell mass 
returning to pre-pregnancy levels (a). Image taken from (Rieck and Kaestner, 2010). 
 
pregnancy; a pancreas-specific deletion of Foxm1 results in gestational diabetes (Zhang 
et al., 2010). In addition, inhibition of serotonin synthesis, normally increased in response 
to PL signaling, results in decreased beta cell mass expansion and glucose intolerance 
during pregnancy (Kim et al., 2010). A gene misregulated in mature onset diabetes of the 
young (MODY1), Hepatic nuclear factor alpha (Hnf4alpha (Stoffel and Duncan, 1997)), 
is required for beta cell mass expansion. A beta cell-specific deletion of Hnf4alpha 
results in decreased beta cell proliferation, beta cell mass, pancreatic insulin content, and 
islet size resulting in impaired glucose tolerance. Hnf4alpha is required for transcription 
of suppression of tumorigenicity 5 (St5), encoding a protein that mediates ERK 
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phosphorylation (Gupta et al., 2007).  An additional mechanism for glucose homeostasis 
regulation and beta cell proliferation is at the epigenetic level. Menin1 functions as part 
of a histone methyltransferase complex to promote tri-methylation of histone 3 lysine 4 
(H3K4), thereby maintaining expression of cell cycle inhibitors Cdkn1b and Cdkn2c. 
Menin1 is normally downregulated in beta cells during pregnancy, and artificially 
maintained expression during pregnancy causes decreased beta cell proliferation and 
maternal hyperglycemia (Karnik et al., 2007). 
 In addition to factors that regulate beta cell proliferation, factors regulating beta 
cell survival are also required for beta cell mass expansion during pregnancy. The 
transcription factor c-myc regulates both proliferation and survival. Ectopic expression of 
c-myc in the beta cell results in increased proliferation and apoptosis, thereby resulting in 
diabetes reinforcing the importance of the properly balancing proliferation and apoptosis 
(Laybutt et al., 2002). Additionally, inhibiting caspase 3 while over expressing c-myc 
results in increased beta cell proliferation and beta cell mass (Radziszewska et al., 2009). 
A signaling cascade required for beta cell survival is neural growth factor (NGF) 
signaling. Expression of neural growth factor receptor (NGFr, p75) in islets increases 
during pregnancy (Rieck et al., 2009), and NGF signaling contributes to beta cell survival 
(Navarro-Tableros et al., 2004). Together, this work suggests that the delicate balance of 
beta cell proliferation and survival is regulated by a complicated network of signaling 
pathways and transcription factors. 
Obesity: Another physiological cause of insulin resistance is obesity. Obese humans and 
rodents must expand their beta cell mass to compensate for obesity-induced insulin 
resistance and failure to do so results in type 2 diabetes. Several factors and pathways 
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required for beta cell mass expansion during pregnancy are utilized in the obese state. For 
example, Foxm1 is required for beta cell mass expansion in both instances; islets isolated 
from obese, non-diabetic C57BL/6 Leptin
ob/ob
 mice express higher levels of Foxm1 than 
islets isolated from obese, diabetic BTBR Leptin
ob/ob
 mice. In the non-diabetic mice, 
Foxm1 activates a transcriptional network required for beta cell proliferation. 
Additionally, a study was conducted where islets were isolated from non-diabetic 
cadaveric donors with a body mass index (BMI) ranging from 24 to 51 (a BMI of 30 or 
greater is considered obese) and the expression levels of FOXM1 increased with body 
mass (Davis et al., 2010). These data suggest a correlative relationship between Foxm1 
expression and obesity and suggest that Foxm1 is required to prevent obesity induced 
diabetes. Further supporting this notion, Skp2, a target of Foxm1, is responsible for 
degradation of the cell cycle inhibitor Cdkn1b and is required for beta cell proliferation. 
A null mutation of Skp2 limits beta cell mass expansion following a high fat diet (Zhong 
et al., 2007).  
 In addition to intrinsic factors controlling beta cell mass expansion in obese 
animals, extrinsic factors also regulate beta cell proliferation in this metabolic state. 
Neurons from the liver are responsible for non-cell autonomously activating ERK 
signaling in the beta cells. Additionally, ectopic activation of ERK signaling restores beta 
cell proliferation and blood glucose levels in mouse models of diabetes (Imai et al., 2008; 
Imai et al., 2009). These data demonstrate that ERK signaling is required for beta cell 
mass expansion during pregnancy and in the obese state. Additionally, this work indicates 
the importance of ectodermally-derived cells in regulation of beta cell mass expansion.  
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Differences in beta cell mass expansion between humans and rodents: In both humans 
and rodents beta cell mass expands in younger organisms through beta cell proliferation 
(Dor et al., 2004; Kassem et al., 2000; Teta et al., 2007). Additionally, beta cell mass 
expands in response to physiological stresses such as pregnancy and obesity; however, 
the mechanisms by which the beta cell population expands differ between rodents and 
humans (Butler et al., 2007). In mice and rats, beta cell mass expands due to increased 
beta cell proliferation and hypertrophy with no discernable changes in cell death. 
Conversely, in humans, beta cell mass expands in the obese state approximately 50 
percent and this increase in mass occurs through increased beta cell hypertrophy (Butler 
et al., 2003). Intriguingly, during pregnancy, beta cell mass increases approximately 1.5 
fold although no changes in proliferation, hypertrophy, or cell death could be detected 
although an increased number of small islets were identified suggesting increased beta 
cell neogenesis during human pregnancy (Butler et al., 2010). However, this work is not 
without caveats. It is well known that murine beta cells undergo a discrete proliferation 
response within a defined time window and it is likely that the 18 pregnant human donors 
examined were not within an analogous gestational age (Karnik et al., 2007; Rieck and 
Kaestner, 2010). This study also included donors with inflammatory disease that may 
have adversely affected beta cell mass expansion (Genevay et al., 2010). It is important to 
note that the pregnancy associated hormones prolactin, PL, and human growth hormone 
all stimulate beta cell proliferation in islets isolated from mice, rats, and humans 
suggesting that proliferation could be a conserved mechanism of beta cell mass expansion 
during pregnancy (Brelje et al., 1993). Additionally, while the study identified no 
changes in proliferation during pregnancy, it is critical to note that low levels of beta cell 
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proliferation does, in fact, occur in humans (approximately 1 percent) suggesting that 
beta cells in adult humans are capable of proliferating (Butler et al., 2010).  
 There are several reasons why increased beta cell proliferation does not occur to 
the same extent in rodents and humans. One difference among species that may result in 
decreased beta cell proliferation in humans is the length of telomeres. As cells replicate, 
telomeres shorten decreasing the capacity for further replication. In adult humans, active 
telomerase is rarely detected resulting in cellular senescence. Conversely, in the mouse, 
while telomeres do become shorter in the adult, active telomerase can be detected in 
many adult tissues allowing for continued extension of telomeres and replication of adult 
cells (Prowse and Greider, 1995). Additionally, most human studies are conducted in 
pancreata from adult donors while most murine studies are conducted in relatively young 
mice. In both species, epigenetic modifications increase with age rendering the beta cells 
unable to replicate (Chen et al., 2009a; Dhawan et al., 2009). Therefore, this inability to 
standardize the relative ages in humans and rodents poses difficulty in analyzing data.    
While some fundamental differences exist between beta cell mass expansion in 
rodents versus humans, several factors required for beta cell mass expansion in rodents 
are conserved in humans. Beta cell proliferation in mice requires CyclinD and Cyclin 
Dependent Kinase 4 (CDK4). Similarly, beta cell proliferation in humans requires 
CyclinD, CDK4, and CDK6 (Georgia and Bhushan, 2004; Kushner et al., 2005; Rane et 
al., 1999). Several factors regulating beta cell proliferation in mice including Cdkn2a, 
Cdkn2b (p15
Ink4b
), cell division cycle homolog 123 (CDC123), and CDK11A have been 
identified as genes that are misregulated in type 2 diabetes genome wide association 
studies (Saxena et al., 2007; Scott et al., 2007; Zeggini et al., 2007). Furthermore, 
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epigenetic modifications at the Cdkn2a/Cdkn2d (p16
Ink4a
/p19
Arf
) locus increase with age 
in both mice and humans resulting in inhibition of the cell cycle suggesting a conserved 
epigenetic mechanism for negatively regulating beta cell proliferation (Chen et al., 
2009a; Dhawan et al., 2009). Additionally, Wnt signaling has been implicated in the 
onset of diabetes in both mice and humans. Recent genome wide association studies 
indicate that variants of transcription factor 7-like 2 (TCF7L2), a transcription factor that 
functions downstream of Wnt signaling, increase susceptibility for the onset of type 2 
diabetes (Chandak et al., 2007; Dahlgren et al., 2007; van Vliet-Ostaptchouk et al., 2007). 
Depletion of TCF7L2 in cultured human islets decreases beta cell proliferation and 
increases beta cell apoptosis suggesting that Wnt signaling regulates beta cell mass 
expansion in humans (Liu and Habener, 2008; Lyssenko et al., 2007; Shu et al., 2008). 
Wnt signaling also regulates beta cell mass expansion in rodents. Expression of the 
transcription factor Sox6 is decreased in mice fed a high fat diet in Leptin
ob/ob
 mice 
(Iguchi et al., 2005). Sox6 interacts with beta catenin, a downstream mediator of Wnt 
signaling, to negatively regulate CyclinD expression and beta cell proliferation (Iguchi et 
al., 2007). A recent study identified the association between Foxm1 and Wnt signaling; 
Foxm1 is required for beta catenin translocation to the nucleus and controls expression of 
Wnt target genes in gliomas (Zhang et al., 2011). Together, these data suggest that factors 
required for beta cell mass expansion are conserved in rodents and humans. 
Mechanisms of beta cell mass expansion for cell-based therapies: In the case of type 1 
diabetes or late stage type 2 diabetes, the most common medical treatment is exogenous 
insulin injections which are exceedingly effective but come with the caveat that they do 
not precisely regulate glucose levels, a caveat that can lead to secondary complications. 
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In non-insulin dependent type 2 diabetic patients, several drugs are used to decrease beta 
cell hypoplasia. Treatments such as exenatide, gastrin, various growth factors and 
glitazones are used to preserve and/or increase the beta cell mass. These treatments, 
however, are also hindered by significant side effects. For example, patients who take 
Pioglitazone to treat diabetes have an increased risk of heart failure, bone loss, and 
myocardial infarction (Buchanan et al., 2002; Lin et al., 2005). Additionally, the use of 
sulfonylurea drugs decreases blood glucose levels but accelerates loss of beta cell mass 
necessitating exogenous insulin injections (Maedler et al., 2005; Matthews et al., 1998). 
Because of the complications associated with current treatments for diabetic patients, 
considerable effort has been devoted to replacement of beta cells. 
 Several cellular sources of functional beta cells for diabetic patients have been 
considered including islet transplantations from cadaveric donors, directed differentiation 
of beta cells from embryonic stem cells (ES cells) or induced pluripotent stem cells (iPS 
cells), transdifferentation of other adult cell lineages into beta cells, and increased 
replication of beta cells in vivo (Figure 1.7). Islet transplantation from cadaveric donors is 
greatly hindered by the lack of available donors; approximately 3 donors are required to 
treat each diabetic patient (Shapiro et al., 2000). Additionally, because of the autoimmune 
response that resulted in beta cell destruction in the case of type 1 diabetes, patients 
receiving islet transplantation require immunosuppressive drugs. Unfortunately, 
immunosuppression inhibits beta cell proliferation in a diabetic setting indicating that the 
transplanted islets will be unable to expand their beta cell mass (Nir et al., 2007). 
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Figure 1.7: A schematic of alternative sources for developing beta cells. Currently, the 
only source of cells for beta cell transplantation is human islets from cadaveric donors. 
Considerable effort has been devoted to understanding the gene regulatory networks 
required for in vivo beta cell replication and beta cell mass expansion. Additionally, 
several groups have identified factors that promote transdifferentiation of liver or other 
pancreatic cell lineages into beta cells. Lastly, very promising studies have demonstrated 
that ES cells and iPS cells can be differentiated into beta-like cells that are responsive to 
blood glucose in vivo. Image taken from (Claiborn and Stoffers, 2008). 
 
Another mechanism of generating beta cells for transplantation in diabetic 
patients is directed differentiation of pluripotent cells into functional beta cells or beta 
cell precursors. However, to date, this approach has not been successfully executed. In 
vitro differentiation of ES cells towards a beta cell fate resulted in the production of 
insulin-expressing beta-like cells. These cells, however, were unable to secrete insulin in 
response to glucose concentration (D'Amour et al., 2006).  Further refinement of this 
directed differentiation paradigm allowed the same group to generate ES cell-derived 
pancreatic endoderm progenitors. When these progenitors were transplanted into the fat 
pads or kidney capsules of mice, they were able to mature and generate glucose-
responsive beta cells that rescued hyperglycemia in diabetic mice (Kroon et al., 2008). 
These data suggest that in vivo cell types, such as endothelial cells, neurons, and/or other 
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endocrine cell lineages, are required to improve maturation. Unfortunately, 
transplantation of an impure population of progenitor cells has the potential to lead to 
teratoma formation (Kroon et al., 2008).  
Induced pluripotent stem cells (iPS cells) function similarly to ES cells in terms of 
pluripotency and differentiation potential providing patients with an autologous source of 
cells for transplantation without the ethical considerations of ES cells (Maehr et al., 2009; 
Takahashi and Yamanaka, 2006; Wernig et al., 2007; Yu et al., 2007). Recently, 
investigators used a directed differentiation paradigm to generate beta-like cells from iPS 
cells and transplanted the cells into the liver of hyperglycemic mice. The transplanted 
cells secreted insulin and reduced blood glucose levels in a dose-dependent manner 
(Alipio et al., 2010). In this study, the injected cellular population was predominantly 
beta-like cells, however, other cell lineages were detected, and the investigators did not 
conduct a careful analysis of teratoma formation. Therefore, careful analysis of tumor 
formation needs to be conducted before this treatment is considered clinically relevant. In 
addition to the inherent risk of tumor formation in these studies, obtaining a sufficient 
number of beta cells for transplantation may be difficult because derivation of beta cells 
from pluripotent stem cells is inefficient and mature beta cells replicate at low rates. 
Approximately 420,000 beta cells will be required for each transplantation (Shapiro et al., 
2000).  Therefore, future efforts should be devoted to generating a pure population of 
beta-like cells and understanding mechanisms for beta cell mass expansion in order to 
produce enough beta-like cells for transplantation. 
Although these efforts at generating beta cells from pluripotent cells is promising, 
another mechanism for increasing beta cell mass is by expanding the existing beta cell 
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population through increased proliferation and augmented beta cell survival. One 
controversial source for adult-stem cell derived beta cells is the bone marrow. One group 
injected recipient mice with GFP-positive bone marrow cells and sacrificed the animals 6 
weeks later. At this time, the group observed GFP-positive beta-like cells that 
incorporated into the existing islets suggesting that bone marrow stem cells could be an 
autologous source for generating beta cells (Ianus et al., 2003). However, at the same 
time other groups found that the GFP-positive bone marrow did not give rise to GFP-
positive beta like cells (Choi et al., 2003; Hess et al., 2003). Interestingly, although 
differentiation of bone marrow into beta-like cells could not be repeated, several groups 
determined that bone marrow transplantation increased beta cell proliferation and could 
ameliorate hyperglycemia following pancreatic injury (Choi et al., 2003; Hasegawa et al., 
2007; Hess et al., 2003). Additionally, bone marrow transplantation improves 
vascularization of islets (Mathews et al., 2004). Together these data suggest that bone 
marrow transplantation may contribute to in vivo expansion of endogenous pancreatic 
beta cells. In fact, in a recent study, patients that were newly diagnosed with type 1 
diabetes were treated with immunosuppressive drugs followed by bone marrow 
transplantation and more than half the patients in this study remained insulin-independent 
for more than a year (Voltarelli et al., 2007).  
Transdifferentiation from multiple cell lineages into pancreatic beta cells is also a 
promising avenue to pursue. Ectopic expression of three transcription factors MafA, 
Neuorg3, and Pdx1 in the exocrine pancreas results in transdifferentiation of cells into 
what appeared to be mature beta cells. These exocrine-derived beta cells express markers 
of mature beta cells and contained mature insulin granules (Zhou et al., 2008). 
30 
 
Additionally, ectopic expression of either Neurog3 or NeuroD in the liver induced 
reprogramming of hepatic progenitor cells in pancreatic cell lineages, specifically beta 
cells. In this model, the newly produced beta cells can reduce hyperglycemia in animals 
treated with streptozotocin, a drug that is toxic to beta cells (Kojima et al., 2003; Yechoor 
et al., 2009). While this approach is promising, considerable research will be required for 
this to become clinically relevant. In both approaches, the newly produced beta cells do 
not form clusters or undergo morphogenesis into islets, suggesting they may not function 
as well as endogenous beta cells. Additionally, viral delivery of transcription factors is 
not clinically feasible.  
Generation of new pancreatic beta cells remains a very promising treatment for 
both type 1 and type 2 diabetic patients. My thesis research has identified two factors that 
may be applied to current paradigms for generated beta cells. First, NC derivatives are 
required for beta cell maturation (Plank et al., 2011b). Second, the transcription factor 
Foxd3 regulates beta cell mass expansion during pregnancy (Plank et al., 2011a). 
 
Dissertation research 
Function of Foxd3 in progenitor cells: Foxd3, a Forkhead transcriptional regulator, is 
required for the maintenance of every progenitor cell lineage tested to date. Foxd3 is 
expressed in the progenitors of early embryo as early as the 4 cell stage and expression 
persists in the inner cell mass and trophectoderm cells at the blastocyst stage and in the 
epiblast at 6.5 dpc (Hanna et al., 2002; Tompers et al., 2005). Foxd3 null blastocysts are 
indistinguishable from controls and maintain expression of pluripotency markers such as 
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Oct4, Sox2, and Fgf4. However, these embryos die around 6.5 dpc due to a catastrophic 
loss of epiblast cells and an expansion of extra embryonic tissue (Hanna et al., 2002). 
Foxd3 is also required in the extraembryonic tissues; Foxd3 null extraembryonic tissues 
precociously differentiate into trophoblast giant cells at the expense of 
spongiotrophoblast cells and labyrinthine cells, lineages that appear slightly later in 
placental development (Tompers et al., 2005). Additionally Foxd3 null embryonic stem 
cells (ES cells) and trophoblast stem cells cannot be established de novo from embryos 
demonstrating the requirement for Foxd3 in maintaining progenitor cell lineages (Hanna 
et al., 2002; Tompers et al., 2005). Together these data demonstrate and absolute 
requirement for Foxd3 in the early mammalian embryo. 
To characterize the function of Foxd3 in ES cells, our lab generated an allele of 
Foxd3 where the entire coding sequence is flanked by LoxP sites (Foxd3
Lby.3
, called 
Foxd3
fl
). Using the appropriate mouse line expressing Cre recombinase, Foxd3 can be 
deleted in the desired temporal or spatial manner. In order to conditionally delete Foxd3 
from ES cells, we generated ES cells from blastocysts carrying a Tamoxifen-inducible, 
ubiquitously expressed Cre recombinase (CAAG-Cre
ER
) and 2 Foxd
fl
 alleles. The entire 
Foxd3 coding sequence was deleted upon addition of 2 M of Tamoxifen (TM) (Liu and 
Labosky, 2008).  After 12 hours of culture with TM, Foxd3 protein was reduced but 
could still be detected. However, 24 hours after TM addition, Foxd3 protein was rarely 
detected (Figure 1.8). In the absence of Foxd3, stem cell proteins and their mRNAs 
including Oct4, Sox2, and Nanog are maintained at relatively normal levels suggesting 
that Foxd3 is not required for their expression. Although these proteins required for 
pluripotency are maintained, ES cells lacking Foxd3 lose key stem cell properties. They 
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Figure 1.8: Generation of Foxd3 mutant ES cells. ES cells were derived from blastocysts 
carrying 2 alleles of Foxd3 that were flanked by LoxP sites (Flox) and a ubiquitous 
CreER. When cultured with Tamoxifen (TM) to induce Cre activity, the entire Foxd3 
coding sequence was excised.  Using immunocytochemistry we demonstrated that Foxd3 
protein (red) can still be detected after 12 hours of TM treatment. However, by 24 hours 
after TM addition Foxd3 protein is rarely detected in ES cells. NT, not treated (control). 
 
are no longer pluripotent as they differentiate into mesendoderm and trophectoderm 
lineages while cultured in conditions that normally maintain pluripotency. Additionally, 
inducible-mutant ES cells lose self-renewal capacity and undergo aberrant apoptosis (Liu 
and Labosky, 2008). Due to the multiple issues surrounding the feasibility and ethical 
considerations of using ES cells from humans, one focus of stem cell biologists is 
determining the transcriptional networks controlling stem cell properties in both ES cells 
and iPS cells. While Foxd3 is not one of the “core” transcription factors sufficient for 
reprogramming somatic cells into iPS cells (Yu et al., 2007), it is indispensible for 
generating iPS cells; mouse embryonic fibroblasts (Mefs) lacking Foxd3 cannot be 
reprogrammed in pluripotent stem cells (Suflita, Ess, and Labosky, 2011 unpublished 
data). Together, these data demonstrate that Foxd3 functions downstream of, or in a 
pathway parallel to, other stem cell factors and is required for self-renewal and 
pluripotency of ES cells.    
F
o
x
d
3
D
A
P
I
12 hours 24 hours
NT NT TMTM
33 
 
 In addition to expression in the early embryo, Foxd3 is also one of the earliest 
markers of the NC lineage (Hromas et al., 1999; Labosky and Kaestner, 1998). NC cells 
are a multipotent, transient migratory cell lineage derived from the dorsal neural tube; as 
the neural tube closes, NC cells located at the dorsal aspect of the neural tube undergo an 
epithelial to mesenchymal transition (EMT) and migrate to various regions in the embryo 
giving rise to disparate cell types such as neurons, glia, craniofacial mesenchyme, 
melanocytes, and vascular smooth muscle (Le Douarin, 1999). In combination with the 
Flox
fl
 mice mentioned above, Cre recombinase driven by the Wnt1 promoter was used to 
delete Foxd3 in the NC. Foxd3
fl/-
; Wnt1-Cre mice die perinatally, likely due to lack of 
innervation of the diaphragm (Mundell and Labosky, 2011; Teng et al., 2008).  NC 
progenitors cannot be maintained in the absence of Foxd3 leading to a catastrophic loss 
of craniofacial mesenchyme and lack of peripheral, and specifically, enteric nervous 
system derivatives (Teng et al., 2008). Additionally, in the absence of Foxd3, individual 
NC progenitors aberrantly differentiate into mesenchymal derivatives at the expense of 
neural and glial lineages (Mundell and Labosky, 2011). This mouse model was used 
extensively in my thesis work. Altogether, data from our lab indicates that Foxd3 is 
required to maintain progenitor cell properties in multiple disparate progenitor cell 
lineages.  
 Although the requirement for Foxd3 in progenitor cell lineages is well 
established, the mechanism by which Foxd3 functions is less clear. In Xenopus, Foxd3 
functions as a transcriptional repressor and interacts with the Groucho related protein, 
Grg4, to induce mesoderm (Steiner et al., 2006; Yaklichkin et al., 2007). However, data 
obtained using other experimental systems suggests that Foxd3 can function as both a 
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repressor and activator in different biological contexts (Lee et al., 2006; Pan et al., 2006; 
Thomas and Erickson, 2009). Additionally, data from two independent groups suggests 
that Foxd3 may function in ES cells to “poise” loci for transcription. A relay-model has 
been suggested based on the evidence that Foxd3 binds to target genes and/or their 
regulatory regions to inhibit transcription in ES cells. As the cell differentiate into B cells, 
Foxd3 is replaced by Foxp1 and transcription of target genes ensues (Liber et al., 2010). 
Similarly, a complementary model suggests that Foxd3 functions as a “pioneer factor” 
and occupies the Albumin1 locus in ES cells thereby maintaining the unmethylated state 
of a single CpG residue. Upon differentiation into endoderm, Foxd3 is replaced by a Foxa 
family member resulting in activation of Albumin1 expression (Xu et al., 2007). Both 
models suggest that Foxd3 is required prior to activation of target genes to maintain a 
binding site for other Forkhead proteins. 
Summary of findings: While there is an established literature detailing the requirement 
for mesodermal and endodermal cues in pancreas and beta cell development, the role of 
ectodermal derivatives is less clear. A recent study demonstrated that NC inhibits 
proliferation of insulin-expressing cells (Nekrep et al., 2008). We sought to characterize 
the precise timing of NC migration to the pancreas and to further analyze the effect of NC 
derivatives in the pancreas on beta cell development and maturation. Our work 
demonstrated that NC reaches the dorsal pancreatic bud between the 26 and 27 somite 
stage and reaches the ventral pancreatic between the 27 and 28 somite stage 
(approximately 10.25 dpc), much earlier than was previously thought (Horb and Slack, 
2000; Percival and Slack, 1999). To determine the effect of NC derivatives on developing 
beta cells, we used the NC specific deletion of Foxd3; ENS progenitors, including those 
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that innervate the pancreas, are absent in embryos lacking Foxd3 in the NC (Teng et al., 
2008). In agreement with previous data, we found that proliferation of insulin-expressing 
cells and insulin-positive area were increased in mutant embryos. Additionally, using a 
combination of gene expression analysis and transmission electron microscopy, we 
determined that NC is required for beta cell maturation. Together, these data suggest that 
NC negatively regulates beta cell proliferation while positively regulating beta cell 
maturation. 
 Unexpectedly, our laboratory showed that Foxd3 is also expressed in the 
pancreatic primordium beginning at 10.5 dpc and becomes predominantly localized to the 
beta cells in the adult (Perera et al., 2006). To determine the role of Foxd3 in the 
pancreatic epithelium, we generated Foxd3
fl/-
; Pdx1-Cre mice to characterize the 
phenotype of mice lacking Foxd3 in the entire Pdx1 expression domain including the 
pancreatic epithelium. Pancreata from pancreas-specific Foxd3 mutant mice developed 
normally and the mice were euglycemic under basal physiological conditions. To 
determine if Foxd3 is required for beta cell mass expansion, we analyzed the requirement 
for Foxd3 in the pancreas during pregnancy. In the absence of Foxd3, beta cell 
proliferation was decreased resulting in decreased beta cell mass and glucose intolerance 
at 15.5 days gestation.   
Together, my work has generated data regarding cell autonomous and non-cell 
autonomous regulators of beta cell mass expansion during embryogenesis and in the adult 
mouse.  Identification of signaling molecules from the NC required for beta cell 
maturation and this information can be utilized to improve directed differentiation 
paradigms to generate beta cells from pluripotent stem cells. Ideally, these molecules will 
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be sufficient for beta cell maturation in vitro eliminating the need to transplant an impure 
population of cells. Additionally, identifying and inhibiting the signaling factor in the NC 
that restricts beta cell proliferation may also aid in the generation of a large number of 
beta cells. I have also demonstrated that expression of Foxd3 within the pancreatic 
epithelium is required for beta cell mass expansion and the proposed future directions 
will elucidate the function of Foxd3 in beta cells. Identification and manipulation of 
extracellular signaling pathways and/or cell surface markers functioning upstream or 
downstream of Foxd3 may lead to the generation of small molecules that can be used to 
facilitate the expansion of beta cell mass in vivo.   
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CHAPTER II 
 
INFLUENCE AND TIMING OF ARRIVAL OF MURINE NEURAL CREST  
ON PANCREATIC BETA CELL DEVELOPMENT AND MATURATION 
 
This work was published in its entirety under the same title in the January 15, 2011 issue 
of Developmental logy (Plank et al., 2011b). 
 
Introduction 
A fundamental question in the field of developmental biology is how cells from 
one germ layer regulate normal development of a separate germ layer. Organ 
development is synchronously regulated to assure proper postnatal function, and 
coordination of innervation with morphogenesis is critical to this process. This issue is of 
particular interest to investigators studying pancreatic development; it is well known that 
endoderm development is dependent upon signaling from surrounding mesoderm tissues. 
Factors secreted by the mesoderm-derived notochord are largely responsible for 
development of the dorsal pancreas bud; in the absence of the notochord, expression of 
pancreas and endocrine cells markers are eliminated (Kim et al., 1997). In addition to the 
notochord, the developing vasculature produces inductive cues to influence early 
endoderm differentiation (Jung et al., 1999; Lammert et al., 2001). Subsequent to this 
induction, signals from mesodermally-derived pancreatic mesenchyme regulate 
proliferation of pancreatic progenitors to promote pancreatic outgrowth (Golosow and 
Grobstein, 1962; Wessells, 1967). Specifically, FGF10 signaling from pancreatic 
mesenchyme maintains Ptf1a expression in the dorsal pancreatic bud and is required for 
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growth, differentiation, and branching morphogenesis of the developing pancreas 
(Bhushan et al., 2001; Jacquemin et al., 2006).  
In addition to mesodermally-derived tissues, a role for ectodermally-derived 
tissues in pancreas development was recently described. While ectodermally-derived 
neural signals had been implicated in growth and/or function of adult endocrine pancreas 
(Edvell and Lindstrom, 1998; Imai et al., 2008; Razavi et al., 2006), a recent study 
demonstrated for the first time that the ectodermally-derived neural crest regulates 
embryonic development of the pancreas (Nekrep et al., 2008). However, the relationship 
between neural crest populating the pancreas and the developmental switch between 
immature Insulin-expressing cells to mature beta cells remained unclear. Neural crest is a 
multipotent embryonic cell lineage that migrates ventrally from the dorsal neural tube 
and, among other functions, generates enteric nervous system derivatives that innervate 
endodermally-derived organs of the gut (Le Douarin, 1999). Molecular control of 
specification, maintenance, migration and function of the neural crest is at least partially 
controlled by the transcription factors Sox10 and Foxd3 (Labosky and Kaestner, 1998; 
Nelms, 2010; Sauka-Spengler and Bronner-Fraser, 2008; Southard-Smith et al., 1998). 
Phox2b is a downstream target of Sox10, and both Phox2b and Sox10 are required for 
neural and glial differentiation in the gut (Herbarth et al., 1998; Pattyn et al., 1999; 
Southard-Smith et al., 1998). Phox2b
-/-
 embryos lack neural crest cells within the 
pancreas, resulting in a profound increase in proliferation of Insulin-expressing cells 
(Nekrep et al., 2008). To date, this model of neural crest regulation of beta cell 
proliferation has not been validated in an independent neural crest-deficient system, and 
the timing of neural crest arrival into the pancreatic primordium had not been described. 
39 
 
The transcription factor Foxd3, one of the earliest markers of neural crest (Labosky and 
Kaestner, 1998), is required for maintenance of neural crest progenitors. In the absence of 
neural crest expression of Foxd3, there is a catastrophic loss of this lineage including the 
entire enteric nervous system (Teng et al., 2008). Using neural crest-specific lineage 
labeling, we determined the timing and patterning of neural crest arrival at the developing 
pancreas. In addition, with a genetic manipulation that disrupts neural crest, we 
demonstrate that pancreatic beta cell development and maturation depends on interactions 
with neural crest derivatives.  
 
Materials and methods 
Mouse lines: Tg(Wnt1-Cre)11Rth (referred to as Wnt1-Cre), two independent Foxd3 null 
alleles, Foxd3
tm1.Lby 
and Foxd3
tm2.Lby
 (Foxd3
-
), and Foxd3
tm3.Lby 
(Foxd3
fl
) mice were 
interbred to generate Foxd3
fl/+ 
(control) and Foxd3
fl/-
; Wnt1-Cre (mutant) embryos. These 
mouse lines and genotyping were previously described (Danielian et al., 1998; Hanna et 
al., 2002; Teng et al., 2008). For lineage analyses, a reporter allele, 
Gt(ROSA)26Sor
tm1(EYFP)Cos 
(R26R
YFP
, (Srinivas et al., 2001)), was also used. Mice were 
maintained on an outbred genetic background consisting of CD-1, 129S6 and C57BL/6J. 
All mouse lines were maintained under protocols approved by the Vanderbilt University 
Institutional Animal Care and Use Committee (IACUC). To generate embryos for 
dissections and further analysis, mice of the appropriate genotypes were mated, dams 
checked daily for the presence of a vaginal plug, and noon on the day of the plug 
considered 0.5 days post coitum (dpc). To measure BrdU incorporation, pregnant dams 
were injected with 50 mg BrdU/kg body weight one hour before sacrifice. 
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Histology and Immunohistochemistry: At 11.5 dpc or younger, embryos were dissected 
from the placenta and surrounding maternal tissues and fixed in 4% paraformaldehyde 
(PFA) in PBS for 4 hours. For embryos aged 13.5 dpc or older, the pancreas, duodenum, 
stomach, and spleen were dissected from the embryo in cold PBS and fixed in 4% PFA in 
PBS for 4 hours. Yolk sacs or embryonic tissues were removed for DNA extraction and 
PCR genotyping. Tissues were processed, embedded, and sectioned following standard 
procedures (Presnell, 1997). For whole mount immunohistochemistry, 9.5 to 10.25 dpc 
embryos were fixed and then permeabilized in 0.5 % Triton X-100 at room temperature 
for 30 minutes. Non-specific antigen recognition was minimized by blocking in 1% BSA, 
10% normal donkey serum and 0.1% Triton X-100 in PBS. Embryos were then incubated 
with primary antibodies, washed, and subsequently incubated with secondary antibodies; 
each step was performed overnight at 4C. Finally, samples were washed overnight in 
PBS with 0.1% Triton X-100. For 9.5-10.25 dpc embryos, the hindlimb and surface 
ectoderm were removed and the gut tube was separated from the neural tube to facilitate 
imaging. The following primary antibodies were used: chicken anti-GFP (1:500, Abcam), 
mouse anti-b-III Tubulin (1:500, Covance,TUJ1), rabbit anti-PGP9.5 (1:1000, AbD 
Serotec) rabbit anti-Fabp7 (1:1000, a kind gift from Dr. Thomas Muller, (Kurtz et al., 
1994; Schnutgen et al., 1996)), guinea pig anti-Pdx1 (1:2500) and goat anti-Pdx1 
(1:10000, both Pdx1 antibodies were kind gift from Dr. Christopher Wright, (Boyer et al., 
2006; Hingorani et al., 2003)), guinea pig anti-Insulin (1:500, Millipore), rabbit anti-
Glucagon (1:500, Millipore), rabbit anti-Pancreatic Polypeptide (1:100, Millipore), rat 
anti-Somatostatin (1:100, Millipore), rabbit anti-Ghrelin (1:100, Phoenix 
Pharmaceuticals), rabbit anti-Glut2 (1:1000, Millipore), rat anti-BrdU (1:250, Accurate 
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Biochemical), mouse anti-Neurog3 (1:1000, Developmental Studies Hybridoma Bank), 
rabbit anti-Foxd3 (1:1000, (Tompers et al., 2005)). The secondary antibodies used were: 
biotin donkey anti-chicken (1:500), biotin donkey anti-mouse (1:500), Cy2 donkey anti-
mouse (1:500), Cy2 donkey anti-guinea pig (1:500), Cy2 donkey anti-rabbit (1:500), Cy3 
donkey anti-mouse (1:500), Cy3 donkey anti-guinea pig (1:500), Cy3 donkey anti-rabbit 
(1:500), Cy3 donkey anti-rat (1:500), Cy3 donkey anti-goat (1:800), Cy5 donkey anti-
rabbit (1:500), Cy5 donkey anti-mouse (1:500), and Cy5 donkey anti-guinea pig (1:500). 
All secondary antibodies were purchased from Jackson ImmunoResearch. To detect YFP 
and Neurog3 protein, tyramide signal amplification was used (Invitrogen). BrdU was 
detected as previously described (Plank et al., 2011a; Teta et al., 2007). Tissue sections 
were imaged using either a Zeiss Axioskop2 plus with a Q-Imaging Retiga 2000R Fast 
1394 camera or an Olympus FV1000 Confocal Laser Scanning Microscope. 
Transmission electron microscope (TEM) analyses were completed with the assistance of 
the Vanderbilt Cell Imaging and Shared Resource using standard procedures (Tweedie et 
al., 2006). 
Quantification and Statistical Analysis: To quantify pancreatic alpha, beta, delta, epsilon, 
and PP cell area, the Glucagon-, Insulin-, Somatostatin-, Ghrelin-, or PP-positive area 
was determined using ImageJ (NIH) and divided by the total pancreatic area from 5-7 
evenly spaced sections throughout the pancreas. Approximately 10 percent of the total 
pancreatic area was quantified for each cell type. Similarly, Neurog3-positive cells were 
quantified: the number of Neurog3-positive cells per section was divided by the 
pancreatic area. The percent of Glut2- and/or Pdx1-positive Insulin-expressing cells was 
calculated by counting the number of Insulin-expressing cells co-expressing Glut2 and/or 
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Pdx1 divided by the total number of Insulin-expressing cells. Two endocrine cell clusters 
from 5 evenly spaced sections throughout the pancreas were analyzed (10 clusters total at 
each age). At least 250 Insulin-positive cells from each animal were counted.  The 
percent of endocrine cell clusters in contact with neurons was calculated by determining 
the number of endocrine cell clusters (in this assay, a cluster was defined as having more 
than 5 cells) in contact with neurons divided by the total number of endocrine cell 
clusters per section. At least 4 evenly spaced sections throughout the pancreas were 
analyzed per embryo or mouse, accounting for approximately 5 to 8% of the total 
pancreatic area. Statistical significance for each assay was determined using a two-tailed 
Student’s t-test. 
RNA Isolation and Real Time PCR: The pancreatic primordium was dissected and stored 
in RNA Later (Ambion). RNA was isolated using QIAshredder columns and the RNeasy 
Mini Kit (Qiagen) and contaminating genomic DNA removed with Turbo DNase 
(Ambion). cDNA was generated using the Superscript First Strand Synthesis (Invitrogen) 
and 2 ng of cDNA was amplified using Power SYBR Green PCR Master Mix (Applied 
Biosystems). All samples were run in duplicate and 4-6 biological replicates were used in 
each case. The relative amount of mRNA was determined by comparison to 
Hypoxanthine Phosphoribosyl Transferase (Hprt) and a two-tailed Student’s t-test was 
used to determine statistical significance. Primer sequences are in Table 2.1.  
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Table 2.1- qRT-PCR Primer Sequences 
Gene Name Forward Primer Sequence (5’3’) Reverse Primer Sequence (5’3’) 
Gcg AGGAATTCATTGCGTGGCTG CAATGGCGACTTCTTCTGGG 
Ins1 CAGCAAGCAGGTCATTGTTT GGGACCACAAAGATGCTGTT 
Mafa TCGACCTGATGAAGTTCGAG CAGAAGCTGGGCGAAGAG 
Mafb CCCACACATTGGCAACTAAC AACGGAAGGGACTTGAACAC 
Neurog3 ATCCATCACTTTTTCCAGGGTG TCATCTATGGGCCAAGAGCTG 
Nkx2.2 GCAGCGACAACCCCTACA ATTTGGAGCTCGAGTCTTGG 
Pdx1 CTGAGGGACAAAGATGCAGA TTCTAATTCAGGGCGTTGTG 
 
 
Neural crest arrival at the pancreatic primordium  
occurs between the 26 and 27 somite stages 
Signals from the neural crest regulate proliferation of Insulin-expressing cells that 
in turn influence initial beta cell mass (Nekrep et al., 2008); however, the timing of 
interactions between neural crest and the pancreatic primordium has not been carefully 
defined. By 9.0 days post coitum (dpc, 13-15 somites) the endoderm-derived gut 
epithelium forms two outpocketings that will become the dorsal and ventral pancreatic 
buds. Mesoderm-derived pancreatic mesenchyme surrounds both buds, and interactions 
between these tissues are required for subsequent branching morphogenesis (Gittes et al., 
1996; Golosow and Grobstein, 1962). To determine when migratory neural crest first 
makes physical contact with the pancreatic primordium, we analyzed the neural crest 
lineage in Wnt1-Cre; R26R
YFP/+
 (control) embryos from 9.5 dpc-10.25 dpc. At the 26 
somite stage (10.0 dpc), YFP-positive neural crest cells were detected in the anterior 
foregut (Figure 2.1A) but were not in the vicinity of the pancreatic primordium (Figure 
2.1D). The pancreatic epithelium was identified by Pdx1 expression. However, by the 27 
somite stage and afterwards (Figure 2.1B-C), YFP-positive neural crest cells were present 
within the pancreatic mesenchyme adjacent to the epithelium. This demonstrated that 
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neural crest arrival at the pancreatic primordium begins between the 26 and 27 somite 
stages (approximately 10.0 dpc). Additionally, because a new pair of somites is formed 
approximately every 2 hours in the mouse embryo (Tam, 1981), these data provide, for 
the first time, a precise characterization of the timing of neural crest migration to the 
pancreatic primordium. These data suggest that neural crest is proximal to the pancreatic 
epithelium well in advance of significant branching and the secondary transition, a key 
developmental stage initiating around 13.5 dpc that marks a wave of Insulin-positive cell 
differentiation. In addition, this contradicts previous studies concluding that only 
mesodermally- and endodermally-derived tissues were present in dorsal pancreatic buds 
at 11.5 dpc (Horb and Slack, 2000; Percival and Slack, 1999). We also observed that NC 
enters the mesenchyme surrounding the dorsal pancreas prior to the ventral pancreas; 
YFP-positive NC cells are present in the mesenchyme surrounding the dorsal pancreas by 
the 27 somite stage (Figure 2.1E-F) while YFP-positive cells are not detected adjacent to 
the ventral pancreas until the 28 somite stage (Figure 2.1 G-H). This timing confirms that 
NC arrival at the pancreatic buds parallels the timing of pancreas development as the 
dorsal bud undergoes branching morphogenesis and expansion slightly earlier than the 
ventral bud (Jorgensen et al., 2007). 
 
Foxd3 is required for NC arrival at the developing pancreas 
Loss of Foxd3 in the NC results in a loss of most NC derivatives, however, some 
regions of the embryo, such as the outflow tract, are only mildly perturbed (Teng et al., 
2008). To determine if Foxd3 function in the NC is required for the NC that migrates to 
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Figure 2.1: NC cells enter the pancreatic primordium between the 26 and 27 somite 
stages. (A-C). Whole mount immunofluorescence for Pdx1 marking the pancreatic 
epithelium (red), and YFP marking NC cells (green), illustrates the path and timing of 
NC migration. In these samples NC was lineage labeled with Wnt1-Cre driven 
recombination of R26R
YFP
 in control embryos (Wnt1-Cre; R26R
YFP/+
). NC cells have not 
reached the pancreatic primordium by the 26 (A) somite stage, by the 27 somite stage (B) 
migrating NC cells had just reached the pancreatic epithelium, and at the 28 somite stage 
(C), the leading edge of the NC migratory stream was past the pancreatic primordium. 
(D-F) Higher magnification of the dorsal and ventral pancreatic buds illustrate that the 
YFP-positive NC cells have not reached the dorsal bud at the 26 somite stage (D) but 
have arrived at the dorsal bud at the 27 somite stage (E) and the ventral bud at the 28 
somite stage (F). (G-H) Higher magnification images of the ventral bud demonstrate no 
YFP-positive NC cells present near the ventral bud at the 27 somite stage (G) but NC are 
at the ventral bud at the 28 somite stage (H). The cartoon illustrates the orientation of the 
embryos with the boxed region corresponding to the area shown in A-C. VP, ventral 
pancreas; DP, dorsal pancreas; *, sympathetic ganglia. N=2-3 embryos per time somite 
stage. Imaging done by Nathan Mundell. 
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the developing pancreas, we analyzed the NC lineage in control and mutant embryos with 
a Cre-activatable lineage label, R26R
YFP/+
. In contrast to controls (Figure 2.2A-B), mutant 
NC cells, identified with YFP expression, were not found near the pancreatic epithelium, 
identified by Pdx1 and Glucagon expression, at 10.5 or 11.5 dpc (Figure 2.2E-F). These 
data confirm a cell autonomous requirement for Foxd3 within NC fated to enter the 
pancreas. 
To further characterize NC in control embryos and determine if NC cells were 
present in the pancreata of mutant embryos at later developmental time points, we 
analyzed the NC lineage at 15.5 and 17.5 dpc. As pancreatic development progresses, the 
branches of pancreatic epithelium, identified by Pdx1 expression, invade the surrounding 
mesenchyme, and we observed NC cells interspersed throughout the developing pancreas 
(Figure 2.2C- D). However, NC cells were never present near the pancreas in mutant 
embryos (Figure 2.2G-H) supporting our earlier observations that Foxd3 expression in 
the NC is required for maintenance of NC (Teng et al., 2008), including NC derivatives 
in the pancreas. 
 
Neurons and glia are absent in mutant pancreata 
Normally, NC cells differentiate to form neurons and glia of the sensory, sympathetic, 
and enteric nervous systems (Adams and Bronner-Fraser, 2009) and in a previous report 
using mouse embryos homozygous for a null mutation in Phox2b (Phox2b
-/-
) lacking 
much of the NC, neurons and glia are absent from the   
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Figure 2.2: The NC does not populate the pancreas in the absence of Foxd3. (A-B) 
Immunofluorescence on sections of embryonic tissue demonstrated that YFP-positive NC 
cells (green) are adjacent to the Pdx1-positive pancreatic epithelium (red) at 10.5 (A) and 
11.5 dpc (B) in control embryos (Wnt1-Cre; Foxd3
flox/+
; R26R
YFP/+
). (C-D) As pancreatic 
branching ensues, YFP-positive NC cells (green) become intermingled with pancreatic 
epithelial cells (red) and are closely associated with cells expressing higher levels of 
Pdx1 at 15.5 (C) and 17.5 dpc (D). (E-H) YFP-positive cells were not detected in the 
pancreatic primordium of mutant embryos (Wnt1-Cre; Foxd3
flox/
; R26R
YFP/+
) at any 
developmental time point. Arrows illustrate YFP-expressing cells. Scale bars, 100 m. 
N=3-4 embryos in each group.  
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pancreas (Nekrep et al., 2008).  To further characterize this finding using a NC-specific 
mutation, we analyzed the timing of neural and glial differentiation in pancreata from 
control embryos at various developmental stages. Very few TUJ1-positive neurons and 
no FABP7-positive glia were present at 13.5 dpc (data not shown). However, by 15.5 and 
17.5 dpc, both neurons and glia were intermingled with pancreatic epithelial cells, 
identified by Pdx1 expression  (Figure 2.3A-B), suggesting that neural and glial 
differentiation in the pancreas began between 13.5 and 15.5 dpc and NC derivatives are 
in position to affect beta cell development by the beginning of the secondary transition. 
In addition, by 17.5 dpc, neurons and glia are closely associated with cells expressing 
high levels of Pdx1, indicative of endocrine cells. Consistent with our earlier observations 
(Figure 2.1-2.2), Foxd3 mutant embryos completely lacked neurons and glia in the 
pancreas (Figure 2.3C-D) supporting our conclusion that pancreatic neurons and glia are 
derived from the NC. 
 
NC cells regulate proliferation of Insulin-expressing cells and Insulin-positive 
area 
Analysis of the Phox2b
-/-
 embryos lacking NC demonstrated that signals from the 
NC regulate insulin-expressing cell proliferation and the total number of Insulin-
expressing cells (Nekrep et al., 2008). In Phox2b
-/-
 embryos, NC cells migrate to the 
endoderm of the foregut but then undergo apoptosis prior to differentiating into enteric 
neurons (Pattyn et al., 1999). Because the NC is more significantly ablated in Foxd3 NC-
conditional null embryos (no NC cells migrate into the foregut in mutants, (Teng et al., 
2008)), it leaves open the possibility that beta cell development may be more severely   
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Figure 2.3: Neurons and glia are absent in pancreata from embryos with a NC specific 
deletion of Foxd3. (A-B) Immunofluorescent analyses of sections of embryonic pancreata 
demonstrated that TUJ1-expressing neurons (red) and FABP7-expressing glia (blue) were 
present in control pancreata at 15.5 (A) and 17.5 (B) dpc. TUJ1- and FABP7-expressing 
cells were not detected at any stages in mutant pancreata (C-D). The pancreas was 
indicated by Pdx1-positive cells (green). Arrows, TUJ1-positive cells; arrowheads, 
FABP7-positive cells. N=3-4 embryos in each group.  
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altered in this genetic model. To determine if the insulin-expressing cell area is greater in 
Foxd3 NC mutant embryos, we assayed insulin- and glucagon-positive area in mutant 
and control pancreata at 17.5 dpc. Similar to the previous study, the area occupied by 
insulin-expressing cells in the pancreas was increased approximately 1.5 fold (Figure 
2.4A) while glucagon-positive area was unchanged (Figure 2.4B) in mutants compared to 
controls. In addition, we analyzed PP-, Somatostatin-, and Ghrelin-positive area and 
found that the area of these endocrine cell lineages was similar between mutant and 
control embryos (Figure 2.4C). To determine if Nkx2.2 expression, a transcription factor 
required for initial beta cell differentiation and, to a lesser extent, alpha and PP cell 
differentiation was altered in our system (Sussel et al., 1998), we used real time PCR 
(qPCR) to analyze Nkx2.2 mRNA expression. At both 13.5 and 15.5 dpc, Nkx2.2 was 
significantly increased (Figure 2.4D), consistent with previous findings (Nekrep et al., 
2008). To resolve whether the increase in Insulin-positive area was due to changes in cell 
proliferation, we assayed BrdU incorporation in mutant and control pancreata. In both 
15.5 and 17.5 dpc embryos, BrdU incorporation was increased (85% at 15.5 dpc and 29% 
at 17.5 dpc) in Insulin-expressing cells from embryos lacking Foxd3 in the NC (Figure 
2.4E). These results suggested that NC-derived cells negatively regulate proliferation in 
Insulin-expressing cells. In contrast, BrdU incorporation in Glucagon-expressing cells of 
control and mutant embryos was unchanged at both times (Figure 2.4F). These data agree 
with the previous report that signals from the NC regulate Insulin-expressing, but not 
Glucagon-expressing, cell area and proliferation (Nekrep et al., 2008). 
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Figure 2.4: NC-derived cells regulate Insulin-expressing cell expansion. (A) The Insulin 
(Ins)-positive area from mutants and controls was calculated and indicated that mutants 
have a greater Ins-positive area than controls at 17.5 dpc. (B) The Glucagon (Gcg)-
positive area was similar between mutants and controls at 17.5 dpc. (C) The Pancreatic 
Polypeptide (Ppy), Somatostatin (Sst), and Ghrelin (Ghrl)-positive areas were slightly 
increased but not to a statistically significant level in mutants compared to controls at 
17.5 dpc. (D) qPCR analyses indicated that Nkx2.2 mRNA expression was increased in 
mutants compared to controls at 13.5 and 15.5 dpc. (E) BrdU incorporation in Insulin-
positive cells was greater in mutants than controls at 15.5 and 17.5 dpc. (F) BrdU 
incorporation in Gcg-positive cells was unchanged in mutants and controls at 15.5 and 
17.5 dpc.  (G) qPCR analyses indicated Neurog3 mRNA expression was increased in 
mutants compared to controls at 13.5 and 15.5 dpc. (H) The total number of Neurog3-
positive cells per pancreatic area was unchanged between mutants and controls at 13.5 
and 15.5 dpc. Purple lines and bars represent control embryos; red bars, represent mutant 
embryos. Error bars indicate SEM. * p < 0.05, ** p < 0.01.  N= 3-5 embryos per group. 
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NC cells do not regulate beta cell neogenesis 
While proliferation changes profoundly influence the final number of beta cells, 
endocrine cell neogenesis also plays a significant role. To analyze beta cell neogenesis, 
we quantified Neurog3 mRNA expression, an indicator of endocrine cell neogenesis (Gu 
et al., 2002; Schwitzgebel et al., 2000). qPCR analyses demonstrated increased Neurog3 
expression in pancreata from mutant embryos at both 13.5 and 15.5 dpc (Figure 2.4G), 
when Neurog3 is playing a profound role in the generation of new beta cells (Gu et al., 
2002). This result is consistent with 2 possibilities: 1) an increase in Neurog3 mRNA 
expression per individual cell or 2) an increase in the number of cells expressing 
Neurog3, suggesting increased endocrine cell neogenesis. To distinguish between these 
two explanations, we used immunohistochemistry and quantified the total number of 
Neurog3-positive cells per pancreatic area and discovered that the number of cells 
expressing Neurog3 was similar between mutants and controls (Figure 2.4H) suggesting 
that NC cells are not required for endocrine cell neogenesis, but that regulation of 
Neurog3 levels on a per cell basis was disrupted. During embryogenesis, Neurog3-
positive precursors are unipotent (Desgraz and Herrera, 2009); therefore, it is possible 
that individual endocrine progenitors expressing high levels of Neurog3 may be mis-
specified to a beta cell fate resulting in increased Insulin-positive area. Because we did 
not detect changes in the proportion of other pancreatic endocrine cells in mutant 
embryos (Figure 2.4B-C), it is unlikely that endocrine progenitors are reallocated to a 
beta cell fate. However, the possibility remains open that Neurog3 may regulate other 
aspects of beta cell development such as self-renewal and maturation. 
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NC cells regulate beta cell maturation 
 Although increased Insulin-expressing cell area is significant, it is more 
physiologically important that the Insulin-expressing cells are capable of responding to 
glucose stimulation. Unfortunately, embryos with a NC-specific deletion of Foxd3 or a 
homozygous null mutation in Phox2b result in perinatal lethality, so beta cell function 
cannot be tested in postnatal animals. As an alternative, we first examined expression of 
definitive markers of mature beta cells. The transcription factor MafA is a key regulator 
of glucose stimulated Insulin secretion and is expressed upon maturation (Zhang et al., 
2005). Similarly, Pdx1 is strongly expressed in mature beta cells (Ohlsson et al., 1993). 
Alternatively, MafB is expressed in immature Insulin-expressing cells and immature and 
mature Glucagon-expressing cells while Glucagon (Gcg) is expressed in all alpha cells 
(Artner et al., 2006; Matsuoka et al., 2003). Therefore, to determine if signals from NC-
derivatives are required for beta cell maturation, we analyzed mRNA expression of MafA 
and Pdx1 in addition to MafB, Ins1, and Gcg at 17.5 dpc. Expression of MafB and Gcg 
were unchanged in mutant embryos while expression of Ins1 appeared increased in 
mutant embryos, although this trend was not statistically significant. Importantly, 
expression of both MafA and Pdx1 mRNA was significantly decreased, suggesting that 
signals from NC derivatives positively regulate beta cell maturation (Figure 2.5A). To 
examine beta cell maturation on a more cell biological level, we analyzed protein 
expression of Pdx1 and Glut2, the glucose transporter utilized by beta cells that is critical 
for glucose stimulated Insulin secretion (Guillam et al., 1997). There was a significant 
decrease (approximately 6 percent) in the percentage of Insulin-positive cells co-
expressing Glut2 and Pdx1 (Figure 2.5B-D). Additionally, there was an increase 
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(approximately 15 percent) in the percentage of Insulin-positive cells that do not express 
Pdx1 or Glut2, further suggesting a decrease in beta cell maturation (Figure 2.5B-D). We 
extended this analysis of Pdx1 and Glut2 expression to 18.5 dpc and found similar 
results. Again, we observed an increase the percentage of cells expressing Insulin but not 
Pdx1 or Glut2 (Figure 2.5E-G). Our data demonstrate that although the majority of 
Insulin-expressing cells co-express Pdx1 and Glut2, there is a significant fraction of 
Insulin-expressing cells that do not express Pdx1 or Glut2. The presence of this small but 
significant population of cells supports the conclusion that signals from NC derivatives 
are critical for beta cell maturation. 
To analyze beta cell maturation at higher resolution, we used transmission 
electron microscopy (TEM). Mature Insulin containing granules can be identified by the 
presence of electron dense cargo surrounded by an electron-free halo (Figure 2.5H-I, 
black arrows) while immature Insulin containing granules can be identified by the 
presence of less dense cargo surrounded by the characteristic halo (Figure 2.5H-I, white 
arrows). These criteria were applied for the identification of Insulin-expressing cells. Our 
TEM analyses revealed striking defects within the Insulin-expressing cells from mutant 
embryos (Figure 2.5I). First, the number of granules in all cells analyzed from mutant 
embryos was decreased compared to controls (Figure 2.5H). Second, although some 
granules from mutant embryos had the morphology characteristic of Insulin granules, a 
significant proportion of the granules in 3 out of 6 cells from mutant embryos were 
abnormal. These abnormal granules were less dense than Insulin granules and were not 
surrounded by the characteristic halo (Figure 2.5I, arrowheads). Previous data, together 
with our data here (Figure 2.4-5) suggest that NC-derived cells regulate beta cell   
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Figure 2.5: Beta cell maturation is impaired in the absence of NC. (A) MafA and Pdx1 
mRNA was decreased in mutants (red bars) compared to controls (purple line) while 
MafB, Ins, and Gcg mRNA were similar between mutants and controls at 17.5 dpc. N= 5 
pancreata in each group. (B-G). Immunofluorescent analyses of Pdx1 (blue) and Glut2 
(red) expression in Insulin-positive cells (green) indicated that a greater proportion of 
Insulin-positive cells from mutant embryos (C, F) do not co-express Glut2 or Pdx1 
compared to control littermates (B, E) at 17.5 (B-C) and 18.5 dpc (E-F). Quantification of 
immunofluorescent analyses at 17.5 dpc (D) indicated that the proportion of Ins-positive 
cells that do not express Glut2 or Pdx1 (blue portion of the graph) was increased while 
the proportion of Insulin-positive cells that co-expressed both Pdx1 and Glut2 (red) are 
decreased in mutant embryos. Quantification of immunofluorescent analyses at 18.5 (G) 
indicated that the proportion of Insulin-positive cells that do not co-express Glut2 or 
Pdx1 (blue) was increased in mutant embryos. Arrows indicate Insulin-positive cells that 
do not express Pdx1 or Glut2. N=3-4 embryos per group. * p < 0.05, ** p < 0.01, *** p < 
0.001. Note the vertical y-axis extends from 80-100 %. (H-I) Transmission electron 
microscopy revealed there were fewer Insulin granules in pancreata from mutant embryos 
(I) compared to controls (H) at 17.5 dpc. Additionally, abnormal granules in Insulin-
expressing cells were also present in mutant samples but not in controls. Black arrows 
indicate examples of mature Insulin granules, white arrows indicate examples of 
immature Insulin granules, and white arrowheads indicate examples of abnormal 
granules. n, nucleus; dashed line, nuclear membrane; solid line, cell membrane. Scale 
bars represent 500 nm. Error bars represent SEM. 
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development in two independent manners. First, NC cells regulate Nkx2.2 expression, 
proliferation of Insulin-expressing cells and Insulin-positive area (Figure 2.4), (Nekrep et 
al., 2008). Second, NC cells positively regulate expression of MafA and Pdx1, and thus, 
beta cell maturation (Figure 2.5). 
 
NC-derived cells directly contact Insulin- and Glucagon-expressing cells 
 To determine whether NC derivatives signal to Insulin-expressing cells through 
juxtracrine or paracrine signaling, high magnification images of Insulin-expressing cell 
clusters from control animals were analyzed. By 15.5 dpc, approximately 55 percent of 
Insulin-expressing clusters were in direct contact with TUJ1-expressing neurons (Figure 
2.6A, D). This increased to approximately 84 percent of Insulin-expressing clusters in 
contact with TUJ1-expressing neurons by 17.5 dpc (Figure 2.6 B, D), and continued until 
postnatal day 1 when nearly every Insulin- expressing cluster (98.9%) was contacted by 
TUJ1-expressing neurons (Figure 2.6C,D). In addition, by 17.5 dpc we detected TUJ1-
positive projections between endocrine cells (Figure 2.6B, inset) demonstrating that by 
late embryogenesis, NC derivatives enter endocrine cell clusters. Together, these data 
suggest a model where NC-derived cells signal to the pancreas through juxtracrine 
signaling and this mechanism of regulation of beta cell development begins prior to 15.5 
dpc. 
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Figure 2.6: Neurons directly contact Insulin-expressing cells. (A-C) High-resolution 
(100X) confocal images of sections from control embryonic pancreata demonstrated that 
TUJ1-positive neurons (green) directly contact Insulin-expressing beta cells (red) at 15.5 
dpc (A). TUJ1-positive neurons also contact both and Insulin (red)- and Glucagon (blue)-
expressing beta and alpha cells at 17.5 dpc (B), and postnatal day 1 (C). The inset in B is 
an example of a TUJ1-positive cell that had a projection between a Glucagon (blue)- and 
an Insulin (red)- expressing cell at 17.5 dpc. Arrows indicate TUJ1-positive cells in direct 
contact with cells expressing Insulin and arrowheads indicate TUJ1-positive cells in 
direct contact with Glucagon (blue)-expressing cells. (D) Quantification of the number of 
Insulin-positive clusters that were in direct contact with neurons at each time examined. 
Error bars indicate SEM. N= 2-3 embryos/animals with at least 10 Insulin-positive 
clusters per sample. 
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Conclusion 
To understand the importance of the NC on development of the pancreatic 
primordium, we first sought to precisely characterize the timing of NC arrival at the 
developing pancreas and determined that NC enters the pancreatic mesenchyme between 
the 26 and 27 somite stages (approximately 10.0 dpc, Model in Figure 2.7A). As the 
pancreatic epithelium branches and invades the surrounding mesenchyme, NC cells 
intermingle with acinar and pancreatic endocrine cells (Figure 2.7A). By 15.5 dpc, the 
majority of Insulin-expressing cell clusters were directly contacted by NC derivatives, 
suggesting that these cells may signal through direct cell-cell contact. This process is 
complete by postnatal day 1 when the overwhelming majority of Insulin-expressing cell 
clusters were contacted by NC derivatives. Our data, for the first time, precisely defines 
the stage at which this critical ectoderm-endoderm interaction is initiated, and confirms 
that NC is the sole source of pancreatic neurons and glia. 
Earlier work demonstrated that loss of NC increased proliferation and, therefore 
increased the overall number of Insulin-expressing cells present in the embryonic 
pancreas (Nekrep et al., 2008). We show here, that in the absence of Foxd3, and therefore 
the NC, the Insulin-expressing area increased but, in addition, expression of beta cell 
maturation markers decreased, suggesting that NC promotes differentiation of Insulin-
expressing cells to mature beta cells. In the absence of NC, increased proliferation of 
Insulin-expressing cells is associated with decreased or delayed beta cell maturation, 
suggesting that the immature beta cells are expanding (Figure 2.7B). Our work 
demonstrates a novel manner by which the ectodermally-derived NC influences 
development of the endodermally-derived beta cell and shows for the first time  
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Figure 2.7: Model of NC migration into the pancreatic primordium and regulation of 
beta cell development.  (A) The pancreatic bud (blue) outpockets from the gut epithelium 
(red) between 9.0 and 9.5 dpc. Precisely by the 27 somite stage, migrating NC cells 
(green) enter the mesenchyme adjacent to the dorsal pancreatic bud (mesenchymal cells 
are not depicted here for simplicity), and by the 28 somite stage migrating NC cells enter 
the mesenchyme adjacent to the ventral pancreatic bud. As significant pancreatic 
branching ensues, NC cells become surrounded by the pancreatic epithelium. Between 
13.5 and 15.5 dpc, endocrine cell clusters (purple) delaminate from the pancreatic 
epithelium and NC derivatives are found in direct contact with endocrine cells. (B) By 
15.5 dpc and onwards, the majority of endocrine cell clusters are directly contacted by 
NC-derived TUJ1-positive neurons. Signals from NC derivatives positively regulate 
MafA, Pdx1, and Glut2 expression and, therefore, beta cell maturation while negatively 
regulating Insulin-expressing cell proliferation and Insulin-expressing cell area. 
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that NC derivatives are critical regulators of beta cell development and maturation. This 
in turn suggests that identification of NC-derived signals may be important for the 
optimization of generation of glucose-responsive beta cells in vitro. Currently, in the 
most successful methods of producing human embryonic stem cell (hESC)-derived beta 
cells, the Insulin-expressing cells stall at an immature beta-cell stage (D'Amour et al., 
2006). However, transplantation of a heterogeneous population of cells consisting mostly 
of pancreatic progenitor cells into adipose tissue or the kidney capsule of a host mouse 
provides a permissive environment for beta cell development and maturation, and 
transplanted cells become glucose responsive and can rescue glucose stimulated Insulin 
secretion in a beta cell ablated mouse model (Kroon et al., 2008). To our knowledge, no 
one has examined innervation in these models and it is possible that contaminating 
ectodermal cells were transplanted and/or that resident postnatal NC progenitor cells in 
the host may function to facilitate beta cell maturation in situ. Co-culture of NC stem 
cells and adult islets in vitro increases beta cell proliferation and function (Olerud et al., 
2009), therefore, identification of NC-specific factors that augment beta-cell maturation 
has the potential to improve these directed differentiation schemes. 
 
 
 
 
 
 
 
 
65 
 
CHAPTER III 
 
LOSS OF FOXD3 RESULTS IN DECREASED BETA CELL PROLIFERATION 
AND GLUCOSE INTOLERANCE DURING PREGNANCY 
 
This work was published in its entirety under the same title in the December 2011 issue 
of Endocrinology (Plank et al., 2011b). Copyright 2011, The Endocrine Society. 
 
Introduction 
Approximately 7 percent of pregnant women are affected by gestational diabetes 
mellitus (GDM), a disease resulting from the inability of the resident beta cell population 
to produce sufficient insulin during pregnancy (Parsons et al., 1992). GDM increases the 
risk of complications to both mother and newborn child; the mother is more likely to 
develop Type 2 diabetes (T2D) later in life and the child is more likely to be born with 
birth defects, macrosomia and an increased risk of developing T2D (Bellamy et al., 2009; 
Brelje et al., 1993; Feig et al., 2008; Lindsay, 2008; Mathiesen and Vaz, 2008). During 
normal murine pregnancy, beta cells proliferate, or self-renew, thereby expanding the 
total beta cell mass to meet the mother’s increasing demand for insulin (Dor et al., 2004; 
Dor and Melton, 2008; Freemark et al., 2002; Parsons et al., 1992; Sorenson and Brelje, 
1997; Teta et al., 2007; Vasavada et al., 2000). This mechanism of beta cell mass 
expansion during human pregnancy remains controversial. Analogous measurements are 
not ethically feasible in humans, however, morphological analyses of human pancreata 
indicate that beta cell mass is increased during pregnancy (Butler et al., 2007; Van 
Assche et al., 1978). Recent work analyzing pancreata from 38 cadaveric donors (18 
pregnant, 20 controls) suggested that beta cells do not proliferate during human 
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pregnancy. Instead, an increased number of smaller islets and insulin-positive cells were 
observed within the ductal epithelium (Butler et al., 2010). However, this work is not 
without caveats. It is well known that murine beta cells proliferate within a defined time 
window and it is likely that the 18 pregnant human donors examined were not within an 
analogous gestational age (Karnik et al., 2007; Rieck and Kaestner, 2010). This study 
also included donors with inflammatory disease that may have adversely affected beta 
cell mass expansion (Genevay et al., 2010). It is important to note that the pregnancy 
associated hormones prolactin, placental lactogen (PL) and human growth hormone all 
stimulate beta cell proliferation in islets isolated from mice, rats, and humans suggesting 
that cell proliferation is a conserved mechanism of beta cell mass expansion during 
pregnancy (Brelje et al., 1993). While much of beta cell proliferation is controlled 
systemically (Porat et al., 2011), cell-autonomous control of beta cell proliferation is also 
a factor. Therefore, it is important to identify factors required for murine beta cell self-
renewal because the associated gene regulatory networks controlling beta cell mass 
expansion are likely to be conserved in human beta cells. 
To date, there are only a few existing mouse models of GDM. A heterozygous 
deletion of the Leptin receptor (Lepr
db/+
) causes extreme insulin resistance, and during 
pregnancy this results in maternal hyperglycemia (Yamashita et al., 2001).  A beta cell-
specific deletion of Hnf4 results in decreased beta cell proliferation, beta cell mass, 
pancreatic insulin content, and islet size resulting in impaired glucose tolerance (Gupta et 
al., 2007). The transcription factor Foxm1 functions downstream of PL signaling. A 
pancreatic deletion of Foxm1 results in decreased beta cell proliferation and beta cell 
mass in adult mice, and pregnant mutant mice have GDM by 15.5 days gestation, two-
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thirds of the way through gestation (Zhang et al., 2010). In addition, inhibition of 
serotonin synthesis, normally increased in response to PL signaling, results in decreased 
beta cell mass expansion and glucose intolerance during pregnancy (Kim et al., 2010). An 
additional mechanism for glucose homeostasis regulation and beta cell proliferation is at 
the epigenetic level. Menin1 (Men1) functions as part of a histone methyltransferase 
complex to promote tri-methylation of histone 3 lysine 4 (H3K4), thereby maintaining 
expression of cell cycle inhibitors p27 and p18. Men1 is normally downregulated in beta 
cells during pregnancy, and artificially maintained expression during pregnancy causes 
decreased beta cell proliferation and maternal hyperglycemia (Karnik et al., 2007). 
Recent work highlights two proteins of the Polycomb complex required for beta cell 
proliferation: Ezh2 and Bmi1 facilitate epigenetic modifications permitting beta cell 
proliferation during basal physiological conditions (Chen et al., 2009a; Dhawan et al., 
2009).  
Foxd3, a Forkhead transcriptional regulator, is critical for self-renewal of multiple 
progenitor cells (Labosky and Kaestner, 1998; Nelms et al., 2011; Teng et al., 2008; 
Tompers et al., 2005; Xu et al., 2009).  Foxd3 is expressed within the pancreatic 
primordium in two distinct cell populations: NC cells fated to innervate the pancreas 
(Plank et al., 2011b) and pancreatic beta cells (Perera et al., 2006). Pancreatic co-
expression of Foxd3 and insulin begins by 15.5 dpc, and in adults, Foxd3 is expressed in 
beta cells (Perera et al., 2006). This expression is also observed in human and rat islets, 
suggesting a conserved function among mammalian species (Perera et al., 2006; White et 
al., 2008). Because Foxd3 is required for embryonic stem (ES) cell and NC progenitor 
cell self-renewal (Liu and Labosky, 2008; Mundell and Labosky, 2011; Nelms et al., 
68 
 
2011; Teng et al., 2008), and beta cell mass expansion is primarily accomplished through 
self-renewal of existing beta cells (Dor et al., 2004; Dor and Melton, 2008; Teta et al., 
2007), we hypothesized that Foxd3 is required for beta cell self-renewal, and by 
extension, beta cell mass expansion during pregnancy. Using a Pdx1-Cre transgenic 
mouse, we deleted Foxd3 within the Pdx1-Cre expression domain, including the pancreas 
(Wicksteed et al., 2010). While these mice are unaffected under normal conditions, they 
suffer from glucose intolerance during pregnancy. In the absence of Foxd3 in the Pdx1 
expression domain Foxm1, Ezh2, Skp2, Akt2, and Cdkn1a are misregulated and the mice 
suffer from pregnancy-associated defects in beta cell proliferation, beta cell mass, and 
hyperglycemia.  
 
Materials and Methods 
Mouse lines: Mice with a Foxd3 null allele, Foxd3
tm2.Lby
 (called Foxd3
- 
throughout), and a 
conditional Foxd3 allele, Foxd3
tm3.Lby
 (called Foxd3
fl
 throughout), were bred to mice 
carrying a Pdx1-Cre transgene (Tg (Ipf1-cre) 1Tuv) to generate mice lacking Foxd3 
expression in the Pdx1-Cre expression domain (Foxd3
fl/-
; Pdx1-Cre) and littermate 
controls (Foxd3
fl/+
). The Foxd3
-
 allele was used to minimize the number of 
recombination events mediated by Cre recombinase and allow direct comparisons 
between animals. These mouse lines and genotyping were previously described (Hanna et 
al., 2002; Hingorani et al., 2003; Teng et al., 2008). For timed matings, females were 
checked daily for presence of a vaginal plug; noon on the day of an observed plug was 
considered 0.5 days gestation. Mice were housed on ALPHA-Dri bedding (Shepherd 
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Specialty Papers) and fed Laboratory Rodent Diet 5001 (Labdiet). All mouse lines were 
maintained on an outbred genetic background consisting primarily of CD-1 and 
C57BL/6NHsd and handled in accordance with AAALAC standards and protocols with 
approval from the Vanderbilt University Institutional Animal Care and Use Committee 
(IACUC).  
BrdU Incorporation and Immunohistochemistry: For BrdU incorporation analyses on 
pregnant mice, mice were injected with 50 mg 5-bromo-2-deoxyuridine (BrdU) per kg 
body weight at noon at 13.5 and 14.5 days gestation. Similarly, to analyze BrdU 
incorporation in postnatal day 14 mice, mice were injected with BrdU at 13 days of age. 
To assess BrdU incorporation in 8 week old mice, BrdU was placed in the drinking water 
(0.8 mg/mL) for 1 week and treated water replaced after 4 days to ensure BrdU activity. 
Pancreata were dissected and fixed overnight in 4 percent paraformaldehyde in phosphate 
buffered saline (PBS) and histological experiments performed using standard procedures 
(Tompers et al., 2005). For BrdU detection and betacell size analyses, 
immunohistochemistry was performed as described (Teta et al., 2007) with rat anti-BrdU 
(1:250, Accurate Chemical), guinea pig anti-insulin (1:500, Millipore), Cy2-donkey anti-
guinea pig (1:500, Jackson Immunoresearch), Cy3-donkey anti-rat (1:500, Jackson 
Immunoresearch), and Cy5-donkey anti guinea pig (1:500, Jackson Immunoresearch) 
antibodies. To detect Foxd3 protein, slides were incubated in citrate unmasking solution 
(Vector Laboratories) for 2 hours at high pressure. Antibody for Foxd3 was as described 
(Tompers et al., 2005) and detected with donkey anti-biotin secondary antibody (Jackson 
Immunoreserach) followed by Tyramide Signal Amplification (Invitrogen TSA Kit #22). 
Sections were counter-stained with 4', 6-diamidino-2-phenylindole (DAPI) (1:2000, 
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Sigma). For beta cell mass analyses, immunohistochemistry was performed using guinea 
pig anti-insulin (1:500, Millipore) and biotin-donkey anti-guinea pig (1:500, Jackson 
Immunoresearch) antibodies. The signal was amplified using RTU (Vector Laboratories) 
and 3’3 diaminobenzidine (DAB, Vector Laboratories). Sections were counterstained 
with Hematoxylin (Richard Allen Scientific). TUNEL analysis was completed with the In 
Situ Cell Death Kit (Roche).  
Quantitative Analyses and Imaging: For BrdU incorporation, islets from 5 sections 
evenly spaced throughout the pancreas (accounting for approximately 5 to 8 percent of 
total pancreatic mass) were imaged using a Zeiss AxioSkop2 Plus equipped with a Q 
Imaging Retiga 2000R camera. The total number of BrdU-positive beta cells was divided 
by the total number of beta cells. For beta cell mass, the pancreas was embedded in a 
manner to ensure equal representation of the dorsal and ventral pancreas. Five evenly 
spaced pancreatic sections (accounting for 5 to 8 percent of the total pancreatic mass) 
were imaged using an Ariol SL-50 imaging system. Insulin-positive area and total 
pancreatic area were determined using ImageJ software (National Institutes of Health) 
and beta cell mass determined by dividing total betacell-positive area by total pancreatic 
area multiplied by pancreatic wet weight. To determine beta cell size, every islet from 4 
evenly spaced sections (accounting for approximately 4 to 6 percent of total pancreatic 
mass) was imaged as above (Crawford et al., 2009). The total insulin-positive area from 
each section was calculated using Adobe Photoshop. The area was then divided by the 
total number of beta cells per section. At least 5,000 b cells per animal were counted. 
Gene Expression analyses by TaqMan Low Density Arrays and Quantitative Real Time 
PCR (qRT-PCR): Islets were isolated following standard procedures by the Vanderbilt 
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Islet Procurement and Isolation Core (Brissova et al., 2004). To assay Foxd3 and Skp2 
expression in the presence of placental lactogen (PL), islets were cultured in 50 ng/mL 
PL for 4 days (Zhang et al., 2010). Total RNA was collected with the RNeasy Mini Kit 
(Qiagen), contaminating DNA removed with Turbo DNase (Ambion) and cDNA 
generated from 400 ng total RNA using the High Capacity cDNA Reverse Transcription 
kit (Applied Biosystems); genes included in this array are shown in Table 3.1. 100 ng of 
cDNA was prepared for analysis using TaqMan Universal PCR Master Mix (Applied 
Biosystems) and analyzed on a custom TaqMan Low Density Array (Applied 
Biosystems). The sequences for the primers and probes were previously published (Gu et 
al., 2011). The relative amount of RNA was determined with 18S rRNA as a reference. 
For qRT-PCR, 4 ng of cDNA per sample was prepared with Power SYBR Green PCR 
Master Mix (Applied Biosystems). All samples were run in duplicate, and the relative 
amount of RNA was determined by comparison to Hypoxanthine guanine phosphoribosyl 
transferase (Hprt) mRNA. The following primer sequences were used:  
Foxd3:5’GTCCGCTGGGAATAACTTTCCGTA3’and 5’ATGTACAAAGAATGTCCCTCCCACCC3’  
Skp2: 5’AGCCGAGGTGAATGAGAGTT3’ and 5’AGCATGAATGCTCCACAAAG3’ 
HPRT:5’TACGAGGAGTCCTGTTGAATGTTGC3’and 5’GGGACGCAGCAACTGACATTTCTA3’. 
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Table 3.1: Genes assayed by TaqMan Low Density Array. Relative mRNA levels of the 
listed genes were assayed using a TaqMan Low Density array. Genes were clustered into 
groups based on the function of the produced protein. Note, some genes were included in 
multiple categories.  
Insulin signaling Cell Cycle Beta Cell Function Pancreas 
Development 
Akt1 Akt1 Foxo1 Arx 
Akt2 Akt2 Gjd2 Foxa2 
Foxo1 Bmi1 Glut2 Gcg 
Irs2 Ccnd2 Ins1 Hnf4a 
Prkca Cdc25a Ins2 Isl1 
Pten Cdk4 MafA MafA 
Rictor Cdkn1a Nkx2.2 MafB 
Sgk1 Cdkn1b Pdx1 Neurog3 
 Cdkn2a Snap25 Nkx2.2 
 Cdkn2b Stx1 Nkx6.1 
 Cdkn2c Stxbp1 Pax6 
 Ezh2 Vamp2 Pdx1 
 Foxm1  Ptf1a 
 Men1   
 Prdm16   
 Pten   
 Rictor   
 Skp2   
 
 
Intraperitoneal Glucose Tolerance Testing (IPGTT): Following a 16-hour fast, mice were 
subjected to an intraperitoneal injection of 2 mg dextrose per gram body weight. Glucose 
measurements were obtained with blood samples from the tail vein using a glucometer 
(FreeStyle) prior to injection and at 15, 30, 60, 90, and 120 minutes post injection.  
Serum Insulin Assays: Blood samples obtained from the saphenous vein were collected in 
a Microvette CB 300 (Fisher Scientific) capillary tube prior to injection of dextrose, as 
above, and 15 and 30 minutes post-injection. Serum insulin content was measured using 
Insulin Ultra-Sensitive ELISA (Alpco Diagnostics). All samples were run in duplicate. 
Islet Perifusions: Islet perifusions were performed as described using 16.7 mM glucose 
and 20 mM KCl in 5.6 mM glucose as stimuli (Tweedie et al., 2006). Insulin was 
extracted from perifusates in acid alcohol for 48 hours and insulin levels measured using 
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radioimmunoassays performed by the Vanderbilt Hormone Assay and Analytical 
Services Core. The total amount of insulin was normalized to 100 islet equivalents (IEQ) 
to standardize the data for comparison.  
Statistical Significance: Two-tailed Student’s t-tests were used to determine statistical 
significance for each assay except IPGTTs. In the case of IPGTTs, statistical significance 
was determined using “repeated measures ANOVAs with Bonferoni post-hoc tests”.  
 
Foxd3 is not required to maintain euglycemia under basal physiological conditions 
To analyze the function of Foxd3 in beta cells, we used a Pdx1-Cre transgene to 
generate mice lacking pancreatic Foxd3 (Foxd3
fl/-
; Pdx1-Cre) along with control 
(Foxd3
fl/+
) and heterozygous littermates (Foxd3
fl/- 
and Foxd3
fl/+
; Pdx1-Cre) (Hanna et al., 
2002; Hingorani et al., 2003; Teng et al., 2008), referred to as mutant, control, and 
heterozygote, respectively. We chose Pdx1-Cre to delete Foxd3 because Pdx1-Cre mice 
are euglycemic (Ackermann-Misfeldt et al., 2008; Morioka et al., 2007; Xie et al., 2010; 
Zhang et al., 2010). All Foxd3 expressing cells within the pancreatic endoderm are 
contained within the Pdx1 expression domain (Perera et al., 2006). Using quantitative 
real time PCR (qRT-PCR), we verified that Foxd3 mRNA was decreased approximately 
3-fold in mutant islets, confirming that Pdx1-Cre deleted the Foxd3 coding region  
(Figure 3.1A). It is important to note that Foxd3 is also expressed in NC derivatives that 
innervate the islets (Mundell and Labosky, 2011; Plank et al., 2011b; Teng et al., 2008), 
therefore, residual Foxd3 expression is likely due to expression within this lineage. 
Additionally, using immunofluorescence analysis of Foxd3 protein expression, we could   
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Figure 3.1: Validation of loss of Foxd3 and Foxd3 expression in pancreatic islets during 
pregnancy. A. qRT-PCR data showed that Foxd3 expression was decreased in mutant 
islets (white bars) using Pdx1-Cre (left graph). Foxd3 mRNA levels were decreased in 
islets isolated from 15.5 days gestation (D.G.) control (black bars) and mutant (white 
bars) mice compared to islets from control virgin mice (right graph). Foxd3 expression in 
virgin controls was arbitrarily set to 1. There was no statistical difference between the 
Foxd3 mRNA levels in virgin mutants compare to controls or mutants at 15 D.G. B-E. 
Immunohistochemistry for Foxd3 demonstrated that Foxd3 (red) was detected in the 
nuclei of insulin-expressing b cells (green) from control animals (B). B’ and C’ show the 
red channel alone. Foxd3 protein was not detected in b cell nuclei in mutant animals (C). 
Nuclear expression of Foxd3 is indicated by arrows (B’ inset) and non-specific 
cytoplasmic staining is indicated by arrowheads (C’ inset). Additionally, 
immunofluorescent analyses confirmed that Foxd3 is not expressed in beta cells during 
pregnancy. Foxd3 protein (red) was not detected in the nuclei of beta cells (insulin, 
green) in mutant (E and E’) or control animals (D and D’) at 15.5 D.G. F. Foxd3 
expression decreased while Skp2 expression increased in islets isolated from wild type 
females cultured with human PL (white bars). Foxd3 and Skp2 mRNA levels in islets 
cultured without PL was arbitrarily set to 1 (black bars).  n=3-4 mice in each group. Error 
bars indicate standard error of the mean (SEM). * p < 0.05, ** p < 0.01. Abbreviations: 
D.G., days gestation; PL, human placental lactogen. 
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not detect the protein in the nucleus of the islets from mutant mice (Figure 3.1C) 
compared to controls (Figure 3.1B). Because Pdx1-Cre is active in the hypothalamus 
(Honig et al., 2010; Song et al., 2010; Wicksteed et al., 2010), a region of the central 
nervous system critical for metabolic control, we analyzed Foxd3 mRNA expression in 
the hypothalamus of control animals using RT-PCR and determined that Foxd3 mRNA 
was not detectable in this region (Figure 3.2).  
 
 
Figure 3.2: Foxd3 expression was not detected in the hypothalamus. RT-PCR specific 
for Foxd3 mRNA indicated that Foxd3 was not expressed in the hypothalamus but was 
expressed in islets as expected. HPRT is a housekeeping gene that serves as a loading 
control. Note: 30 PCR cycles were needed to detect Foxd3 while 25 PCR cycles were 
used to detect HPRT. 
 
Additionally, Foxd3 expression in both forms of heterozygous mice (Foxd3
fl/-
 and 
Foxd3
fl/+
; Pdx1-Cre) is not statistically different than Foxd3
fl/+
 controls (Figure 3.3). The 
observation that Foxd3 expression in heterozygotes is similar to control mice is consistent 
with previous reports suggesting that Foxd3 functions as a transcriptional repressor 
(Steiner et al., 2006), and our data suggest the hypothesis that Foxd3 can autoregulate its 
own transcription.  
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Figure 3.3: Foxd3 is expressed at normal levels in heterozygous mice. Expression of 
Foxd3 in islets isolated from Foxd3
fl/-
 and Foxd3
fl/+
; Pdx1-Cre animals was similar to 
Foxd3 expression in Foxd3
fl/+
 controls. The expression in heterozygous animals was 
normalized to the expression in Foxd3
fl/+
 controls and this value was arbitrarily set to 1 
(red line). n=3 animals per group. 
 
To determine the requirement for Foxd3 in maintaining euglycemia under basal 
physiological conditions, we performed IPGTTs on 38-week (data not shown) and 52-
week old mice (Figure 3.4) fed a normal chow (5.1% fat/kcal). At both ages and for both 
genders, glucose clearance curves showed no significant differences between mutants, 
heterozygotes, and controls, suggesting that Foxd3 is not required to maintain glucose 
tolerance under normal physiological conditions.  
 
 
Figure 3.4: Aged mutant mice maintain glucose tolerance. IPGTTs on one-year old mice 
indicate mutant mice () had glucose tolerance curves similar to control littermates (). 
n= 7-10 mice in each group. Error bars indicate SEM. 
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Differential expression of Foxd3 during pregnancy 
Because Foxd3 is required for proliferation and/or self-renewal of other cell 
lineages (Hanna et al., 2002; Liu and Labosky, 2008; Mundell and Labosky, 2011; Teng 
et al., 2008; Tompers et al., 2005) and it is expressed in adult beta cells (Perera et al., 
2006), we hypothesized that Foxd3 plays a similar role in beta cells.  To test this, we used 
pregnancy as a model because during pregnancy, murine beta cells self-renew to expand 
beta cell mass (Karnik et al., 2007; Parsons et al., 1992; Rieck and Kaestner, 2010; 
Sorenson and Brelje, 1997). To determine if Foxd3 is differentially regulated during 
pregnancy, we analyzed Foxd3 expression in islets from control and mutant females at 
15.5 days gestation and found that, surprisingly, Foxd3 mRNA levels were approximately 
5 fold downregulated in wild type females at 15.5 days gestation (Figure 3.1A). These 
levels were similar to the levels detected in the mutant tissue, suggesting an almost 
complete loss of Foxd3 transcription. Additionally, Foxd3 protein was not detected in the 
nucleus of beta cells from control or mutant mice during pregnancy (Figure 3.1D-E). 
These data indicate that Foxd3 is negatively regulated in response to pregnancy cues. 
During pregnancy, PL, growth hormone, and prolactin are upregulated and stimulate beta 
cell mass expansion. Although prolactin and growth hormone regulate beta cell 
proliferation, the most potent stimulus for beta cell proliferation during pregnancy is PL 
(Nielsen et al., 2001; Parsons et al., 1992; Sorenson and Brelje, 1997). Therefore, to 
determine if Foxd3 expression decreases in response to placental lactogen (PL), we 
cultured islets isolated from wild type mice in the presence and absence of PL. To 
establish that our culture system worked as expected, we analyzed expression of Skp2 
after 4 days in culture. Skp2 is a target of Foxm1 that increases expression in response to 
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PL (Zhang et al., 2010). We found that Skp2 expression was increased, thereby validating 
this system (Figure 3.1F). At the same time, Foxd3 mRNA levels were decreased 
approximately 6.7 fold supporting the notion that PL is a potent regulator of Foxd3 
expression during pregnancy (Figure 3.1F). 
 
Requirement for Foxd3 to maintain euglycemia during pregnancy 
 To assess the ability of beta cells from mutant mice to meet the metabolic 
challenges of pregnancy, we analyzed pregnant females for their ability to clear glucose. 
To establish a baseline, IPGTTs on eight-week old virgin control and mutant mice 
demonstrated that, as expected, Foxd3 was not required to maintain glucose tolerance 
(Figure 3.5A). However, when the same mice were tested during pregnancy, mutants 
showed severe defects in glucose tolerance at 15.5 days gestation compared to controls, 
illustrated by both glucose tolerance curves and the calculated area under the curve 
(Figure 3.5 B and C). There were no defects observed in heterozygous mice at either 
stage (Figure 3.6 A and B).  
To determine if impaired glucose tolerance in mutant mice resulted from reduced 
levels of secreted insulin, we measured serum insulin levels during an IPGTT from both 
virgin and pregnant mice. As expected, mutant and control serum insulin levels were 
similar prior to pregnancy (Figure 3.7A), confirming that insulin production and secretion 
is not impaired in virgin Foxd3 mutant mice. However, during pregnancy, mutant mice 
had decreased serum insulin levels in response to a glucose stimulus (Figure 3.7B)  
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Figure 3.5: Glucose tolerance was impaired in Foxd3
flox/-
; Pdx1-Cre mice during 
pregnancy. A. IPGTTs demonstrated that 8 week old virgin Foxd3
flox/-
; Pdx1-Cre (, 
mutant) and Foxd3
flox/+ 
(, control) female mice exhibited normal glucose tolerance. B. 
IPGTTs on the same mice at 15.5 days gestation showed mutant mice had impaired 
glucose tolerance while controls did not. C. The area under the curve of mutant mice 
(white bars) at 15.5 days gestation was greater than pregnant control
 
(black bars) mice 
and virgin control and mutant mice. n= 10 mice in each group. Error bars indicate SEM. 
* p< 0.05, *** p< 0.001. Abbreviations: A.U.C., area under the curve; D.G., days 
gestation. 
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Figure 3.6: Foxd3 heterozygous animals are phenotypically indistinguishable from 
control littermates. A-B. IPGTTs on Foxd3
fl/-
 () and Foxd3fl/+; Pdx1-Cre () animals 
each carrying one intact Foxd3 locus in the pancreas demonstrated that mice 
heterozygous for Foxd3 were euglycemic prior to pregnancy (A) and at 15.5 days 
gestation (B). n=8-12 animals per group.  C. The b-cell mass in pregnant heterozygous 
females at 15.5 days gestation was not statistically different from Foxd3
fl/+
 controls at the 
same time (compared to 1.53 mg for controls as shown in Figure 3.8). n=3 animals in 
each group. Error bars indicate SEM.   
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Figure 3.7: Serum insulin levels were decreased in mutant mice at 15.5 days gestation. 
A. ELISAs using serum collected from mutant and control virgin mice demonstrated that 
virgin mutant mice (white bars) had serum insulin levels similar to control
 
mice (black 
bars). n=9-10 animals in each group. B. In contrast, mutant mice at 15.5 days gestation 
had reduced insulin serum levels 15 and 30 minutes after a glucose injection compared to 
controls. n= 9-10 animals in each group. Error bars indicate SEM. * p< 0.05, ** p< 0.01. 
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suggesting that Foxd3 is required to produce sufficient insulin levels to maintain glucose 
homeostasis in response to metabolic demand. 
 
Genes required for cell proliferation and beta cell function are misregulated in 
Foxd3 mutant mice 
 To understand where Foxd3 functions in the known molecular pathways 
regulating glucose homeostasis, and to characterize genes misexpressed in mutant mice, 
we used TaqMan Low Density Arrays to evaluate expression of 47 genes (Table 3.1) 
implicated in either beta cell mass expansion/proliferation, beta cell function,  insulin 
signaling and/or pancreas development (Figure 3.8). Several genes that regulate beta cell 
proliferation including Cdkn1a, Cdkn2a, Ezh2, Foxm1, and Skp2 were misregulated in 
virgin mutant animals compared to virgin controls. There was a slight, but statistically 
significant, reduction in Cdkn1b expression. Additionally, Ezh2 and Akt2 were also 
severely downregulated in pregnant mutants compared to pregnant controls while Skp2  
was upregulated in pregnant mutants. These data suggest impaired beta cell proliferation 
that will impact beta cell mass expansion. In addition to expression changes in genes 
regulating beta cell proliferation, several genes required for glucose stimulated insulin 
secretion were also misregulated. In virgin mutants, MafA, Foxa2, and Nkx2.2 mRNA 
levels were significantly repressed compared to virgin controls suggesting there may be 
defects in glucose stimulated insulin secretion in Foxd3 mutant animals. Interestingly, in 
the pregnant mutants both MafA and Foxa2 were upregulated while the mRNA encoding 
the SNARE protein Snap25 was significantly decreased.  Both Ins2 and Vamp2 were  
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Figure 3.8: Gene expression profiling in Foxd3 mutant and control pancreata. A. A 
TaqMan Low Density Array was used to analyze gene expression from mutant and 
control pancreata prior to and during pregnancy. The heat map illustrates relative changes 
in gene expression in mutant compared to controls at each stage (p < 0.10). Grey 
rectangles indicate no significant change in gene expression (p > 0.10). n=4 mice in each 
group. Abbreviations: D.G., days gestation; NC, no change. 
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slightly decreased in pregnant mutants compared to controls (less than 20 percent 
decrease in gene expression) but this change in expression is not likely to be biologically 
relevant. Lastly, a few genes required for pancreatic development were misregulated in 
the virgin Foxd3 mutant animals. Both Sox9 and Gcg were upregulated in the absence of 
Foxd3 although we did not detect changes in alpha cell mass (data not shown).  An 
increase in these Sox9 and Gcg genes may indicate the onset of an embryonic 
developmental program to compensate for defects in the adult mice. Although there was a 
slight reduction of Irs2 and Sgk1 (less than 20 percent change in gene expression) in 
pregnant mutant animals, the mRNA levels of these genes were very similar to those of 
controls suggesting there were no defects in insulin signaling in islets from mutant 
animals. Together these data suggest misregulation of genes known to control beta cell 
proliferation and beta cell function may account for glucose intolerance during pregnancy 
in Foxd3 mutant animals. 
 
Beta cell mass, proliferation, and size are decreased in mutant mice 
 Several of the misregulated genes (Ezh2, Foxm1, Skp2, and Akt2) are required for 
beta cell proliferation and beta cell mass expansion. Therefore, we quantified beta cell 
mass in 2 week and 8 week old virgin and 10 week old pregnant mice at 15.5 days 
gestation with and without the deletion of Foxd3. At 2 weeks of age, beta cell mass was 
similar in mutant and control mice. However, by 8 weeks of age beta cell mass in mutant 
mice was decreased 23 percent compared to controls (Figure 3.9A) although these mice 
were euglycemic (Figure 3.5A). Unsurprisingly, beta cell mass was decreased 30 percent 
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in pregnant mutant mice compared to control mice (Figure 3.9A). Predictably, beta cell 
mass was unchanged in heterozygous animals at 15.5 days gestation compared to controls 
(Figure 3.6C). These data demonstrate that, in agreement with previous studies, a 25 to 
30 percent decrease in beta cell mass can be tolerated under basal physiological 
conditions in virgin mice (Ackermann-Misfeldt et al., 2008; Peshavaria et al., 2006). 
However, our data indicate that, during pregnancy a 30 percent decrease in beta cell mass 
may contribute to impaired glucose tolerance. Consistent with decreased beta cell mass, 
we detected an increase in alpha to beta cell area at 15.5 days gestation (Figure 3.9B). 
This change in proportion between alpha to beta cell area during pregnancy may also 
contribute to the defects in glucose tolerance.  
Because we observed a defect in beta cell mass in 8 week old virgin and 10 week 
old pregnant mice, we assessed beta cell proliferation at these stages. Beta cells 
proliferate slowly in virgin mice at 8 weeks of age (reviewed in (Ackermann and 
Gannon, 2007)), therefore we measured BrdU incorporation for 1 week. The percent of 
beta cells that incorporated BrdU was similar between mutant and control mice (Figure 
3.9D). This result was surprising, because beta cell mass was decreased by 23 percent in 
mutant mice at 8 weeks of age (Figure 3.9A). To determine if there was a defect in 
betacell proliferation at earlier developmental stages, we assessed BrdU incorporation in 
younger mice (between 13 and 14 days) since beta cells proliferate more rapidly in 
neonatal rodents than adult rodents (Scaglia et al., 1997). At this time, BrdU 
incorporation in beta cells was similar between mutant and control animals (Figure 3.9C) 
supporting the notion that proliferation defects are not the fundamental cause of the 
slightly decreased beta cell mass in virgin mutants. During pregnancy, murine beta cells  
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Figure 3.9: Beta cell mass, beta cell proliferation, and beta cell size were decreased in 
mutant mice. A. The total beta cell mass was calculated and was similar between female 
mutant (white bars) and control (black bars) mice at 2 weeks of age. However, mutant 
mice had decreased beta cell mass compared to controls at both 8 weeks of age and 15.5 
days gestation. B. The alpha to beta cell area was calculated by measuring the total 
glucagon-positive area divided by the total insulin-positive area. In virgin animals, the 
alpha to beta cell area ratio was similar between controls and mutants. However, the 
alpha to beta cell area was increased in pregnant mutants compared to pregnant control 
littermates suggesting a deficiency in the beta cell mass. C-E. BrdU incorporation 
between postnatal days 13 and 14 (C), 7 and 8 weeks of age (D) and 13.5 and 15.5 days 
gestation (E) was calculated by quantifying the number of BrdU/Insulin double-positive 
cells. BrdU incorporation between postnatal days 13 and 14 and 7 and 8 weeks of age 
was unchanged. In contrast, during pregnancy, BrdU incorporation between 13.5 and 
15.5 days gestation was decreased approximately 2 fold in mutant mice compared to 
controls. n=3-4 animals per group. F. Beta cell size was calculated by measuring the 
insulin-positive area divided by the total number of beta cells from evenly spaced 
sections throughout the pancreas. In both virgin and pregnant females, beta cell size was 
decreased in mutant animals compared to control littermates. n=4-6 mice in each group. 
Error bars indicate SEM. * p<0.05. Abbreviations: D.G., days gestation.  
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proliferate to compensate for increased metabolic demand (Parsons et al., 1992; Sorenson 
and Brelje, 1997; Van Assche et al., 1978), and it is possible that different transcriptional 
networks and signals regulate this compensatory proliferation. Because beta cell 
proliferation during murine pregnancy peaks just prior to 15.5 days gestation (Karnik et 
al., 2007; Rieck and Kaestner, 2010; Zhang et al., 2010), we monitored BrdU 
incorporation between 13.5 and 15.5 days gestation. The percent of beta cells co-labeled 
with BrdU was approximately two-fold lower in mutants compared to controls (Figure 
3.9E and Figure 3.10A-B) indicating that although Foxd3 was not absolutely required for 
beta cell proliferation, during pregnancy fewer Foxd3 mutant beta cells proliferate 
compared with beta cells from control littermates. Another potential cause of decreased 
beta cell mass is increased beta cell apoptosis. To determine if Foxd3 is required for 
betacell survival, we analyzed apoptosis at 15.5 days gestation, and in all samples 
analyzed we were unable to detect any TUNEL-positive beta cells (Figure 3.10C-D).  
 Another factor affecting beta cell mass is the size of individual cells. To 
determine if decreased hypertrophy contributes to decreased beta cell mass in both virgin 
and pregnant mutants, we analyzed beta cell size by measuring the total insulin-positive 
area divided by the total number of betacells. We found that beta cell size was decreased 
in both virgin and pregnant mutants compared to control littermates (Figure 3.9F). This 
suggests that in virgin mutant mice, decreased hypertrophy contributed to decreased beta 
cell mass. However, in mutant mice, both decreased hypertrophy and proliferation 
combine to impact beta cell mass during pregnancy. Together with the results above, 
these data suggest that Foxd3 is required to maintain beta cell proliferation and size 
during pregnancy.   
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Figure 3.10: Foxd3 is required for beta cell proliferation but not beta cell survival. A-B. 
During pregnancy, fewer beta cells from mutant females (B) incorporate BrdU (red) 
compared to control littermates (A). Beta cells are indicated by insulin 
immunofluorescence (green). n = 4-6 mice in each group. Arrows indicate BrdU-positive 
b cells. Images were taken at 400x magnification. C-D. Using TUNEL assay together 
with insulin immunofluorescence, we were unable to detect TUNEL positive b cells in 
control (C) or mutant (D) mice. n= 4 animals in each group. Arrows indicate rare 
TUNEL-positive acinar cells. Images were taken at 200x magnification. 
 
  
91 
 
Foxd3 is not required to regulate glucose stimulated insulin secretion 
 Another physiological change caused by pregnancy is the response of beta cells to 
glucose. During pregnancy, beta cells become more sensitive to blood glucose levels and 
secrete more insulin when presented with lower glucose concentrations (Brelje et al., 
1993; Parsons et al., 1992; Sorenson and Brelje, 1997). Because several genes required 
for beta cell function (MafA, Snap25, Foxa2, and Nkx2.2) were misregulated in the 
absence of Foxd3, we analyzed glucose stimulated insulin secretion using islet perfusion 
assays at 15.5 days gestation. The amount of secreted insulin was similar between mutant 
and control animals using both high glucose (16.7 mM) and KCl (20 mM in 5.6 mM 
glucose) to elicit a response (Figure 3.11). This suggests that although genes required for 
glucose stimulated insulin secretion were misregulated in the mutant animals, Foxd3 
isnot required for enhanced glucose stimulated insulin secretion during pregnancy. These 
data further indicate that mutant beta cells function normally on a per cell basis and 
impaired glucose stimulated insulin secretion is not the underlying cause of glucose 
intolerance during pregnancy. Together, all of our data point to the conclusion that 
decreased beta cell mass in the absence of Foxd3 results in decreased serum insulin 
levels and glucose intolerance during pregnancy.  
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Figure 3.11:  Foxd3 is not required for glucose stimulated insulin secretion during 
pregnancy. Islet perifusion assays were used to analyze insulin secretion in response to 
various stimuli (low glucose, high glucose, and KCl) and insulin levels from perifusates 
was normalized to 100 islet equivalents. The normalized amount of secreted insulin was 
similar between mutants (and controls (). Note, all mice were at 15.5 D.G. 
Abbreviations: IEQs, islet equivalents; G 16.7, 16.7 mM glucose; G 5.6, 5.6 mM glucose; 
KCl 20, 20 mM KCl in 5.6 mM glucose. n= 2 animals per genotype. 
 
 
Discussion 
 Foxd3 is dramatically downregulated during pregnancy in response to PL, and 
loss of Foxd3 results in impaired glucose tolerance during pregnancy, suggesting an 
important role for this protein during this metabolically challenging process. Here we 
characterized the role of Foxd3 in maintaining glucose homeostasis and beta cell mass 
expansion during pregnancy. Although beta cell mass was normal at postnatal day 14, 
and mutant mice were euglycemic under basal physiological conditions, pregnant mutant 
females were glucose intolerant during pregnancy, had decreased beta cell mass due to 
decreased beta cell proliferation and beta cell size, and several genes required to regulate 
cell proliferation were misregulated. These data clearly show that a pancreas-specific 
deletion of Foxd3 is a novel mouse model of glucose intolerance during pregnancy.  
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The primary mechanism of beta cell mass expansion during normal homeostasis 
and pregnancy is beta cell proliferation, or self-renewal, of existing beta cells (Dor et al., 
2004; Dor and Melton, 2008; Teta et al., 2007). Beta cells from Foxd3 mutant mice 
showed decreased BrdU incorporation during pregnancy, indicating that loss of Foxd3 
functionally impacts beta cell self-renewal at a time when beta cells must rapidly 
replicate to compensate for metabolic demand. Because Foxd3 is expressed in embryonic 
insulin-producing cells and the mutant pancreas develops normally, Foxd3 must not 
control the cell cycle directly and must not regulate embryonic beta cell proliferation. 
This finding is not surprising because postnatal and embryonic beta cells utilize different 
molecular pathways to regulate proliferation (Georgia and Bhushan, 2004, 2006; Kushner 
et al., 2005; Rane et al., 1999; Zhang et al., 2006). In addition, our data raise the 
possibility that Foxd3 regulates a “replication refractory period” that normally prevents 
serial beta cell proliferation (Salpeter et al., 2010; Teta et al., 2007), and Foxd3 may 
repress genes necessary to shorten the replication refractory period and therefore decrease 
the proportion of proliferating beta cells.  
To identify the pathways through which Foxd3 function impacts beta cell 
proliferation, we analyzed gene expression differences between mutant and control 
pancreata and identified several misregulated genes required for cell proliferation. Foxm1 
transcription was decreased 2.3 fold in virgin Foxd3 mutants; Foxm1 is required for beta 
cell proliferation following a 60 percent partial pancreatectomy and during pregnancy as 
a downstream mediator of PL signaling (Ackermann-Misfeldt et al., 2008; Ackermann 
and Gannon, 2007; Zhang et al., 2006). Additionally, there is a large variation in beta cell 
size in Foxm1 mutant mice (Zhang et al., 2006), suggesting that decreased Foxm1 
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expression may be partially responsible for decreased beta cell size in Foxd3 mutant 
animals. Another downregulated transcript, Skp2, is a target of Foxm1 (Wang et al., 
2005), supporting the notion that the Foxm1 pathway was affected in Foxd3 mutants. The 
cyclin dependent kinase inhibitor Cdkn1a was drastically upregulated in islets isolated 
from mutant animals. Cdkn1a inhibits CDK4 activity causing cell cycle arrest at G1 
(Harper et al., 1993) and increased levels of Cdkn1a may restrict b cell proliferation in 
Foxd3 mutants. The enhancer of zeste homolog 2, Ezh2, was also downregulated in islets 
from both virgin and, importantly, pregnant mutant mice. This protein is a histone 
methyltransferase required to repress the Ink4a/Arf locus that in turn regulates Foxm1 
transcriptional activity and inhibits beta cell proliferation (Chen et al., 2009a; 
Kalinichenko et al., 2004). A beta cell-specific deletion of Ezh2 resulted in decreased 
beta cell proliferation and hyperglycemia (Chen et al., 2009a). Although its role in 
regulating beta cell proliferation during pregnancy has not been analyzed, it is likely that 
pregnant Ezh2 mutant mice will continue to have severe defects in glucose homeostasis. 
In addition to genes misregulated in virgin mutants, Akt2 was downregulated in pregnant 
Foxd3 mutants, and a compound mutation of Akt2 and Akt1 results in beta cell 
proliferation defects (Chen et al., 2009b). Because Ezh2 and Akt2 were downregulated in 
mutant mice during pregnancy, it is likely that they contribute to the proliferation defects 
observed during pregnancy. These data suggest that alteration of multiple parallel and 
interacting pathways in Foxd3 mutants decreases proliferation, and Foxd3 impacts 
several factors that together control beta cell proliferation, beta cell size, and beta cell 
mass expansion during pregnancy (model, Figure 3.12).   
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Figure 3.12: Model of Foxd3 function in the b cell. Foxd3 regulates several factors that 
control b cell proliferation including Foxm1, Skp2, Ezh2, Akt2 and Cdkn1a. Arrows do 
not imply direct interactions. 
 
Interestingly, Foxd3 mutant mice exhibit a physiological defect during pregnancy 
despite the observation that Foxd3 is no longer expressed in maternal islets by 15.5 days 
gestation. This suggests that Foxd3 is required prior to pregnancy to permit beta cell 
proliferation during gestation and does not agree with models in which Foxd3 acts as a 
direct activator of genes required for beta cell proliferation. In ES cells, Foxd3 is required 
to maintain multipotency by inhibiting differentiation (Liu and Labosky, 2008). At a 
mechanistic level, Foxd3 “poises” the silent Alb1 locus for transcription (Xu et al., 2009). 
Even though ES cells do not express Alb1, the locus is epigenetically modified in the 
pluripotent stem cells compared to primary fibroblasts that lack the potential to generate 
endoderm and express Alb1 (Xu et al., 2009). Similarly, Foxd3 represses transcription of 
the B cell specific Lambda5-PreB1 locus in ES cells, maintaining the locus in an inactive 
state despite active epigenetic marks. As cells differentiate toward a B cell fate, the 
Foxd3 mediated repression is relieved, concomitant with a different Forkhead protein 
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replacing Foxd3 at this binding site (Liber et al., 2010). A similar mechanism may occur 
in the pancreatic beta cell. Similar to the case of Alb1, Foxd3 may establish or maintain 
epigenetic mark(s) critical for upregulation of genes controlling beta cell proliferation 
when needed or, as in the VpreB1 locus, remain as the last barrier to active transcription 
so that when needed, downstream genes can be activated quickly. When beta cells are 
stimulated to proliferate during pregnancy, Foxd3 may then be replaced by another 
Forkhead family member (perhaps Foxa1, Foxa2 or Foxm1) to activate expression of 
target genes regulating beta cell proliferation. Foxa1 and Foxa2 are required for 
activation of Pdx1, and through Pdx1, they regulate pancreatic differentiation and growth 
(Gao et al., 2008) while Foxm1 regulates beta cell proliferation (Ackermann-Misfeldt et 
al., 2008; Zhang et al., 2006; Zhang et al., 2010). Therefore, it is feasible that this 
mechanism is conserved in beta cells and Foxd3 is required to “poise” target genes while 
other Forkhead transcription factors are required for direct activation of gene expression. 
Because Foxd3 was deleted from the pancreatic epithelium early in development prior to 
beta cell differentiation, target loci may never be “poised” and other Forkhead proteins 
may not have access to promote transcription of genes required for proliferation. 
Unfortunately, testing this model with the available reagents is not feasible. Ideally, to 
determine if Foxd3 is required to “poise” a locus for transcription, we would acutely 
ablate Foxd3 expression prior to pregnancy using a Tamoxifen-inducible Cre 
recombinase. However, we found that while both control and conditionally mutant 
female mice injected with Tamoxifen to activate Cre could mate, they were unable to 
become pregnant in a predictable manner (n = 9 females) even 6 weeks after the 
Tamoxifen injection. These findings are consistent with previously published data; rats 
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injected with Tamoxifen had smaller uteri and ovaries and their estrous cycles were 
arrested in diestrus (Kim et al., 2002; Orcheson et al., 1998; Tower et al., 2009). 
Therefore, this model awaits identification of direct targets of Foxd3, an active goal of 
our future work. 
In summary, we have shown here that Foxd3 is required to regulate glucose 
homeostasis, beta cell proliferation, and beta cell mass during pregnancy. We have 
identified genes implicated in cell proliferation that are misregulated in the absence of 
Foxd3, and these data suggest that identification of molecules such as Foxd3 that control 
beta cell proliferation could be extended and co-opted for therapeutic applications 
requiring precise control of in vivo or in vitro expansion of existing beta cells. 
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CHAPTER IV 
 
IDENTIFICATION OF FOXD3 TARGET GENES 
 
Genes misregulated in the absence of Foxd3 
Because Foxd3 is a critical regulator of stem cell properties in multiple lineages (Hanna 
et al., 2002; Liu and Labosky, 2008; Mundell et al., 2011; Mundell and Labosky, 2011; 
Teng et al., 2008; Tompers et al., 2005), Foxd3 target genes functioning directly 
downstream must regulate self-renewal, pluripotency, and/or survival of stem cells. I 
chose to attack this problem as a direct extension of my work in pancreatic beta cells 
because the discovery of genetic regulatory cascades controlling beta cell expansion is a 
key approach to unlocking this process for therapeutic applications. ES cells were used 
for initial identification of Foxd3 target genes because they are amenable to genetic 
manipulation and generating a large amount of biological material is relatively easy. 
Additionally, ES cells lacking Foxd3 have a distinct phenotype: 1) decreased capacity to 
self-renew, 2) decreased pluripotency, 3) increased apoptosis, and 4) maintained 
expression of stem cell proteins (Liu and Labosky, 2008).  In order to assay gene 
expression in the absence of Foxd3, I used ES cells expressing the ubiquitous CAAG-
Cre
ER
 transgene and carrying 2 Foxd3
flox
 alleles (Foxd
fl/fl
; CAAG-Cre
ER
). The entire 
Foxd3 coding sequence is excised when these ES cells are cultured with Tamoxifen (TM) 
added to the medium. In untreated ES cells (control), Foxd3 protein was readily detected 
(Figure 1.8). Following 12 hours of TM treatment (induced mutant), the level of Foxd3 
protein expression was decreased but not abolished. However, after 24 hours of TM 
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treatment, Foxd3 protein was rarely detected (Figure 1.8). Therefore, my experiments 
assessing the effects of the loss of Foxd3 were completed at 24, 48, or 72 hours post TM 
treatment. As an initial characterization of genes misregulated in the absence of Foxd3, 
we performed a microarray pilot study (n=1 hybridization of samples) using the 
Affymetrix Gene/Exon microarray to determine which genes were misregulated in the 
absence of Foxd3 after 24 hours of TM treatment. We parsed the results obtained from 
the microarray and selected genes that encode proteins with functions related to the 
regulation of stem cell properties or genes that produce proteins with an unknown 
function. Genes that were misregulated in the absence of Foxd3 and were chosen for 
future analysis are illustrated in Table 4.1. Using quantitative reverse transcription PCR 
(qRT-PCR) to verify expression, I demonstrated that 12 of the 34 genes identified in the 
preliminary microarray were significantly misregulated (p < 0.05) in ES cells in the 
absence of Foxd3 (Figure 4.1). 
 
 
Figure 4.1: Genes that are misregulated in the absence of Foxd3 after 24 hours of culture 
with TM (induced mutant). The bars representing expression levels are color-coded based 
on biological function. The fold change in ES cells cultured for 24 hours without TM 
(control) is set to 1. Error bars indicate SEM.  
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Table 4.1: Genes misregulated in the absence of Foxd3 in ES cells (Fold change > 1.5). 
The gene names, fold change in the cells lacking Foxd3 compared to controls, and a brief 
statement of biological function are included. 
Gene Name 
Fold 
Change 
Biological Information 
Otx1 1.99 Regulates cell fate (Bicoid family member) 
EG432649 1.9 Ubiquitin cycle/ligase activity 
Ube1y1 1.81 Ubiquitin-activating enzyme E1 
Tub 1.77 Tubby candidate gene 
Grhl3 1.73 Developmental transcription factor 
Hist1h2bb 1.68 Histone 2B gene 
Socs2 1.63 Regulates cell growth 
2410076i21Rik 1.62 Differentially expressed in ICM and ES cells 
4930463MO5Rik 1.61 Suppresses p53 (ortholog of Klf4b) 
5430411c19Rik 1.61 Expressed in obese and aged mice and human diabetic patients 
Ngfr 1.61 Nerve growth factor (p75)- marker of NC stem cells 
Clec2d 1.59 Natural killer cell receptor 
LOC668686 1.58 Similar in sequence to apoptosis regulatory protein (Siva1) 
E130309F12Rik 1.56 Regulates PRG3 (an apoptotic gene) 
Eras 1.55 Promotes proliferation and self-renewal in mouse ES cells 
Dub2a 1.54 Deubiquitinating enzyme 2a 
Nrg3 1.53 Regulates proliferation and differentiation of satellite cells 
Pmaip1 1.52 Promotes caspase expression and apoptosis 
Sox15 1.51 Regulates myogenesis and CTCF expression 
Fosb -2.21 Required for osteoblast differentiation 
Pi15 -2.13 Expressed in CNS 
Safb -1.89 Ubiquitously expressed nuclear matrix protein 
Tac1 -1.87 Neurotransmitter 
LOC345350 -1.84 Similar to Ubiquitin-conjugated enzyme, E2Q 
LOC674405 -1.78 Binds DNA and heterochromatin 
Evc2 -1.68 Unknown function 
Sox4 -1.65 Cardiac outflow tract development 
CDC2L1 -1.64 Regulates cell cycle 
Fibin -1.64 Secreted from lateral plate mesoderm 
CLIP2 -1.62 Deleted in Williams Syndrome 
Hirip3 -1.59 Associated with histones 
Bnc1 -1.55 Zinc finger protein; associated with colony formation 
Gap43 -1.52 Required for axonal regeneration 
Smarcd3 -1.51 Plays a role in neural stem cells and myogenesis 
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Direct targets of Foxd3 
Although the role of Foxd3 in regulating ES cell properties is well established, 
only a few Foxd3 target genes have been identified. To determine which of the 
misregulated genes are direct targets of Foxd3, we used a bioinformatics approach 
(rVista) to identify Foxd3 binding sites that are conserved between rodents and humans 
less than 20 kb upstream or downstream of the misregulated genes. Following the 
identification of putative Foxd3 binding sites, I used Chromatin Immunoprecipitation 
(ChIP) assays followed by quantitative PCR (qPCR) to amplify the putative binding sites 
and determine if Foxd3 occupied these regions in the genome. Using this assay, I 
determined that 6 of the 12 misregulated genes (Sox4, Safb, Sox15, Fosb, Pmaip1 and 
Smarcd3) are direct targets of Foxd3 (Figure 4.2, left). Additionally, 3 of these targets are 
conserved in human ES cells (SOX4, PMAIP1 and SMARCD3, Figure 4.2, right).  
 
 
Figure 4.2: Direct targets of Foxd3. Left- using ChIP assays, we show here that 6 of the 
12 misregulated genes are direct transcriptional targets of Foxd3 (Sox4, Safb, Sox15, 
Fosb, Pmaip1, Smarcd3). An intergenic enhancer at the lambda5-VpreB (Vpreb) locus 
serves as a positive control (Liber et al., 2010). Cells lacking Foxd3 (induced mutant, red 
bars) and the HPRT coding sequence were negative controls. Right- 3 of the 6 targets 
identified in mESCs (PMAIP1, SMARCD3, SOX4) are conserved in hESCs. Human 
chromatin from Steve Dalton, UGa, hESC Core Laboratory. The negative control for 
these experiments is the FOXD3 coding region. 
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We hypothesize that all 6 identified targets of Foxd3 regulate ES cell properties, 
and a brief summary of the function of each protein is included below. The transcription 
factor Sox4 is required for cardiac outflow tract development, derived from the NC 
(Maschhoff et al., 2003; Schilham et al., 1996; Ya et al., 1998). Additionally, in 
developing B cells, Sox4 co-occupies a site in an intergenic enhancer of the lambda5-
preB locus with Foxp1 and transcription of the surrounding genes (Lambda5 and PreB) is 
required for B cell differentiation. Prior to occupancy of Foxp1 and Sox4, Foxd3 and 
Sox2 bind this region to “poise” the locus for transcription (Liber et al., 2010). The 
transcription factor FBJ osteosarcoma oncogene B (Fosb) promotes osteoblast 
differentiation while inhibiting adipogenesis (Sabatakos et al., 2000). The transcriptional 
modulator Sox15 regulates skeletal muscle differentiation in multiple progenitor cell 
lineages (Beranger et al., 2000; Lee et al., 2004; Savage et al., 2009). Smarcd3 (also 
called Baf60c), a member of the Swi/Snf chromatin remodeling complex, associates with 
MyoD to promote transcription of genes required for myogenesis (Forcales et al., 2011; 
Ochi et al., 2008). While all 4 factors have been implicated in regulating differentiation 
of disparate lineages, no one has carefully investigated the role of these proteins in 
maintaining ES cell properties, and I hypothesize that Sox4, Fosb, and Sox15 are critical 
regulators of pluripotency in ES cells. 
In addition to genes that regulate pluripotency, two Foxd3 targets may regulate 
self-renewal of ES cells. The protein Smarcd3 is a component of a Swi/Snf complex in 
neural stem cells and is required to regulate self-renewal in this cell lineage (Lamba et al., 
2008). While Smarcd3 mRNA can be detected in ES cells (Figure 4.1), to date, no one 
has analyzed a role for this protein in regulating self-renewal of ES cells. In addition, the 
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nuclear scaffolding protein, Safb, is ubiquitously expressed, but a clear role for its 
function has yet to be determined. Some groups suggest that Safb may regulate the cell 
cycle consistent with the possibility that Safb may be required for ES cell proliferation 
and/or self-renewal (Debril et al., 2005; Huerta et al., 2007; Tapia et al., 2009).  These 
findings suggest that these targets of Foxd3 may regulate self-renewal in ES cells. 
Lastly, targets of Foxd3 are also required to prevent aberrant apoptosis. Safb 
indirectly represses apoptotic genes in breast cancer cells (Chan et al., 2007; Lee et al., 
2007). Therefore, decreased Safb expression in ES cells (Figure 4.1) may lead to an 
increase in apoptosis. Finally, Pmaip1 is a direct target of Foxd3 and is a critical regulator 
of cell death. Pmaip1 (also called Noxa) is required for the activation of caspases and 
contributes to p53-dependent apoptosis (Li et al., 2006; Oda et al., 2000; Yakovlev et al., 
2004). Altogether, these data from our laboratory and others suggests that Foxd3 
functions upstream of critical regulators of stem cell property. Prior to this work, only a 
few direct targets of Foxd3 were identified. This work uncovered several factors that 
function downstream of Foxd3 and further characterization of these target genes will 
further elucidate gene regulatory networks controlling ES cell properties.   
In addition to this candidate gene approach, members of the laboratory are taking 
an unbiased approach to determine all the loci occupied by Foxd3 in ES cells; we have 
generated an ES cell line carrying a Flag-tagged allele of Foxd3 in the endogenous Foxd3 
locus (Michael Suflita, unpublished data). While the commercially available antibody 
works well for ChIP assays, ChIP-Seq applications required a robust signal. Therefore, 
these ES cells, and mice generated from these cell lines, will be used in ChIP-Seq 
experiments in collaboration with Dr. Klaus Kaestner at the University of Pennsylvania 
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to determine all Foxd3 target genes in ES cells, pancreatic beta cells, and NC progenitors 
allowing us to determine whether Foxd3 target genes are conserved among disparate cell 
lineages. Once additional targets are identified, their expression will be manipulated to 
further identify pathways and potential nodal points to manipulate cell fate specification 
and beta cell mass expansion.   
 The mechanism of action of Foxd3 is unresolved; there are several findings 
suggesting that Foxd3 functions as a transcription repressor, while others suggest that 
Foxd3 functions as an activator (Lee et al., 2006; Pan et al., 2006; Steiner et al., 2006; 
Thomas and Erickson, 2009). While it is possible that Foxd3 can function as either an 
activator or a repressor in different cellular contexts, the strongest evidence demonstrates 
that Foxd3 functions as a transcriptional repressor in mesoderm induction in Xenopus 
(Steiner et al., 2006; Yaklichkin et al., 2007), therefore, I chose to focus on analyzing 
Foxd3 targets that were upregulated in the absence of Foxd3, indicating that Foxd3 
normally represses their transcription. Messenger RNA encoding the transcription factor 
Sox15 is upregulated approximately 2 fold in the absence of Foxd3 (Figure 4.1). This 
increase in Sox15 mRNA levels persists for at least 72 hours in culture with TM added 
(Figure 4.3, left).  
Additionally, using an embryoid body (EB) assay to analyze gene expression in 
differentiated cells, I demonstrated that Sox15 mRNA levels quickly decrease upon 
differentiation (Figure 4.3, right, red line). These data are in agreement with published 
work demonstrating that Sox15 is expressed in ES cells but not in differentiated cell 
lineages (Maruyama et al., 2005). Consistent with increased Sox15 mRNA levels in the 
absence of Foxd3 in ES cells, Sox15 mRNA levels persist in the EBs lacking Foxd3 
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(Figure 4.3B, blue line). Together, these data indicate that Sox15 expression decreases 
upon differentiation and is consistent with the hypothesis that Foxd3 represses Sox15 
transcription directly.  
 
 
Figure 4.3: Left- qRT-PCR analysis of relative expression of Sox15 in ES cells cultured 
with and without TM for the indicated amount of time. Sox15 expression in induced 
mutant ES cells was increased at all 3 time points compared to untreated controls. The 
red line indicates relative expression in untreated (control) ES cells. Right- expression of 
Sox15 in untreated (control) and TM treated (induced mutant) EBs determined by qRT-
PCR compared to untreated ES cells at Day 0 (D0). In control EBs (red line), Sox15 
expression decreases upon differentiation and is barely detectable by 3 days in culture. 
Alternatively, Sox15 expression persists in induced mutant EBs (blue line) and does not 
decrease until after 3 days in culture. Error bars indicate SEM. ** p<0.01, *** p<0.001.  
 
To ensure that increased Sox15 mRNA levels were due to an increase in 
transcription, I used ChIP to analyze phosphorylated-Ser5 RNA PolymeraseII (p5PolII) 
occupancy at the transcription start site of Foxd3 target genes. The Ser5 residue of PolII 
is only phosphorylated when transcription is initiated; therefore, an increase in p5PolII 
occupancy suggests an increase in transcription while a decrease in p5PolII occupancy 
suggests decreased transcription (Rahl et al., 2010). As expected, there was an increase of 
p5PolII at the proximal promoter of Sox15 in mutant ES cells compared to controls. 
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Alternatively, there was a decrease of p5PolII at the proximal promoter of Sox4, a gene 
with decreased expression in the absence of Foxd3 (Figure 4.1). The distal promoter of 
Albumin1 (Alb1) served as a negative control because this region of the genome is not 
transcribed and PolII is not recruited to that site (Figure 4.4). These data are consistent 
with the hypothesis that Foxd3 represses Sox15 transcription in ES cells. 
 
 
Figure 4.4: ChIP assays were used to determine p5PolII occupancy at the proximal 
promoter of genes misregulated induced mutant ES cells. The data represent the ratio of 
PolII occupancy in mutant ES cells compared to controls. The red line indicates PolII 
occupancy in controls. Error bars indicate SEM. 
 
Manipulating expression of Foxd3 target genes 
The significance of this work stems from the identification of novel regulators of 
self-renewal, pluripotency, and/or survival of ES cells. Because Sox15 is a direct target of 
Foxd3, and Sox15 is a critical regulator of skeletal muscle differentiation in vitro 
(Beranger et al., 2000; Lee et al., 2004; Savage et al., 2009), I sought to first characterize 
the effects of loss of Foxd3 on genes that function downstream of Sox15 and are required 
to regulate skeletal muscle development. Skeletal muscle is derived from paraxial 
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mesoderm and requires the myogenic bHLH transcription factors, MyoD and Myf5 
(Figure 4.5). Following determination to the skeletal muscle lineage, myoblast progenitor 
cells divide, align, and fuse to generate multinucleated myotubes , resulting in mature 
muscle fibers that also contain muscle stem cells (Figure 4.5). A putative stem cell 
population, the satellite cells, is capable of proliferating to generate new myoblasts that 
fuse with mature muscle fibers, and production of myoblasts from satellite cells requires 
the function of Myf5 (Kuang et al., 2007).  
 
 
Figure 4.5: Schematic of myogenesis in culture. Image from “Developmental Biology” 
Ninth Edition by Scott Gilbert (Gilbert, 2010). 
 
The transcription factors Pax3 and Sox15 function upstream of Myf5 and MyoD 
(Beranger et al., 2000; Lee et al., 2004; Savage et al., 2009). Sox15 null animals cannot 
regenerate skeletal muscle following injury, while overexpression of Sox15 results in 
increased Pax3 expression, decreased Myf5 expression, and an expansion of immature 
myoblasts (Maruyama et al., 2005; Savage et al., 2009). Because Sox15 is upregulated in 
Foxd3 induced mutant ES cells and Sox15 inhibits myogenesis, I hypothesized that 
Foxd3 induced mutant ES cells cannot be directed to produce mature muscle. To 
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determine if genes functioning downstream of Sox15 are misregulated in the absence of 
Foxd3, I assayed mRNA levels of myogenic genes using qRT-PCR. As expected, Myf5 
expression decreased while Pax3 expression increased (Figure 4.6), suggesting that 
Foxd3 functions upstream of Sox15 to regulate myogenesis. These data, together with 
previous work in the lab (Liu and Labosky, 2008), suggest that Foxd3 induced mutant ES 
cells precociously express genes required for mesoderm induction but cannot differentiate 
into skeletal muscle. This hypothesis will be directly tested using differentiation 
paradigms. 
 
 
Figure 4.6:  qRT-PCR data demonstrating the relative expression of Foxd3, Myf5, and 
Pax3 mRNA in Foxd3 induced mutant ES cells cultured for 24, 48, and 72 hours. Myf5 
expression is decreased while Pax3 expression is increased. Red line indicates expression 
of these mRNAs in control ESCs with no TM treatment. Error bars indicate SEM.  * p < 
0.05, *** p < 0.001 
 
Together, these data are consistent with the model in Figure 4.7 in which Foxd3 
represses Sox15 transcription resulting in increased Pax3 and decreased Myf5. An 
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increase in Pax3 expression in the skeletal muscle progenitors results in an increase self-
renewal and decreased differentiation, limiting the number of mature skeletal muscle 
fibers (Epstein et al., 1995; Young and Wagers, 2010). Additionally, decreased Myf5 
results in decreased generation of skeletal muscle.  
To determine if Foxd3 target genes regulate stem cell properties, induced cassette 
exchange (ICE) will be used to easily manipulate gene expression (Iacovino et al., 2011a; 
Iacovino et al., 2011b). Using ICE, Foxd3 target genes will be overexpressed in a 
Doxycycline inducible manner (Figure B.3). Using this method, I generated 12 ES cell 
lines to overexpress Sox15 (6 lines contain Sox15-Myc and 6 lines contain Sox15-HA). 
 
 
Figure 4.7: Model of Foxd3 and Sox15 in ES cells in the process of skeletal muscle 
differentiation. In a control progenitor cell (left), Foxd3 represses Sox15 allowing precise 
regulation of Pax3 and Myf5 and proper skeletal muscle development. In the absence of 
Foxd3 (right), Sox15 is upregulated resulting in an increase in Pax3 and a decrease in 
Myf5 expression. Based on data available in the literature, I hypothesize that these 
changes in gene expression will result in an increase in skeletal muscle progenitors but an 
inability to generate skeletal muscle from ES cells lacking Foxd3. 
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While the specific concentration of Doxycycline to induce overexpression of Sox15 has 
not been determined, I have confirmed that the cell lines do, in fact, express high levels 
of Sox15 mRNA. Doxycycline will need to be titrated in order for the cells to express the 
appropriate amount of Sox15. Using these cells, we will determine if overexpression of 
Sox15 inhibits self-renewal, survival, and/or skeletal muscle differentiation in vitro. In an 
extension of this approach, expression levels of Foxd3 target genes can be reduced using 
this method with miR30 sequences flanking shRNAs to the genes of interest to ensure the 
shRNAs are transcribed with RNA Polymerase II (Wang et al., 2006). Using the newly 
generated ES cells lines, self-renewal, potency, and survival will be analyzed to 
determine how Foxd3 target genes regulate properties of ES cells. These data will further 
uncover components of gene regulatory networks required to maintain stem cell 
properties. 
In summary, the future directions proposed here take advantage of manipulating 
Foxd3 expression to uncover components of gene regulatory networks controlling stem 
cell properties. Identification of factors that restrain self-renewal and/or factors that 
regulate differentiation to a desired cell lineage will be paramount in generating cell-
based therapies from pluripotent stem cells or adult stem cells. Additionally, the 
experiments proposed here can be extended to beta cell biology. Targets of Foxd3 in the 
beta cell and the NC will be identified in Foxd3 ChIP-Seq experiments from isolated 
islets (proposed in Chapter 5). These targets can be manipulated in ES cells using ICE 
and then ES cells differentiated into the beta cell lineage to determine precisely how 
Foxd3 targets regulate beta cell development and/or beta cell mass expansion. The factors 
identified in these studies can be applied to the generation of beta cells to treat diabetic 
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patients. For example, identification of factors misregulated in the beta cell in the absence 
of NC may identify pathways that can be manipulated to facilitate beta cell maturation in 
directed differentiation protocols. Overall, the data presented and future experiments 
building off my thesis work can affect multiple aspects of stem cell biology and 
regenerative medicine. 
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CHAPTER V 
 
FUTURE DIRECTIONS 
 
Beta cell development in a model of reduced innervation 
Using Wnt1-Cre to delete Foxd3 results in a system where all NC derivatives are 
absent from the ENS providing an ideal model to study the requirement for NC 
derivatives on beta cell development. However, this genetic ablation model cannot be 
used to determine if a reduced number of NC derivatives also effects beta cell 
development, a much more likely in vivo scenario. Using the novel Endothelin receptor 
type B (Ednrb)-iCre transgenic line to delete Foxd3 results in a more restricted loss of 
Foxd3 limited to the vagal NC that gives rise to the ENS. These mutant mice are overtly 
normal but suffer from alteration in patterning the ENS with an overall reduction of 
enteric neurons (Figure 5.1 (Mundell et al., 2011)). To determine if this reduction of NC 
derivatives affects beta cell development, beta cell proliferation and maturation can be 
analyzed in control (Foxd3
fl/+
; Ednrb-iCre) and mutant (Foxd3
fl/-
; Ednrb-iCre) embryos.  
 
 
Figure 5.1: Ednrb-iCre induced Foxd3 mutation. Mutant (Foxd3
fl/-
; Ednrb-iCre) embryos 
have fewer NC derivatives in the ENS than control (Foxd3
fl/+
; Ednrb-iCre) embryos. 
Distal colons from mutant embryos at 15.5 dpc (right) have fewer neurons (Pgp9.5, red) 
and glia (Sox10, green) than control litter mates (left). Nuclei are highlighted with DAPI 
(blue). 
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If a critical mass of NC derivatives is required to restrain beta cell proliferation and 
promote beta cell maturation and this mass is not met in Ednrb-iCre induced mutants, 
these mice would likely have increased insulin-positive area and decreased beta cell 
maturation. If the results from mutant embryos are indistinguishable from controls, the 
amount of NC derivatives in pancreata from mutant embryos is sufficient for proper beta 
cell development. Additionally, these mutant mice are viable; therefore, if beta cell 
development is impaired, physiological experiments can be conducted on adult animals to 
determine if reduction in beta cell maturation is detrimental to normal glucose 
homeostasis. 
 
Identification of pathways regulated by NC derivatives 
To determine which beta cell genes are misregulated in the absence of NC 
derivatives, the mouse Insulin-1 (Ins1) promoter driven GFP allele (Tg(Ins1-
EGFP)Hara1, called MIP-EGFP (Hara et al., 2003)) can be bred with our mice to 
generate Foxd3
fl/+
; Wnt1-Cre, MIP-EGFP (control) and Foxd3
fl/-
; Wnt1-Cre, MIP-EGFP 
(mutant) embryos. The pancreata will be dissected and the EGFP-expressing beta cells 
isolated using flow cytometry (Hara et al., 2003). Once the control and mutant beta cells 
are isolated, RNA will be extracted and gene expression analyzed by high throughput 
analysis such as RNA Tag Profiling (Illumina). The results can be analyzed using 
DAVID Bioinformatics Database (david.abcc.ncifcrf.gov) to identify enriched biological 
themes (Gene Ontology terms) and pathways that are misregulated in the absence of NC 
derivatives (Huang da et al., 2009). Once misregulated pathways are identified, they can 
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be manipulated using pharmacological inhibitors to analyze functions of specific 
pathways in regulating beta cell proliferation and maturation during embryogenesis. 
These data could then be applied to improve cell culture paradigms for generating 
glucose responsive beta cells in vitro.   
 Pathways could also be queried using a candidate approach. One pathway of 
particular interest is extracellular regulated kinase (ERK) signaling. In beta cells, the 
ERK pathway is required for proliferation (Gupta et al., 2007). Additionally, hepatic 
activation of the ERK pathway results in increased beta cell proliferation through a 
neuronal relay suggesting a non-cell autonomous requirement for ERK in cells 
innervating the pancreas (Imai et al., 2008; Imai et al., 2009). To determine if ERK 
signaling is misregulated in the absence of NC derivatives, pancreata from various stages 
of development will be dissected and the beta cells isolated using flow cytometry (see 
above). Western blots can be used to assay the presence and relative concentration of 
phosphorylated ERK which is indicative of active ERK signaling. In the absence of NC 
and increased beta cell proliferation, ERK signaling should also be increased. 
Our work has identified a novel role for NC in regulating beta cell mass 
expansion and maturation. The future directions proposed here will provide more detailed 
information about the requirement for NC derivatives on beta cell mass and function. 
Additionally, the proposed experiments provide an ideal system to identify novel factors 
controlling beta cell proliferation and/or beta cell maturation. 
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PDGF signaling 
PDGF signaling is a critical regulator of beta cell proliferation in both humans 
and rodents (Chen et al., 2011). It is tempting to speculate that Foxd3 may also be altered 
in response to PDGF signaling. To test this hypothesis, the expression of Foxd3 can be 
analyzed in islets cultured with PDGF-AA ligand and in islets isolated from PDGFRalpha 
knockout mice. If PDGF signaling regulates Foxd3 expression, Foxd3 mRNA levels 
should be altered when PDGF signaling is ablated (PDGFRalpha knockout mice 
compared to controls) or when PDGR signaling is activated (islets culture with or without 
PDGF-AA ligand). The results of these experiments may identify the PDGF pathway as a 
novel regulator of Foxd3 expression. Additionally, both PDGF signaling and Foxd3 are 
critical for maintenance of the NC lineage (Mundell and Labosky, 2011; Smith and 
Tallquist, 2010; Teng et al., 2008). These experiments may elucidate a genetic interaction 
between PDGF signaling and Foxd3 that is conserved in multiple cell lineages. 
 In both humans and rodents, PDGF is upstream of Ezh2 transcription and Ezh2 is 
misregulated in the absence of Foxd3 in the beta cell. Therefore, Foxd3 may also function 
to regulate transcriptional targets of PDGF signaling. It is important to note that PDGF 
signaling is not the sole regulator of Ezh2 expression within the beta cell and Foxd3 may 
be acting in a pathway independent of PDGF. To determine if Foxd3 is functioning 
independently of PDGF, islets isolated from pancreas-specific Foxd3 mutant animals and 
control littermates can be cultured with and without inhibitors of PDGF signaling such as 
Sunitinib or U0126 (Peppel et al., 2005; Roskoski, 2007). If Foxd3 functions downstream 
of PDGF signaling, the expression levels of Ezh2 mRNA should be similar in the 
following groups: control treated, mutant untreated, and mutant treated. Additionally, 
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Ezh2 expression should be higher in islets isolated from control animals that were not 
treated with inhibitors. If Foxd3 functions independently of PDGF signaling, the 
expression levels of Ezh2 should be lower in islets isolated from Foxd3 mutant animals 
that were treated with inhibitors than untreated animals (Table 5.1). Together these data 
would allow us to conclude whether Foxd3 is a mediator of PDGF signaling. 
 
Table 5.1: Predicted expression of Ezh2 in islets from Foxd3 mutant mice cultured with 
or without PDGF inhibitor. The color intensity indicates predicted Ezh2 expression with 
dark blue indicating normal levels and lighter shades predicting lower levels of Ezh2. 
 Foxd3 functions downstream of PDGF 
Foxd3 does not function downstream of 
PDGF 
 Untreated Treated Untreated Treated 
Foxd3
fl/+
 (control) 
Normal Ezh2 
expression 
Decreased Ezh2 
expression 
compared to 
untreated controls 
Normal Ezh2 
expression 
Decreased Ezh2 
expression 
compared to 
untreated controls 
Foxd3
fl/-
; Pdx1-
Cre (mutant) 
Decreased Ezh2 
expression 
compared to 
untreated controls 
Ezh2 expression 
that is similar to 
treated controls 
and untreated 
mutants 
Decreased Ezh2 
expression 
compared to 
untreated controls 
Ezh2 expression 
that is less than 
treated controls 
and untreated 
mutants 
 
 
Requirement for Foxd3 in obese animals 
Beta cells in obese animals must expand to combat insulin resistance. Several 
factors required for beta cell mass expansion during pregnancy are also required for beta 
cell mass expansion in the obese state including, but not limited to, Foxm1, Skp2 and 
ERK signaling (Davis et al., 2010; Gupta et al., 2007; Imai et al., 2008; Imai et al., 2009; 
Zhong et al., 2007). Because Foxm1 and Skp2 function downstream of Foxd3, it is likely 
that Foxd3 will also play a role in beta cell mass expansion in rodents fed a high fat diet. 
My preliminary data indicate that Foxd3 is not required for glucose homeostasis in 
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animals fed a high fat diet for 8 weeks (Typical American Diet, TestDiet 5TLN). 
However, it must be noted that during 8 weeks of high fat diet feeding, there was only a 
modest increase in body mass compared to animals fed a normal chow (5.4 grams in 
females and 7.5 grams in males). Therefore, to fully understand the requirement for 
Foxd3 in regulating beta cell mass expansion and glucose homeostasis, physiological 
assays should be conducted when the animals are significantly obese. Additionally, using 
a pure genetic background may decrease variability in the amount of weight gain; the 
animals assayed were on a mixed genetic background consisting of C57BL/6, 129Sv6, 
and CD-1. If Foxd3 is required to maintain glucose homeostasis in obese animals, beta 
cell mass, size, proliferation, and function should be analyzed to determine the 
underlying cause for glucose intolerance. No defects in glucose homeostasis in obese 
Foxd3 mutant mice would suggest that Foxd3 is not required for beta cell mass expansion 
in this model.  
 
Subcellular localization of Foxd3 
In adult mice fed a normal chow (Laboratory Autoclavable Rodent Diet 5010, 5.1 
percent fat), Foxd3 was detected in the nuclei of beta cells and a subset of PP cells 
(Figure 5.2A-C). Alternatively, in adult mice fed a higher fat, breeders chow (PicoLab 
Mouse Diet 20, 9.0 percent fat), Foxd3 was detected in the cytoplasm suggesting a 
change in subcellular localization of Foxd3 stimulated by obesity (Figure 5.2 D-F). 
Additionally, Foxd3 was detected in the cytoplasm of non-diabetic, obese Zucker fatty  
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Figure 5.2: Subcellular localization of Foxd3 in mice fed a normal or higher fat chow. A-
C. Foxd3 was detected in the nuclei of beta cells (A) and a subset of PP cells (B) and 
colocalized with Pdx1 (C) from mice fed a chow consisting of 5.1 percent fat. D-F. 
Alternatively, when animals were fed a diet consisting of 9.0 percent fat, Foxd3 was 
detected in the cytoplasm. Foxd3 was not detected in alpha (D), delta (E), or acinar cells 
(F). Yellow arrows, cells co-expressing Foxd3 and another protein. Red arrows, cells 
expressing Foxd3 only. Green arrows, cells not expressing Foxd3. Image taken from 
(Perera et al., 2006).  
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rats (ZF) while Foxd3 was detected in the nuclei of obese, diabetic rats (Zucker diabetic 
fatty rats, ZDF) suggesting that subcellular localization of Foxd3 may be required to 
prevent the onset of type 2 diabetes (Jetton et al., 2005; Perera et al., 2006; Tokuyama et 
al., 1995).  
While Forkhead proteins are transcription factors and are predominantly localized 
to the nucleus, several Forkhead factors including Foxo4, Foxo6, and Foxm1 can be 
detected in the cytoplasm. Both Foxo4 and Foxo6 contain an atypical nuclear localization 
signal (NLS) required for nuclear import. In some instances, this NLS signal is 
phosphorylated by Akt, resulting in cytoplasmic localization and inhibited transcriptional 
activity of both proteins (Brownawell et al., 2001; Jacobs et al., 2003). Interestingly, 
Foxm1 is also subject to differential subcellular localization; during late G1 and S phase 
of the cell cycle, Foxm1 can be detected in the cytoplasm. However, at the transition 
from G2 to M phase, Foxm1 is phosphorylated in response to ERK signaling resulting in 
nuclear localization (Ma et al., 2005).  Due to the requirement for Foxm1, ERK signaling, 
and Foxd3 in regulating beta cell proliferation (Ackermann-Misfeldt et al., 2008; Chen et 
al., 2011; Davis et al., 2010; Plank et al., 2011a; Zhang et al., 2006; Zhang et al., 2010), 
these data pose an interesting model in which subcellular localization of Foxm1 and 
Foxd3 may be regulated by ERK signaling and is critical for beta cell proliferation.  
 To determine how subcellular localization of Foxd3 is regulated, putative 
phosphorylation sites can be identified using KinasePhos (Huang et al., 2005). Once 
putative phosphorylation sites are identified, they can be mutated, constructs transiently 
transfected into beta cell lines, and subcellular localization characterized using 
immunocytochemistry to determine which phosphorylation sites are required for nuclear 
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and/or cytoplasmic localization of Foxd3 in vitro. Additionally, once potential 
phosphorylation sites and pathways are identified, cultured islets can be treated with 
pharmacological inhibitors of the appropriate pathway to determine if these pathways 
regulate Foxd3 subcellular localization ex vivo. Mouse models can be developed with 
point mutations of Foxd3 to determine the significance of phosphorylation sites in vivo. 
Data from these experiments will provide mechanistic details concerning Foxd3 function 
and localization in beta cells. 
 
Mechanism of Foxd3 function in beta cells 
 Interestingly, mice with a Pdx1-Cre driven deletion of Foxd3 exhibit glucose 
intolerance during pregnancy (Figure 3.5) although Foxd3 expression normally decreases 
during pregnancy (Figure 3.1) suggesting that Foxd3 is required prior to pregnancy to 
establish a ground state in which beta cells will be capable of increased proliferation 
during pregnancy. A relay-model posed by a collaborating group suggests that Foxd3 
binds to an intergenic enhancer at the lambda5-VpreB locus in ES cells. Upon 
differentiation to the B cell lineage, Foxd3 is replaced by Foxp1 and transcription of 
target genes ensues (Liber et al., 2010). Additionally, a complementary model suggests 
that Foxd3 functions as a “pioneer factor” and occupies the Albumin1 locus in ES cells 
thereby maintaining the unmethylated state of a single CpG residue. Upon differentiation, 
Foxd3 is replaced by a Foxa family member resulting in activation of Albumin1 
expression (Xu et al., 2007). Both models suggest that Foxd3 is required prior to 
activation of target genes to maintain a binding site for other Forkhead proteins. 
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Figure 5.3: Model of Foxd3 mechanism in beta cells. Foxd3 is the initial factor in this a 
“relay model” required to increase the transcription of loci required for proliferation. 
Under basal physiological conditions when beta cell proliferation is rare, Foxd3 occupies 
its target loci and chromatin remains in a relatively “closed” conformation. Upon 
stimulation to proliferate, such as PL, Foxd3 is replaced by another Fox protein that 
promotes transcription. In the absence of Foxd3, no Fox proteins occupy target loci 
permitting only low levels of proliferation. Upon proliferation stimuli, other Forkhead 
factors are unable to bind the target loci resulting in low levels of proliferation. 
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Therefore, I propose the following model (Figure 5.3). In beta cells, Foxd3 occupies 
upstream regulatory elements of genes required for transcription. In the absence of a 
proliferation stimulus, Foxd3 continues to occupy these binding sites and allows low 
levels of proliferation. Upon a proliferation stimulus (such as PL), Foxd3 is displaced 
from the binding site and another Forkhead protein (potentially Foxa1, Foxa2, Foxm1, or 
Foxo1) occupies the site promoting an open chromatin confirmation, increased gene 
expression, and increased proliferation. In beta cells lacking Foxd3, key binding sites are 
not accessible for other Forkhead proteins resulting in low levels of transcription and 
basal levels of proliferation. 
To test this model, it is crucial to identify the targets of Foxd3. Our lab has 
generated ES cells with one Flag-tagged allele of Foxd3. These targeted ES cells will be 
used to generate chimeric mice by blastocyst injection. Islets from these mice will be 
isolated and high throughput ChIP-Seq will be performed by Dr. Klaus Kaestner at the 
University of Pennsylvania to determine Foxd3 occupancy sites in the beta cell. Once the 
binding sites are identified, ChIP with antibodies against specific histones and histone 
modifications can be used to determine if there are changes in chromatin occupancy and 
therefore structure in the presence and absence of Foxd3 and during pregnancy.  
Additionally, bisulfite sequencing at Foxd3 occupancy sites will be used to determine if 
there are changes in DNA methylation status in the presence and absence of Foxd3. The 
impact of the forthcoming data from these experiments would be two-fold: 1) the ChIP-
Seq experiments will identify downstream targets of Foxd3 and potentially identify novel 
regulators of beta cell proliferation and 2) the results from the epigenetic experiments 
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will provide information to support or contradict the existing models that Foxd3 functions 
as a “pioneer factor” to poise loci for transcription.   
 
Conclusions 
Our work identified a novel role for the transcription factor Foxd3 in regulating 
beta cell mass expansion during pregnancy. The future directions proposed here will 
determine if Foxd3 functions downstream of PDGF signaling to regulate expression of 
the polycomb protein Ezh2. Additionally, these experiments will determine if Foxd3 is 
required to regulate beta cell mass expansion in the obese state. Finally, the proposed 
genomic experiments will uncover mechanistic data regarding the subcellular localization 
and identification of Foxd3 target genes in the beta cell. 
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APPENDIX A 
 
ECTOPIC EXPRESSION OF CRE RECOMBINASE IN THE CNS  
FROM PDX1-CRE MICE 
 
These data are represented in a manuscript published in the December 2010 issue of 
Diabetes (Wicksteed et al., 2010). Copyright 2010, American Diabetes Association. 
 
 The ability to conditionally ablate expression of specific genes in a temporal or 
spatial manner using Cre recombinase is critical for elucidating the tissue-specific 
function of genes of interest. However, this technology is limited by the expression 
pattern of Cre recombinase. Several Cre transgenic mouse lines have been generated to 
conditionally delete a particular gene of interest from the developing or adult pancreas. In 
the majority of these mouse lines, Cre-recombinase is expressed under control of the well 
characterized Pdx1 or Ins2 promoters. Here, we characterized Cre expression in the 
transgenic mouse line, Tg(Ipf1-Cre)Tuv, which was previously demonstrated to induce 
recombination throughout the entire Pdx1-expression domain (Hingorani et al., 2003). 
However, in addition to inducing expression in the endogenous Pdx1-expression domain, 
this mouse line also induced recombination in the hypothalamus and brain stem. We used 
the Tg(Ipf1-Cre)Tuv  transgenic mouse line to delete Foxd3 in beta cells; therefore, we 
needed to rigorously validate Cre expression in this transgenic mouse. Therefore, genes 
that are expressed within the pancreas and hypothalamus are deleted from both regions 
using Pdx1-Cre or Ins2-Cre making physiological data analysis more difficult because 
the deletions are, therefore, not beta cell-specific. For example, using Tg(Ins2-
Cre)25Mgn, also called Rip-Cre,  to delete Stat3 in beta cells also resulted in deletion of 
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Stat3 in the hypothalamus. These mutant mice were glucose intolerant, overweight, had 
increased fat mass, and increased Leptin levels. When wild type islets were transplanted 
into these animals the defects were not rescued, consistent with the hypothesis that 
reduced expression of Stat3 in the hypothalamus rather than beta cells is responsible for 
the observed defects (Cui et al., 2004). Therefore, when using these transgenic mouse 
lines to delete a gene of interest, it is critical to know whether the gene is expressed in the 
hypothalamus.  
 To determine if recombination occurs in the central nervous system (CNS) of 
Tg(Ipf1-Cre)Tuv mice, we dissected brains from Tg(Ipf1-Cre)Tuv; R26R
LacZ/+
 mice at 
postnatal day 14. The brains were sliced using a disposable razor blade and a mouse brain 
slicer (ASI Instruments, RBM-2000C) as illustrated in Figure A.1 and X-gal stained to 
detect beta-galactosidase activity. We found that Tg(Ipf1-Cre)Tuv mediates 
recombination in the hypothalamus (Figure A.1). 
To determine if this recombination was specific to postnatal animals or if it occurs 
during embryogenesis, we analyzed Cre recombination in the CNS at 15.5 dpc. Beta 
galactosidase activity was detected in the CNS at 15.5 dpc suggesting that Cre 
recombinase is expressed in the hypothalamus and brain stem prior to 15.5 dpc (Figure 
A.2 A-D). Additionally, using the R26R
YFP
 reporter (Srinivas et al., 2001), we detected 
YFP expression in the CNS and pancreas at 15.5 dpc indicative of Cre recombination 
(Figure A.2 E-H). Together these data indicate that Cre-mediated recombination occurred 
prior to 15.5 dpc. 
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Figure A.1: The Tg(Ipf1-Cre)Tuv transgenic line showed localized Cre-mediated 
recombination within specific regions of the brain including the hypothalamus (region B). 
Postnatal day 14 brains were sliced, labeled, and imaged. Top panel: Schematic of brain 
sections used for analysis (http://www.brain-map.org). Middle panel: X-gal staining in 
Tg(Ipf1-Cre)Tuv;R26R
LacZ/+
 brain (n = 4) was localized to the hypothalamus. 
Additionally, pancreata from these mice were X-gal positive. Bottom panel: X-gal 
positive cells were not detected in the hypothalamus or pancreas from Tg(Ipf1-
Cre)Tuv;R26R
+/+
 mice (n=4).   
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Figure A.2: A-D. The Tg(Ipf1-Cre)Tuv transgenic line showed localized Cre-mediated 
recombination within specific regions of the brain including the hypothalamus and brain 
stem at 15.5 dpc (A). The pancreas served as a control for Cre activity (B,D). Beta 
galactosidase activity was not detected in the brain or the pancreas in embryos lacking 
Cre-recombinase (C-D). E-H. Cre-mediated recombination was detected in the brain 
stem, hypothalamus, and pancreas in Tg(Ipf1-Cre)Tuv using the R26R
YFP
 reporter (E-F). 
YFP was not detected in the CNS of pancreas from embryos lacking the Tg(Ipf1-Cre)Tuv 
transgene (G-H). Rt, reticular thalamic nucleus; PH, posterior hypothalamus; IIIv, third 
ventricle; St, stomach; Sp, spleen; DP, dorsal pancreas; D, duodenum; VP, ventral 
pancreas. 
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To determine if Cre mRNA expression can be detected in the hypothalamus, this 
region of the CNS was dissected from adult Tg(Pdx1-Cre)89.1Dam mice. RNA was 
isolated and relative Cre expression was determined using qRT-PCR. Islets isolated from 
the same mice served as a positive control. While the level of Cre recombinase 
expression was higher in the pancreatic islets, Cre expression was detected in the 
hypothalamus (Figure A.3). To serve as a negative control, RNA was extracted from wild 
type hypothalamus and islets and Cre recombinase was not amplified using 40 qRT-PCR 
cycles suggesting that Cre recombinase was not expressed in these samples. The 
expression levels of Cre recombinase within the hypothalamus were indistinguishable 
between Tg(Pdx1-Cre)89.1Dam  and Tg(Ipf1-Cre)Tuv  transgenic mice. 
 
 
Figure A.3: Relative Cre mRNA expression in Tg(Pdx1-Cre)89.1Dam hypothalamus 
and islets (n=3). Cre mRNA was undetectable in hypothalamus and islets of wild type 
controls (not shown, n=2). Error bars indicate SEM. 
 
  
 Together, our data, along with the data of our collaborators (Wicksteed et al., 
2010), indicated that both Pdx1-Cre and Ins2-Cre transgenic lines induce recombination 
within the CNS. Therefore, it is important for investigators using these transgenic lines to 
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ensure that their gene of interest is not expressed within the CNS resulting in non-specific 
effects of the mutation. 
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APPENDIX B 
 
MATERIALS AND METHODS 
 
Mouse lines and husbandry 
 The following mouse lines were maintained and interbred to generate mice and 
embryos of the appropriate genotype: Foxd3
tm3.Lby 
(Foxd3
flox
), Foxd3
tm1.Lby 
(Foxd3
IRES-
GFP
), Foxd3
tm2.Lby 
(Foxd3
GFP
), Tg(Ipf1-Cre)Tuv, Tg (Wnt1-Cre)11Rth, 
Gt(ROSA)26Sor
tm1Sor
 (R26R
LacZ
), Gt(ROSA)26Sor
tm1(EYFP)Cos
 (R26R
YFP
), and Tg(Cag-
cre/Esr1*)5Amc. The mouse lines and genotyping were previously described (Danielian 
et al., 1998; Hanna et al., 2002; Hingorani et al., 2003; Soriano, 1999; Srinivas et al., 
2001; Teng et al., 2008). The primer sequences used for genotyping are listed in Table 
B.1. For timed matings, females were checked daily for presence of a vaginal plug; noon 
on the day of an observed plug was considered 0.5 days post coitum (dpc). All mouse 
lines were maintained on a mixed genetic background consisting primarily of CD-1 and 
C57BL/6NHsd/129S6. Mice were housed on Bed ‘o Cobs corn cob bedding (The 
Andersons) unless they were being fasted; fasted mice were housed on Alpha-Dri 
bedding (Shepherd Specialty Papers) because mice would eat the corn cob bedding, 
therefore interfering with their fast. The mice on a normal chow were fed Laboratory 
Rodent Diet 5001 (Labdiets). All mice were handled in accordance with AAALAC 
standards and protocols with approval from the Vanderbilt University Institutional 
Animal Care and Use Committee (IACUC). 
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Table B.1: PCR Primer Sequences 
Gene  Forward Primer Sequence (5’3’) Reverse Primer Sequence (5’3’) Application 
Cre ACCTGAAGATGTTCGCGATTATCT ACCGTCAGTACGTGAGATATCTT Genotyping 
Foxd3
fl
 CGGCTTTCTTTCGGGGGAC ACATATCGCTGGCGCTGCCG Genotyping 
GFP AAGGGCGAGGAGCTGTTCAC TGCTGCTTCATGGGGTCGG Genotyping 
Wnt1-Cre CTTCTATCGAACAAGCATGCG GCCAATCTATCTGTGACGGC Genotyping 
PGK-neo CTCCGGGCCTTTCGACCTG CTGCGTGCAATCCATCTTGTTC Genotyping 
Clip2 GGAGCAGGGGTTGGTTGGTTGA GCCAACTTGGTCCACAAAATGGCT qPCR following ChIP 
FosB CCACCTCCCTCTGTTATGCCAGG GACTCCTTCAGGCTGTGTTTGCAC qPCR following ChIP 
FosB GCCTCGGGTTCTGCCTTCCA ACACCCCTCTGTTCCTGTCCCA qPCR following ChIP 
hCLIP2 TTGAGGGAGTGGAGGTGTC CAGAACCATGCCCTAGGAGT qPCR following ChIP 
hFOSB GGGTTACTCTGCTTCCCTGA GTGTGACTGGGTGGCTGA qPCR following ChIP 
hFOSB TGGCCTCTCTCTCTCTCCTC GAAGTTGGCGTCCTAGGCT qPCR following ChIP 
hNGFR CAGGATTCAAACCCAAGACC GGCCTTACTCCAGGTCCTTA qPCR following ChIP 
hPMAIP1 AACAAACACAATCGATCTACAGC TGACAGTTAAACAAGAGGACATGA qPCR following ChIP 
hPMAIP1 TCCTACTGATTGCTCTCCCA TAACCCAGCAGGTGCAATAA qPCR following ChIP 
hSAFB GAGGCAAGTAAAGGTTAGCCA GAGAGGTCCCAGAGTAGCCA qPCR following ChIP 
hSMARCD3 ACGAAGATTCCTGAGAGGGA ACTGTTGTTTCAGGGAGCCT qPCR following ChIP 
hSMARCD3 TCATGCTGGACTACCAGGTC CTCAAGATGCACCACTTTGG qPCR following ChIP 
hSOX15 AAAGGTGGAGCTGAGCTGTAG AAGCAGCTGGTTTCCCTAAA qPCR following ChIP 
hSOX4 AAACGCTGGAAGCTGCTC TCAGCCATGTGCTTGAGG qPCR following ChIP 
hSOX4 TTTGAATCGTGATAGCCAGATAA TCCTGAAGCATGAAACTCCA qPCR following ChIP 
Ngfr AAGGCCGGGGAGAGTCACCA GCCTCCCAACTGCCCTGTGT qPCR following ChIP 
Pmaip1 CAGGGCCTGAGGTTTAAACTTTGGTT CCTCAAAACCCTCCGGAAGCTCA qPCR following ChIP 
Pmaip1 TGGGCATAGGGTGTCAAGGATCG ACGTTGTCAGCAGGGGCCAT qPCR following ChIP 
Safb TGCAACACAGAAAAGCTAAAGTGAGCG TGTGAGCCTAGTTCCCTGGTAGGT qPCR following ChIP 
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Table B.1 Continued: PCR Primer Sequences 
Gene  Forward Primer Sequence (5’3’) Reverse Primer Sequence (5’3’) Application 
Smarcd3 GGAGGGATGGGATAGCACTCAGACA GGCATGGTGATGAGCCACAGG qPCR following ChIP 
Smarcd3 CCCCAGCCCCTCCAGATTGC GAGCCAGGGCTGGTGCAGAA qPCR following ChIP 
Sox15 AAGTGTGTGCAGCGGTGCCT TCAGCAAAGCGCTAGCATGACCT qPCR following ChIP 
Sox4 CGACCCCAGCTGGTGCAAGA CATGTCGGGCGACTGCTCCA qPCR following ChIP 
Sox4 TCCTGGGAAGTTGTGGGGCTG TCACTGAGGAGGGGCTAGGTCA qPCR following ChIP 
preB TCCCCATTGCCAGATAGAGACACA TGGGCCCAACAGATTAACACAGAG qPCR following ChIP 
preB TGACTTGCTTGTGCTTGCCTGGAC ATAATAACAAAGTACTGAGAAAAC qPCR following ChIP 
2410076i21Rik GGGAGTCTTGTCCTCACGAT GTTCTTGCTGCCAATGAGTG qRT-PCR 
4930463M05Rik TTTGACCCTTCCACTGAACA GAACAGTGGCATTGTAACCG qRT-PCR 
5430411c19Rik CACCAAATTTGTTCCTGTGG GCAGGCTAACCGCTGTAGAT qRT-PCR 
Bnc1 GTCAGTGAAGACGAGCCAGA TTCTCCTTGTGGAAGAGGCT qRT-PCR 
CDC2L1 CTCTGAGGAGGCCTCTGAAC CTGGAACAACCAAGATGTGG qRT-PCR 
Clec2d TAACAACACGATTCCCATCC GCTACAGATCCACATCCGAA qRT-PCR 
CLIP2 AGGACCGACCCTACTCACAC CACAGTCACATCTCCAAGGG qRT-PCR 
Cr AAATGCTTCTGTCCGTTTGC AATCGCGAACATCTTCAGGT qRT-PCR 
Cre TGCAACGAGTGATGAGGTTC GCAAACGGACAGAAGCATTT qRT-PCR 
Dub2a ATGTGCAGCAGACTGACCTC TTTCTCCGGGATTTCTTCAG qRT-PCR 
E130309F12Rik CTCAACCGCGTCTCAGAGTA GAACCACACACATTCCCAAA qRT-PCR 
EG432649 GCTCACCTCTCCTGATTCGT TGATGTCTGGGATCCTTTGA qRT-PCR 
Eras TACCCGAGTACAAGGCAGTG CATGGTCTTTCACGAAGCAT qRT-PCR 
Evc2 CATCCTGAGAACAAGCTGGA CTCAGAAGTCAGGATGGCAA qRT-PCR 
Fibin ACAGAGGGAGAAGGTGCTGT CAGGCTAGATCCCACTACCC qRT-PCR 
Fosb GGCCTCTCCCTTTATCCTTT CAGACCGGAGATCAGAGTCA qRT-PCR 
Foxd3 GTCCGCTGGGAATAACTTTCCGTA ATGTACAAAGAATGTCCCTCCCACCC qRT-PCR 
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Table B.1 Continued: PCR Primer Sequences 
Gene  Forward Primer Sequence (5’3’) Reverse Primer Sequence (5’3’) Application 
Gap43 CCGTGGACACATAACAAGGA TTCTTCTCCACACCATCAGC qRT-PCR 
Glucagon AGGAATTCATTGCGTGGCTG CAATGGCGACTTCTTCTGGG qRT-PCR 
Grhl3 CGGTTCTGACGTTCACTGTT CTCACAAAGGCATCTGCTGT qRT-PCR 
Hirip3 CAGGAAGCAGGTTAGGGAAG CTCTCCTCCTGGCAGTTAGC qRT-PCR 
Hist1h2bb ATGGGCATCATGAACTCGT GTCGAGCGCTTGTTGTAATG qRT-PCR 
HPRT TACGAGGAGTCCTGTTGAATGTTGC GGGACGCAGCAACTGACATTTCTA qRT-PCR 
Insulin1 CAGCAAGCAGGTCATTGTTT GGGACCACAAAGATGCTGTT qRT-PCR 
LOC668686 CCTGTGTGGGCAGTGTGTAT TCAGGCTTCTCACCATCATC qRT-PCR 
LOC674405 AACTCACATGAGGCTGGCTT CCAAGTGAACCTCTCCTCGT qRT-PCR 
Mafa TCGACCTGATGAAGTTCGAG CAGAAGCTGGGCGAAGAG qRT-PCR 
Mafb CCCACACATTGGCAACTAAC AACGGAAGGGACTTGAACAC qRT-PCR 
Myf5 ATGTAACAGCCCTGTCTGG CAGCACATGCATTTGATACA qRT-PCR 
Myf6 GTAAGGGAGTGCAGATTGTG TGCGTTCCTCTGAAGAAATA qRT-PCR 
MyoD1 CTGATGGCATGATGGATTAC CTCACTGTAGTAGGCGGTGT qRT-PCR 
Myogenin CAACCCAGGAGATCATTTG GTAAGGGAGTGCAGATTGTG qRT-PCR 
Neurogenin3 ATCCATCACTTTTTCCAGGGTG TCATCTATGGGCCAAGAGCTG qRT-PCR 
Ngfr CTGCCTTCCTCTGTCTGTCA CACTGTTGGCTTCAGGCTTA qRT-PCR 
Nkx2.2 GCAGCGACAACCCCTACA ATTTGGAGCTCGAGTCTTGG qRT-PCR 
Nrg3 TTATCGGATCCAACAGACCA CCACGATGACAATTCCAAAG qRT-PCR 
Otx1 TGTTCGCAAAGACTCGCTAC ACCAAACCTGGACTCTGGAC qRT-PCR 
Pdx1 CTGAGGGACAAAGATGCAGA TTCTAATTCAGGGCGTTGTG qRT-PCR 
Pi15 CTGCAGTCAGCCTTGTGATT TATTGGCTGGCAGAGATGAG qRT-PCR 
Pmaip1 GAGTGCACCGGACATAACTG CTCGTCCTTCAAGTCTGCTG qRT-PCR 
Safb AAGGCCATTGAAGATGAAGG CCTCGTCTTCTGGTTTCCTC qRT-PCR 
Skp2 AGCCGAGGTGAATGAGAGTT AGCATGAATGCTCCACAAAG qRT-PCR 
134 
 
Table B.1 Continued: PCR Primer Sequences 
Gene  Forward Primer Sequence (5’3’) Reverse Primer Sequence (5’3’) Application 
Smarcd3 AGATGTGGAGGTGGAGGAAC TCCAGAGCACTGATCTCCTG qRT-PCR 
Socs2 CCGAATGCAGCTATGTGAAA AGACTGAGCCCAACTGTCCT qRT-PCR 
Sox15 AACTACCCAAGGGAGCAGAG CTGCAGTGGGAAGAGGTGTA qRT-PCR 
Sox4 ACTGCAATCGACTGCTTCAG ACGTTGGTAGCCGGAGTATC qRT-PCR 
Tac1 TGATGAAGGAGCTGTCCAAG CACAGGAGTCTCTGCTTCCA qRT-PCR 
Tub CTAGATGATGAGGGCAGCAA CATTGGCCTGTACCATCAAG qRT-PCR 
Ube1y1 GAGGATGCTGAGGAATTGGT ACTTCCGGATAAGGTCGATG qRT-PCR 
Sox15 Insertion ATAGTCGACGCCAACCAGCTCCTCAC ATAGAATTCAAGGGGTTACTGGCATG Subcloning & Sequencing 
Myc AATTCTATCCTTAGAGGACCTTAGGC GGCCGCCTAAGGTGTCATAAGGATAG Subcloning 
HA AATTCATATCCGAACCTGACCTAGGC GGCCGCCTAGGTCCTCCTCGGATAGG Subcloning 
Sox15 Seq GACAGCCTACCTGCCTGGC  Sequencing 
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To assay BrdU incorporation, 5-bromo-2-deoxyuridine (BrdU, Sigma B5002) was 
dissolved in sterile PBS and postnatal pups or pregnant dams were intraperitoneally 
injected with 50 mg BrdU per kg body weight 24 and/or 48 hours prior to sacrifice. In 
contrast, to assess BrdU incorporation in adult mice for 1 week continuously, BrdU was 
placed in the drinking water (0.8 mg/mL) and treated water replaced after 4 days to 
ensure BrdU activity. To induce Cre-mediated recombination and acutely delete the 
Foxd3 coding sequence in Tg(Cag-cre/Esr1)5Amc; Foxd3
flox/flox
 mice, 20 mg Tamoxifen 
(Sigma T5648) was dissolved in 100 L of 100 % ethanol. The Tamoxifen/ethanol 
solution was then diluted in 900 L of corn oil (Sigma C8267) and vortexed for 5 to 10 
minutes. Adult mice were intraperitoneally injected with 100 L (2 mg) of the corn oil 
and Tamoxifen solution one week prior to mating or sacrifice. 
 
Histology and immunohistochemistry 
Beta galactosidase staining: Tissues and embryos were dissected in cold PBS and then 
fixed overnight at 4C in 1 percent formaldehyde (Sigma F1635), 0.2% glutaraldehyde 
(Sigma G6257), 2 mM magnesium chloride, 5 mM EGTA, and 0.02% Nonidet P40 
(NP40, Roche 11 332 473 001). The following day, the samples were washed 3 times for 
30 minutes each in PBS at room temperature. Tissues were permeabilized with 2 mM 
magnesium chloride, 0.01% sodium deoxycholate, and 0.02% NP40 in PBS 3 times for 2 
hours each at room temperature. A 20 mg/mL stock solution of 5-Bromo-4-chloro-
indolyl-beta-D-galactosidase (X-gal, RPI B71800) was prepared by adding 1 g of X-gal 
to 50 mL of N,N-dimethylformamide (DMF, Sigma D4551). This stock solution should 
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be stored at -20C long term. Immediately following permeabilization, the samples were 
stained overnight at room temperature with freshly prepared 5 mM potassium 
hexacyanoferrate (II) trihydrate (Ferro, Sigma P3289), 5 mM potassium ferricyanide (III, 
Ferri, Sigma 455946), 2 mM magnesium chloride, 0.02% NP40, and 1 mg/mL X-gal in 
PBS. Following staining, tissues were washed 3 times for 30 minutes in PBS and were 
imaged or prepared for immunohistochemistry. 
Paraffin embedded sections: Embryos and tissues were dissected in cold PBS and fixed 
overnight in filter sterilized 4% paraformaldehyde (PFA) in PBS. Following fixation, 
embryos were washed 3 times for 30 minutes in PBS and dehydrated using a series of 
ethanol washes. Each ethanol wash was performed at room temperature for 30 minutes 
and the following concentrations of ethanol were used: 1 wash in 30% ethanol and 2 
washes in each of 70, 95, and 100% ethanol. Following the ethanol washes, samples were 
placed in 2 xylenes washes for 30 minutes each. If samples were previously stained for 
beta galactosidase activity, Histoclear™ was used instead of xylenes because xylenes will 
cause the blue signal to fade. Samples were placed in 50% xylenes (or Histoclear™) and 
50% paraffin (Paraplast Plus) followed by 2 washes in molten paraffin at 60C for 30 
minutes. Following the paraffin washes, samples were embedded in Histoplex cassettes 
(Starplex Scientific). Samples were then cut into 7 micron sections using Accu-Edge low 
profile blades (Sakura) and sections were placed on to positively charged slides under 
water at 45C. 
Appropriate slides were chosen for staining after screening the slides on a stereoscope, 
looking for morphological landmarks. Slides were incubated in xylenes twice for 5 
minutes to dissolve paraffin surrounding the tissue and then sections were rehydrated in a 
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series of ethanol washes: 2 washes of 100% and 95% ethanol and 1 wash of 70% 
followed by a 50% ethanol wash. Slides were then placed in distilled water. If necessary 
following rehydration, slides were placed in 3% hydrogen peroxide for 10 minutes if 
biotin-avidin amplification (TSA or DAB) and/or antigen retrieval was performed (see 
Table B.2). Next, tissue sections were outlined using a Pap pen and blocking solution 
(5% normal donkey serum, 0.1% Triton X-100, and 1% bovine serum albumin in PBS) 
was pipetted on top of each section and the slides incubated at room temperature for at 
least one hour. After this blocking step, the blocking solution was removed and primary 
antibody diluted in blocking solution was added to the sections and the slides were 
incubated overnight at 4C. See Table B.2 for appropriate dilutions of primary antibody. 
The following day, slides were washed 3 times in PBS for 3 minutes. Secondary antibody 
was diluted in 0.1% Triton X-100 in PBS. All secondary antibodies were used at a 1:500 
dilution with the exception of Cy3 conjugates which were used at 1:800. Secondary 
antibody solution was added to the tissue as above for the primary antibody and 
incubated for 1 hour at room temperature. When fluorescently conjugated secondary 
antibodies were used, this incubation was performed in the dark (under aluminum foil). 
Following the incubation, slides were washed 3 times for 3 minutes in PBS. To detect 
nuclei, the slides were incubated for 5 minutes in 4’,6-diamidino-2-phenylindole (DAPI) 
in distilled water (1:2000) and washed again. For colorimetric analyses, either 
Hematoxylin (Richard Allen Scientific) or Eosin Y (Thermo Scientific) was used as a 
counterstain. For samples requiring TSA or DAB amplification, protocols from the TSA 
Kit (#22, Invitrogen) or ABC Kit (Vector Labs), respectively, were followed. Samples 
that were fluorescently labeled were mounted with Aqua Polymount (Polysciences, Inc)  
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Table B.2- Antibodies used for immunohistochemistry or immunofluorescent analyses 
Antigen Species Source Conc. Application Special Directions 
bIII Tubulin Mouse Covance (Tuj1) 1:500 PE   
BrdU Mouse Beckton Dickinson 1:100 ICC, PE Unmask with 0.25% Trypsin at 37 C for 5 minutes 
CD31 Mouse Pharmigen 1:100 PE Unmask in 0.1 mg/mL proteinase K at 37C and TSA 
FABP7 Rabbit Dr. Thomas Muller 1:1000 PE   
Foxd3 Rabbit Labosky Lab 1:1000 FS, ICC, PE Unmask in citrate buffer at 95C for 1 hour 
GFP Chicken Abcam 1:500 PE, ICC, WM   
Ghrelin Rabbit Phoenix Pharmaceuticals 1:100 PE Add primary antibodies sequentially 
Glucagon Rabbit Millipore 1:500 FS, PE   
Glut2 Rabbit Millipore 1:1000 PE   
Insulin Guinea Pig Millipore 1:500 FS, PE   
Neurog3 Mouse DSHB 1:1000 FS, PE Unmask in citrate buffer at 95C for 1 hour and TSA 
p75 Rabbit Promega 1:200 WM  
Pancreatic 
Polypeptide 
Rabbit Millipore 1:100 FS, PE   
Pdx1 Guinea Pig Dr. Christopher Wright 1:2500 PE, WM Unmask in citrate buffer at 95C for 1 hour 
Pdx1 Goat Dr. Christopher Wright 1:10000 PE Unmask in citrate buffer at 95C for 1 hour 
Pdx1 Rabbit Dr. Christopher Wright 1:1000 PE Unmask in citrate buffer at 95C for 1 hour 
Pgp9.5 Rabbit AbD Serotec 1:1000 PE   
Phospho-Histone3 Rabbit Upstate 1:250 WM  
Somatostatin Rat Millipore 1:100 FS, PE   
Sox10 Goat Santa Cruz 1:15 WM Use only Cy5 conjugated secondary antibody- No BSA 
Sox15 Rabbit Dr. Ibrahim Adham 1:50 ICC  
Sox9 Rabbit Millipore 1:1000 FS, PE Unmask in citrate buffer at 95C for 1 hour 
Abbreviations: FS: frozen section, ICC: immunocytochemistry, PE: paraffin embedded, WM: whole mount
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while colorimetrically labeled slides were dehydrated in ethanol and xylenes (or 
Histoclear™) and mounted with Cytoseal 60 (Richard Allen Scientific). TUNEL analysis 
was completed with the In Situ Cell Death Kit (Roche). 
Frozen sections: Embryos and tissues were dissected in cold PBS and fixed overnight in 
4% paraformaldehyde (PFA). Following fixation, the embryos were washed 3 times for 
30 minutes in PBS and equilibrated in 30% sucrose until the tissue sank. The tissue was 
then placed in Optimal Cutting Temperature (OCT, Tissue Tek) in cryomolds (Tissue 
Tek) and then frozen on dry ice. Blocks were stored long term at -80C. Seven micron 
sections were cut in a Leica CM3050 S using cryocut low profile blades (Leica) and the 
sections were placed on positively-charged slides (Mercedes Medical 7255/90). The 
slides were stored at -20C until they were processed for immunohistochemistry. 
Slides were washed in PBS for 30 minutes to remove the OCT, permeabilized in 
0.2% Triton-X 100 in PBS for 30 minutes, and sections were circled using a Pap pen. 
Blocking solution (5% normal donkey serum, 0.1% Triton X-100, and 1% bovine serum 
albumin in PBS) was added to the section and the slides were incubated at room 
temperature for at least one hour. After the incubation, the blocking solution was 
removed, primary antibody diluted in blocking solution was added to the sections, and 
slides were incubated overnight at 4C. See Table B.2 for appropriate dilutions of 
primary antibody. The following day, the slides were washed 3 times in PBS for 3 
minutes. Secondary antibody was diluted in 0.1% Triton X-100 in PBS. All secondary 
antibodies were used at 1:500 with the exception of Cy3 conjugates which were used at 
1:800. The secondary antibody was added to the tissue and incubated for 1 hour at room 
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temperature in the dark. Following the incubation, slides were washed 3 times for 3 
minutes in PBS. To detect nuclei, slides were incubated for 5 minutes in 4’,6-diamidino-
2-phenylindole (DAPI) in distilled water (1:2000). Samples were mounted with Aqua 
Polymount (Polysciences, Inc). 
Immunocytochemistry: Cell culture medium was removed and the cells were washed 
with PBS. Four percent PFA in PBS was added to the cells for 30 minutes at room 
temperature. The cells were washed 3 times for 3 minutes at room temperature with PBS. 
Blocking solution (1% normal donkey serum and 0.1% Triton X-100 in PBS) was added 
to the samples for 30 minutes at room temperature. Following the incubation, the 
blocking solution was removed and primary antibody (see Table B.2) diluted in blocking 
solution was added to the samples prior to an overnight incubation at 4C. The next day, 
the primary antibody was removed and samples were washed 3 times for 3 minutes in 
PBS. Secondary antibodies (Cy2 conjugates 1:500, Cy3 conjugates 1:800, and Cy5 
conjugates 1:500) were diluted in 0.1% Triton X-100 in PBS and added to the samples 
for 1 hour at room temperature in the dark. The samples were then washed 3 times for 3 
minutes. DAPI, diluted in distilled water (1:2000), was added to the samples for 5 
minutes. Samples were then mounted with Aqua Polymount (Polysciences, Inc) or 
visualized on an inverted microscope. 
Whole mount immunofluorescence: Embryos and tissues were dissected in cold PBS and 
fixed overnight in 4% paraformaldehyde (PFA). Following fixation, samples were 
washed 3 times for 30 minutes in PBS and then permeabilized for 30 minutes at room 
temperature in 0.5% Triton X-100 in PBS. Following permeabilization samples were 
incubated in blocking solution (10% normal donkey serum and 0.1% Triton X-100 in 
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PBS) overnight at 4C. The next day, blocking solution was removed, primary antibody 
(see Table B.2) diluted in blocking solution was added to the samples and the samples 
were incubated overnight at 4C. The primary antibody was then removed and samples 
washed 4 times for 1 hour each in 0.1% Triton X-100 in PBS. Samples were incubated 
overnight in secondary antibodies (Cy2 conjugates 1:500, Cy3 conjugates 1:800, and Cy5 
conjugates 1:500) diluted in 0.1% Triton X-100 in PBS. The samples were washed 4 
times for 1 hour in 0.1% Triton X-100 in PBS. Nuclei were detected by incubating the 
samples in DAPI (1:2000) diluted in distilled water for 15 minutes at room temperature. 
The samples were mounted on positively charged slides with Aqua Polymount 
(Polysciences, Inc). 
 
Quantitative analyses and imaging 
Paraffin and frozen sections were imaged using a Zeiss AxioSkop2 Plus 
fluorescent microscope equipped with a Q Imaging Retiga 2000R camera or a Zeiss Axio 
Observer A1 fluorescent microscope and an AxioCam MRc5 camera. Images from whole 
mount samples were taken using an Olympus FV1000 scanning laser confocal 
microscope. 
For BrdU incorporation, islets from 5 sections evenly spaced throughout the 
pancreas ensuring equal representation of the dorsal and ventral pancreas (accounting for 
approximately 5 to 8% of total pancreatic mass) were imaged using a Zeiss AxioSkop2 
Plus equipped with a Q Imaging Retiga 2000R camera. The total number of BrdU-
positive beta cells was divided by the total number of insulin-positive beta cells. For beta 
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cell mass, the pancreas was embedded in a manner to ensure equal representation of the 
dorsal and ventral pancreas. Five evenly spaced pancreatic sections (accounting for 5 to 
8% of the total pancreatic mass) were imaged using an Ariol SL-50 imaging system. 
Insulin-positive area and total pancreatic area were determined using ImageJ software 
(National Institutes of Health) and beta cell mass determined by dividing total betacell-
positive area by total pancreatic area multiplied by pancreatic wet weight. To determine 
individual beta cell size, every islet from 4 evenly spaced sections (accounting for 
approximately 4 to 6% of total pancreatic mass) was imaged as above. The total insulin-
positive area from each section was calculated using Adobe Photoshop. The area was 
then divided by the total number of beta cells per section. At least 5,000 beta cells per 
animal were counted. 
 
Physiology assays 
Intraperitoneal glucose tolerance tests: Mice were transferred to cages containing Alpha 
Dri bedding (Shepherd Specialty Papers) and fasted for precisely 16 hours. Twenty 
milligrams of dextrose was dissolved in 1 mL of water and then filter-sterilized. 
Following the fast, the tail vein was punctured and a glucose measurement obtained using 
a glucometer (FreeStyle). The mice were then subjected to an intraperitoneal injection of 
2 mg dextrose per gram body weight. Glucose measurements were obtained with blood 
samples from the tail vein using a glucometer at 15, 30, 60, 90, and 120 minutes post 
injection. In some instances, when mice were extremely glucose intolerant, glucose 
measurements were obtained every 30 minutes until the mouse returned to baseline 
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glucose levels. Following the glucose tolerance test, mice were fed and returned to the 
mouse facility or sacrificed and the pancreas dissected for future analysis.  
Serum insulin levels: Mice were transferred to cages containing Alpha Dri bedding 
(Shepherd Specialty Papers) and fasted for precisely 16 hours. Twenty milligrams of 
dextrose was dissolved in 1 mL of water and then filter sterilized. The mice were 
restrained in a 50 mL conical tube (Falcon) with a large hole at the tip to allow breathing. 
The fur on the upper outer thigh over the saphenous vein was shaved with a disposable 
razor and the area sterilized with isopropanol. The saphenous vein was punctured with a 
19 gauge needle and at least 25 L of blood was collected with Microvette CB 300 
capillary tube (Fisher Scientific). Light pressure was applied to the wound to stop 
bleeding. The mice were then intraperitoneally injected with 2 mg dextrose per gram 
body weight. Blood samples were collected as above at 15 and 30 minutes post glucose 
injection. The samples were then centrifuged at maximum speed for 10 minutes in an 
Eppendorf 5417C centrifuge. The serum was collected and stored at -80C until further 
analysis. Serum insulin content was measured using Insulin Ultra-Sensitive ELISA 
(Alpco Diagnostics) as directed. All samples were run in duplicate. 
Islet perifusion: Islet perifusions were performed by the Vanderbilt Islet Procurement and 
Analysis core as described using 16.7 mM glucose and 20 mM KCl in 5.6 mM glucose as 
stimuli (Brissova et al., 2004). Insulin was extracted from perifusates in acid alcohol for 
48 hours and insulin levels measured using radioimmunoassays performed by the 
Vanderbilt Hormone Assay and Analytical Services Core. The total amount of insulin 
was normalized to 100 islet equivalents (IEQ) to standardize the data for comparison. 
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Embryonic stem cell techniques 
Generating feeders: All manipulations need to be performed with sterile technique, tools, 
and supplies. The heads and all internal organs were removed from 13.5 dpc embryos in 
sterile PBS using sterile dissection tools. The carcasses were transferred to a new dish of 
clean PBS to minimize contamination probability. Following dissection, carcasses were 
loaded into a sterile 3 mL syringe with a 21 gauge needle. The carcasses were passed 
through the needle 5 times resulting in small evenly sized pieces of tissue. The resulting 
pieces were then plated on a 150 mm  tissue culture plate coated with gelatin (0.1%) in 25 
mLs mouse embryonic fibroblast (MEF) medium (10% FBS, 1% penicillin/streptomycin, 
1% L-glutamine in DMEM 11965). Approximately 3 carcasses equivalents are sufficient 
for each 150 mm dish.  
 The cells were grown to confluence and then split 1:3 after approximately 5 days. 
To split MEFs, the medium was aspirated into a vacuum flask and the cells were washed 
with 10 mL PBS to remove residual serum. The cells were trypsinized using 5mL 0.25% 
Trypsin (Gibco) at 37C for 5 minutes. Following trypsinization, 16 mL of MEF medium 
was added to each plate to stop the reaction. The whole volume (21 mL) was divided 
among 3 new gelatinized plates (7mL each) and 13 mL of MEF medium was added to 
each new dish. The cells were passaged 3 or 4 times to produce a sufficient number of 
MEFs. Once a sufficient number was obtained, the cells were harvested and irradiated in 
50 mL of MEF medium in 50 mL conical tubes (Falcon) by the Vanderbilt Transgenic 
Mouse/ESC Shared Resource core using a cesium source. It is extremely important to 
keep the cells on ice during this time as it may take several hours. Only 6.0 x 10
7
 cells 
should be irradiated in each conical tube. Following irradiation, the cells were centrifuged 
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for 3 minutes at 1,000 rpm in an IEC Centra CL2 centrifuge.  Following centrifugation, 
the cells are resuspended in MEF freezing medium (20% FBS, 10% DMSO in MEF 
medium) to give a final concentration of 2.5 x 10
6
 cells/mL. Cells were then aliquoted in 
1 mL aliquots in Cryogenic vials (Nalgene) and the vials were placed in Cryo 1C freezing 
containers (Nalgene) filled with 250 mL isopropyl alcohol and then placed at -80C 
overnight. The following day, the cells were transferred to a liquid nitrogen tank. Before 
use, one vial irradiated MEFs should be plated on gelatinized plates and maintained and 
observed for 5 days to ensure cells are recovered at the appropriate density and there is no 
proliferation in the cultures. 
Isolating Leukemia Inhibitory Factor (LIF): Chinese hamster ovary (CHO) cells carrying 
the expression plasmid 8/242 720 LIFD (Genetics Institute, Cambridge) were grown to 
confluence in CHO medium (10% FBS, 1% L-glutamine, 1% penicillin/streptomycin in 
alpha medium 12561) in a 10 cm tissue culture dish. Once cells reached confluence they 
were split 1:10 using 0.25% Trypsin. Once 100 plates of CHO cells were obtained (2 
passages) the cells were grown to confluence and the medium containing secreted LIF 
was collected, pipetted into 500 L aliquots, and stored at -20C. LIF (1:1000) was tested 
in ESC culture to ensure there was no differentiation of ES cells. If a 1:1000 dilution of 
LIF is not sufficient, different dilutions may be tested. These cells were a generous gift 
from Dr. Klaus Kaestner, University of Pennsylvania. 
Culture: Embryonic stem (ES) cells were grown on irradiated MEFs in ES cell medium 
(15% FBS, 1% L-glutamine, 1% non-essential amino acids, 0.1% gentamicin, 0.1% 
CHO-LIF, and 3 L beta mercaptoethanol in DMEM 11965) at 37C with 5% carbon 
dioxide. Once ES cells were approximately 80% confluent, they were passaged at 1:3. 
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The medium was aspirated, the plate was rinsed with PBS, 1 mL of 0.25% trypsin was 
added to the plate, and the plate was then incubated for 5 minutes at 37C. Following the 
incubation, 5 mL of ES cell medium was added to the plate and the cells were dissociated 
into a single cell suspension by pipetting. The appropriate amount of cells was then 
transferred to a new feeder dish containing ES cell medium. In order to delete Foxd3 
from Foxd3
fl/fl
; CAAG-Cre
ER
 ES cells, 2 m 4-Hydroxytamoxifen (TM) was added to 
culture (Sigma H7904). Stock solutions of TM were prepared in advance (1 mM in 95% 
ethanol) and stored at -20C. 
 When ES cells needed to be frozen for future use, the cells were trypsinized as 
above and 5 mL of ES cell medium was added to stop the reaction. A small amount 
(usually 10 L ) of the cells was diluted 1 to 5 in ES cell medium. The cells were counted 
using a hemacytometer (5 of the 9 squares were counted, see Figure B.1) and the total 
number of cells was calculated using the following calculation: 
# in 5 squares ÷ 5 (# of squares) x (2000) x 5 (dilution factor) x 6 (total volume) = total 
cells. 
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Figure B.1: Schematic of a grid from a hemacytometer. Cells in the red shaded squares 
are counted (5 squares total). Image modified from hausserscientific.com. 
 
The total number of vials needed was calculated by dividing the total number of 
cells by 3x10
7
. The cells were centrifuged for 3 minutes at 1000 rpm. The medium was 
aspirated and cells resuspended in the appropriate amount of freezing medium (30% FBS 
and 10% DMSO in ES cell medium). The cells were frozen overnight at -80C in Cryo 
1C freezing containers (Nalgene) filled with 250 mL isopropyl alcohol. The following 
day the cells were transferred to a liquid nitrogen tank. 
Generation of Doxycycline-inducible ES cell lines: Ten micrograms of the p2loxP vector 
(Iacovino et al., 2011b) was digested with EcoRI and SalI (50 L  reaction, 2 L  each 
enzyme) for 3 hours at 37C. Samples were run on an agarose gel; the band containing 
the 3.5 kb DNA fragment was extracted and purified using the Wizard SV Gel and PCR 
Purification kit (Promega), and was eluted in a final volume of 30 L . Following 
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purification, the samples were treated with 3.5 L  Antarctic Phosphatase buffer (NEB) 
and 1 L  Antarctic Phosphatase. Samples were incubated for 15 minutes at 37C and 15 
minutes at 56C. Another microliter of Antarctic Phosphatase was added and the 37C 
and 56C incubations were repeated. The samples were purified using the Wizard SV Gel 
and PCR Purification kit.  
 Sox15 cDNA was amplified from the pMXs-Sox15vector (Addgene 13359) using 
PCR with Sox15 insertion primers (see Table B.1) and AmpliTaq Gold DNA polymerase 
(Applied Biosystems N8080247). The PCR product was purified with the Wizard SV Gel 
and PCR Purification kit. The purified PCR product was digested with 1uL EcoRI and 
SalI in a total volume of 50 L. DNA samples were purified with the Wizard SV Gel and 
PCR Purification kit.  
The purified vector and PCR products were ligated using T4 DNA Ligase (NEB 
M0202) for 15 minutes at room temperature in a total reaction volume of 10 L  using 
molar ratios of 1:1, 1:3, 3:1, and 1:0 (vector: insert). One microliter of the ligation was 
added to 80 L  of competent DH5alpha cells. The cells were incubated on ice for 10 
minutes followed by a heat shock at 42C for 90 seconds. The samples were then placed 
on ice for 1 minute, 1 mL of LB was added, the samples were incubated at 37C for 1 
hour, and 100 L  was plated on LB amp plates. The plates were incubated at 37C 
overnight. The following day, 24 colonies were picked into 5 mL LB with 5 L  50 
mg/mL ampicillin. The cultures were grown in a shaking incubator overnight at 37C and 
200 rpm. 
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DNA was purified from the bacterial pellets with the Wizard Plus SV Minipreps 
DNA Purification System (Promega). Two microliters from each miniprep were digested 
with EcoRI and SalI in a 50 L reaction and then 10 L  of the digest was run on a 1% 
agarose gel. The presence of a 700 base pair band indicated insertion of the Sox15 cDNA 
into the vector. Four samples with the band corresponding to Sox15 cDNA were 
sequenced by the Vanderbilt University DNA Sequencing Core using both Sox15 
insertion primers (See Table B.1) to ensure the correct sequence.  
The p2lox-Sox15 vector (10 g) was digested with EcoRI and NotI (50 L  
reaction, 2 L  each enzyme) for 3 hours at 37C. The vector backbone was purified 
using the Wizard SV Gel and PCR Purification kit (Promega) and was eluted in a final 
volume of 30 L . Following purification, the samples were treated with 3.5 L  
Antarctic Phosphatase buffer (NEB) and 1 L  Antarctic Phosphatase. The samples were 
incubated for 15 minutes at 37C and 15 minutes at 56C. Another microliter of Antarctic 
Phosphatase was added and the 37C and 56C incubations were repeated. The samples 
were purified using the Wizard SV Gel and PCR Purification kit.  
 Oligos were generated with the HA and Myc tag sequenced flanked by EcoRI (5’) 
and NotI (3’) restriction enzyme sequences (See Table B.1). Seven hundred nanomoles of 
oligo was kinased using the following reaction: 1 L  T4 Polynucleotide Kinase (PNK) 
buffer, 1 L  T4 PNK, 1 L  100 mM ATP. The samples were incubated for 1 hour at 
37C. The forward and reverse oligos were combined and then annealed by heating to 
95C for 5 minutes and then slowly cooling to room temperature. Once oligos were cool, 
they were purified using a phenol: chloroform extraction.  
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The purified vector and annealed oligos were ligated using T4 DNA Ligase (NEB 
M0202) for 15 minutes at room temperature in a total reaction volume of 10 L . Molar 
ratios of 1:1, 1:3, 3:1, and 1:0 (vector: insert) were used. One microliter of the ligation 
was added to 80 L  of competent DH5alpha cells. The cells were incubated on ice for 10 
minutes followed by a heat shock at 42C for 90 seconds. The samples were then placed 
on ice for 1 minute, 1 mL of LB was added, the samples were incubated at 37C for 1 
hour, and 100 L  was plated on LB amp plates. The plates were incubated at 37C 
overnight. The following day, 24 colonies were picked into 5 mL LB with 5 L  50 
mg/mL ampicillin. The cultures were grown in a shaking incubator overnight at 37C and 
200 rpm. 
DNA was purified with the Wizard Plus SV Minipreps DNA Purification System 
(Promega). Two microliters from each miniprep were digested with EcoRI and NotI in a 
50 L  reaction and then 10 L  of the digest was run on a 2% agarose gel. The presence 
of a faint 70 base pair band indicates insertion of the HA or Myc oligo into the vector. 
Three samples with the band corresponding to oligo sequence were sequenced by the 
Vanderbilt University DNA Sequencing Core using the forward the Sox15 insertion and 
the Sox15 Seq primer (See Table B.1) to ensure the correct sequence.  
Once the sequences were verified, a culture carrying p2lox-Sox15-HA and 1 
p2lox-Sox15-Myc DNA was grown in 200 mL LB and 200 L  50 mg/mL Ampicillin 
overnight. The DNA was isolated using the Plasmid Maxi Kit (Qiagen 12162) following 
the standard protocol. The DNA was resuspended in 200 L sterile TE. The amount of 
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DNA was quantified using a NanoDrop Spectrophotometer (ND-1000). A schematic of 
the completed vector is illustrated in Figure B.2. 
 
 
Figure B.2: DNA sequences inserted into the p2LoxP vector. A Kozak sequence and the 
Sox15 cDNA were added between SalI and EcoRI restriction enzyme sites. An HA or 
Myc tag and a stop codon was inserted between EcoRI and NotI restriction enzyme sites. 
Diagram is not drawn to scale. 
 
 
AINV ES cells were cultured as described above for 2 passages (Iacovino et al., 
2011b). Once the cells were 60% confluent following the second passage, 1 g/mL 
Doxycycline (1 mg/mL stock solution is stored at -20C) was added to the culture 
medium to induce expression of Cre recombinase. The following day, the ES cells were 
fed normally and 1 hour later the ES cell medium was aspirated, cells were rinsed with 
PBS, 1 mL 0.25% Trypsin was added to the dish, and the dish was incubated at 37C for 
5 minutes. Following the incubation, 4 mL medium was added, and the cells were 
dissociated into a single cell suspension. The cells were counted (see above) and 5 x 10
7
 
cells were transferred to each of 2- 15 mL conical tubes. The cells were centrifuged at 
1,000 rpm for 3 minutes. The medium was aspirated, the cells were resuspended in 800 
L  sterile PBS, and the resuspended cells were transferred to a Gene Pulser Cuvette 
(BioRad 165-2088). Ten micrograms of p2lox-Sox15-HA or p2lox-Sox15-Myc were 
added to the appropriate cuvette. The cells were electroporated in a Gene Pulser II 
(BioRad) at 500 F and 0.25 mV. The electroporated cells were plated on 10 cm plates 
GCCACC ATG Sox15 HA or Myc Stop
SalI EcoRI NotI
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with irradiated MEFs in ES cell medium. Recombination was mediated using “induced 
cassette exchange” (Iacovino et al., 2011b) as diagrammed in Figure B.3. In correctly 
targeted ES cells, Sox15 was inserted downstream of a tetracycline response element in 
the HPRT locus and the tetracycline reverse transcriptional activator was located in the 
ROSA26 locus. Therefore, in the presence of Doxycycline, expression of Sox15 was 
induced from the HPRT locus.  
 
 
Figure B.3: Induced cassette exchange. Culturing ES cells with Doxycycline 24 hours 
prior to electroporation induces the reverse Tetracycline transactivator causing expression 
of Cre recombinase. Cre mediates recombination placing Sox15 downstream of the 
tetracycline response element (TRE). Additionally, Cre autoexcises its coding sequence 
allowing expression of Neomycin (for positive selection) from the PGK promoter. rtTA 
is expressed from the ROSA26 locus. Schematic is modified from an illustration designed 
by PAL. 
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After 1 day in culture, 30 g/mL Geneticin was added to the medium for positive 
selection. The ES cell medium with Geneticin was refreshed daily. After 8 days in culture 
with Geneticin, ES cell medium was aspirated, and 10 mL PBS was added to each dish. 
ES cell colonies were picked (48 HA and 48 Myc) with a P20 pipette and transferred to a 
96 well dish. Once 96 colonies were picked, 50 L  0.25% Trypsin was added to each 
well. The plate was incubated at 37C for 5 minutes. Following the incubation 100 L  
ES cell medium was added to each well, the cells were dissociated into a single cell 
suspension, and the cells were transferred to a new 96 well plate containing feeders. 
The cells were grown until confluence in the 96 well dish and 6 wells containing 
p2lox-Sox15-HA and 6 wells containing p2lox-Sox15-Myc were split and transferred 
into the top 6 wells of 2-24 well plates containing feeders (1 plate for p2lox-Sox15-Myc 
and 1 plate for p2lox-Sox15-HA). The cells were grown to confluence and then split 1:3. 
Again, the cells were grown to confluence. One of the 3 wells was harvested for 
genotyping and the other 2 were split to 60 mm dishes and cultured normally as above. 
Once an adequate number of plates were obtained, cells were frozen (see technique 
above) at a concentration of 3 x 10
6
 cells/mL in freezing medium (10% DMSO and 20% 
FBS in complete ES cell medium). To genotype ES cells, cells were centrifuged at 1,000 
rpm for 3 minutes. The medium was aspirated and cells were washed with 5 mL PBS. 
The cells were centrifuged at 1,000 rpm for 3 minutes. The wash was repeated twice. 
Once the cells were adequately washed, they were lysed overnight at 55C in lysis buffer 
with Proteinase K (100 mM NaCl, 50 mM Tris-HCl pH 7.5, 10 mM EDTA, 0.5% SDS, 
and 1 mg/mL Proteinase K in sterile water), and DNA was isolated using phenol: 
chloroform extraction. Insertion of the construct was verified using PCR with PGK-Neo 
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primers (see Table B.1). To verify overexpression of Sox15, ES cells were cultured in 
100 ng/mL Doxycycline and the cells were prepared for immunocytochemistry (see 
above) and real time PCR (see below). 
Hanging drop embryoid bodies (EBs): ES cells were grown on a 60 mm dish until they 
were approximately 80% confluent. The ES cells were fed ES cell medium and then 
incubated at 37C for at least 1 hour. The plate of cells was washed with 5 mL PBS, 1 
mL of 0.25% trypsin was added, and the plate was placed in the tissue culture incubator 
for 5 minutes. In order to deplete the feeder cells, dissociated cells were “preplated” as 
follows: cells were dissociated into a single cell suspension, transferred to a gelatinized 
100 mm plate, and incubated for 45 minutes at 37C. During this time, the MEFs adhered 
to the plate while ES cells remained in the medium. The medium was removed and the 
cells were diluted to a final concentration of 2 x 10
4
 cells/mL. A multichannel pipette was 
used to place 96- 20 L  drops of medium containing ES cells on the underside of the lid 
from a 150 mm dish. The total number of drops plated depended on the type of assay 
used. To collect EBs for RNA isolation at 3, 5, 7, 9, and 11 days, 3 dishes were used. The 
150 mm dishes were filled with PBS and the lid containing hanging drops was carefully 
placed on the dish. The remaining cells were harvested for RNA isolation at day 0 (see 
RNA isolation section).  
 After 3 days in culture, hanging drops from one dish were harvested by pipetting 
excess medium on the lid to dissociate the drops from the lid. The samples were 
centrifuged at 1000 rpm for 3 minutes, washed 3 times with PBS, and EBs collected for 
future RNA isolation. EBs from the remaining dishes were collected and transferred to 
non-adherent 96 well plates (Corning Costar 3474). One-hundred microliters of medium 
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was added to each well. After 2 more days in culture, the EBs from 48 wells were 
collected to harvest for RNA. The remaining EBs were transferred to adherent 96 well 
dishes (Corning Costar 3595). After an additional 2 days in culture, the medium from 48 
wells was aspirated, the wells were rinsed with PBS and 25 L of 0.25% Trypsin added 
and the plate was incubated at 37C for 5 minutes. Following the incubation, 100 L of 
medium was added and the cells harvested. The remaining wells were fed by aspirating 
the ES cell medium and replacing it with 100 L fresh medium. On days 9 and 11 in 
culture, EBs were harvested in a manner identical to that at day 7.  
TUNEL assay: ES cells were grown to approximately 80% confluence, the medium was 
aspirated, the cells were rinsed once with PBS, 1 mL of 0.25% Trypsin was added, and 
they were placed in the incubator for 5 minutes. Following the incubation 4 mL of ES 
cell medium was added, the cells were dissociated into a single cell suspension, and a 
1:10 dilution was plated on 4 well chamber slides (Lab-TekII 154917) with and without 
100 ng/mL Doxycycline. ES cell medium was replenished daily. After 2 days in culture, 
ES cell medium was aspirated, and the cells were rinsed with PBS and fixed with 4% 
PFA in PBS for 1 hour at room temperature. Following fixation, the cells were washed 
twice with PBS, permeabilized on ice for 2 minutes in 0.1% Triton-X 100 and 0.1% 
sodium citrate, and washed twice again in PBS. Fifty microliters of Enzyme solution was 
added to 450 L Label solution (proprietary solutions, Fluorescein in situ Cell Death 
Detection Kit, Roche 11684795001) and 150 L of the solution was added to each 
chamber. The slides were incubated in the dark for 1 hour at 37C. Following the 
incubation, cells were washed twice with PBS. To label nuclei, a 1:5000 dilution of DAPI 
in water was added to each well, incubated 3 minutes and then the samples were washed 
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once with PBS. The slides were mounted with Aqua Polymount (Polysciences, Inc). To 
calculate the percentage of cell death, the total number of TUNEL positive cells was 
divided by the total number of nuclei (DAPI) and multiplied by 100%. 
RNA isolation and quantification 
Sample preparation/harvest: Whole pancreata and hypothalamus were harvested by 
dissecting in cold, RNase free PBS (Gibco 14040), immediately placed in RNA Later 
(Ambion AM7020) and stored at -20C until RNA isolation. Islets were isolated from the 
Islet Procurement and Isolation Core (Brissova et al., 2004), washed 3 times in RNase 
free PBS and frozen at -80C until RNA isolation. Cell culture samples were fed with 
complete medium 1 hour prior to harvesting. To harvest, medium was aspirated, the 
dishes were washed with PBS, and 0.25% Trypsin was added to the dish. The cells were 
placed at 37C for 5 minutes. Following the incubation, complete medium was added to 
quench the Trypsin reaction. The cells were centrifuged for 3 minutes at 1000 rpm. The 
medium was aspirated and cell pellets washed three times with PBS. Cells were then 
frozen in liquid nitrogen and placed at -80C until isolation. 
Isolation of RNA: RNA was isolated using the RNeasy Mini Kit (Qiagen 74104) with 
minor modifications. The samples were resuspended in 350 L of buffer RLT. Larger 
tissues (pancreas and hypothalamus) were dissociated using a 19 gauge syringe. The 
samples were then added to a QIAShredder column (Qiagen 79654) and centrifuged at 
maximum speed for 2 minutes. The column was removed and 350 L RNase free 70% 
ethanol was added to the flow-through. This solution was added to an RNeasy Mini 
column and centrifuged for 20 seconds at maximum speed. The flow-through was 
157 
 
discarded, 700 L buffer RW1 was added to the column and the samples were 
centrifuged at maximum speed for 20 seconds. The flow-through was discarded, 500 L 
buffer RPE (with ethanol added) was added to the column, and the samples were 
centrifuged at maximum speed for 20 seconds. Following the wash, the flow-through was 
discarded, 500 L buffer RPE was added to the column and the samples were centrifuged 
for 2 minutes at maximum speed. Prewarmed, nuclease-free water (40 L) was added to 
the column and incubated for 1 minute at room temperature. The columns were then 
transferred to nuclease free Eppendorf tubes and centrifuged for 1 minute at maximum 
speed. The flow-through was added to the column (for a second elution) and the samples 
were centrifuged at maximum speed for 1 minute. 
 To remove genomic DNA, the TURBO DNA-free kit (Ambion Am1907) was 
used. Four microliters (0.1X volume) of TURBO DNase buffer and 1 L TURBO DNase 
were added to the samples and the samples were incubated at 37C for 25 minutes. 
Following incubation, 4.5 L (0.1X volume) TURBO DNase inactivation reagent was 
added to the samples. The samples were incubated at room temperature for 3 minutes and 
then centrifuged for 2 minutes at maximum speed. The supernatant was transferred to a 
clean, nuclease-free Eppendorf tube. The concentration of the samples was determined 
using a NanoDrop Spectrophotometer (ND-1000). 
Reverse transcription: The GoScript Reverse Transcription System (Promega A5001) 
was used to generate cDNA. Using the concentrations obtained from the NanoDrop 
Spectrophotometer (ND-1000), an equal amount of RNA (50ng- 1g) was used for each 
reaction (up to 4 L). RNA was added to nuclease free PCR tubes and nuclease-free 
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water was added to give a total volume of 4 L. One microliter of random primers was 
added to the tubes, and the samples were mixed well, briefly centrifuged, incubated for 5 
minutes at 70C, and then incubated 1 minute on ice. Once the incubation was complete, 
the following kit components were added to each sample: 4 L buffer, 4 L MgCl2, 1 L 
dNTPs, 1 L RNasin, 1 L reverse transcriptase, and 4 L nuclease free water. The 
samples were then mixed, briefly centrifuged, and placed in a thermocycler with the 
following program: 5 minutes at 25C, 1 hour at 42C, 15 minutes at 72C, and held at 
4C. For non-quantitative analyses, 1 L RNaseH was added to each sample and the 
samples incubated at 37C for 20 minutes.    
Quantitative PCR: The GoTaq qPCR Master Mix (Promega A6001) was used for qPCR 
analyses. For each 10 L reaction, the following components were used: 5 L master 
mix, 0.1 L CXR, 1.5 L 2.5 mM oligos (Table B.1), template DNA, and sterile water. 
All samples were run in duplicate or triplicate. The samples were run in a MicroAmp 
plate (Applied Biosystems 4346906) in an Applied Biosystems 7900HT Fast Real-Time 
PCR System. The “standard” real time protocol was used with a TM of 56C and an 
additional dissociation step.  
 The delta-delta Ct (Critical Threshold) method was used to determine relative 
expression in the case of qRT-PCR and fold enrichment in the case of qPCR following 
ChIP experiments. The Ct values were obtained from the real time machine and the 
calculation was performed as follows: 
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Primer Specific Ct – Loading Control Ct = Delta Ct 
 Delta Ct Mutant – Delta Ct Control = Delta Delta Ct 
 2
-Delta Delta Ct
 = Relative Expression or Fold Enrichment 
In the case of qRT-PCR, the Loading Control Ct was HPRT or 18S rRNA. In the case of 
qPCR following ChIP the Loading Control Ct was amplification of the Input sample and 
the Delta Ct Control was the Delta Ct of the IgG sample. 
Taq-Man low density arrays: RNA was isolated using the RNeasy Mini Kit (see above), 
genomic DNA was removed using TURBO DNA-free (Ambion), and cDNA was 
generated using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems 
4374966). Four hundred nanograms of total RNA was diluted in 10 L nuclease-free 
water. The following kit components were added to each sample: 2 L buffer, 0.8 L 
dNTPs, 2 L random primers, 1 L MultiScribe reverse transcriptase, 1 L RNase 
Inhibitor, and 3.2 L nuclease free water. The samples were transferred to a thermocycler 
and the following reaction was used: 10 minutes at 25C, 2 hours at 37C, 5 minutes at 
85C and hold at 4C. 
 Following reverse transcription, the samples were prepared for amplification in 
the Taq-Man low density array using the Taq-Man Universal PCR Master Mix (Applied 
Biosystems 4304437). cDNA (5 L of the above reaction, 100 ng) was added to 45 L 
nuclease free water and 50 L of the Taq-Man Universal PCR Master Mix. The entire 
sample was loaded into a Taq-Man Low Density array card (TaqMan Probes are listed in 
Table B.3), centrifuged at 3000 rpm for 2 minutes, and sealed. The CD that was provided  
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Table B.3: TaqMan probes used for Low Density Arrays 
  
Gene  Name ABI  ID  Number Gene  Name ABI ID  Number 
18S Hs99999901_s1 Irs2 Mm03038438_m1 
4921505C17Rik 
(Rictor) 
Mm01307318_m1 Isl1 Mm00517585_m1 
Akt1 Mm01331624_m1 Mafa Mm00845209_s1 
Akt2 Mm00545827_m1 Mafb Mm00627481_s1 
Arx Mm00545903_m1 Men1 Mm00484963_m1 
Bmi1 Mm03053308_g1 Neurog3 Mm00437606_s1 
Ccnd2 Mm00438072_m1 Nkx2-2 Mm00839794_m1 
Cdc25a Mm00483162_m1 Nkx6-1 Mm00454962_m1 
Cdk4 Mm00726334_s1 Onecut1 Mm00839394_m1 
Cdkn1a Mm00432448_m1 Pax4 Mm01159036_m1 
Cdkn1b Mm00438168_m1 Pax6 Mm00443081_m1 
Cdkn2a Mm01257348_m1 Pdx1 Mm00435565_m1 
Cdkn2c Mm00483243_m1 Prdm16 Mm00712556_m1 
Cdkn2d Mm00486943_m1 Prkca Mm00440858_m1 
Ezh2 Mm00468449_m1 Pten Mm00477210_m1 
Foxa2 Mm00839704_mH Ptf1a Mm00479622_m1 
Foxd3 Mm02384867_s1 Sgk1 Mm00441380_m1 
Foxm1 Mm00514924_m1 Skp2 Mm00449925_m1 
Foxo1 Mm00490672_m1 Slc2a2 Mm00446224_m1 
Gcg Mm00801712_m1 Snap25 Mm00456921_m1 
Gjd2 Mm00439121_m1 Sox9 Mm00448840_m1 
Hnf4a Mm00433964_m1 Stx1a Mm00444008_m1 
Ins1 Mm01950294_s1 Stxbp1 Mm00436837_m1 
Ins2 Mm00731595_gH Vamp2 Mm00494118_g1 
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with the low density arrays containing the real time PCR program (Applied Biosystems) 
was loaded into the computer and the reaction was completed. All samples were run in 
duplicate and data analyzed using the delta delta Ct method. 
 
Chromatin immunoprecipitation 
 ES cells were grown to 80% confluence. The ES cell medium was aspirated, 
replaced with fresh ES cell medium, and placed in the tissue culture incubator for at least 
1 hour. Following the incubation, the plates were rinsed with PBS, 1 mL 0.25% Trypsin 
was added and the plates were placed in the incubator for 5 minutes. Following the 
incubation, 4 mL of ES cell medium was added and the cells were dissociated into a 
single cell suspension by pipetting. The cells were then transferred to a 15 mL conical 
tube and 135 L 37% Formaldehyde was added (1% final concentration of 
Formaldehyde). The samples were incubated at 37C for 10 minutes. Next, 625 L  1M 
glycine (final concentration 0.125 M glycine) was added and samples incubated at room 
temperature for 5 minutes to stop the crosslinking reaction. The samples were centrifuged 
at 1000 rpm for 3 minutes and the supernatant aspirated. Five milliliters of PBS was 
added to wash the cell pellet, the samples were spun at 1000 rpm for 3 minutes, and the 
supernatant aspirated. This PBS wash was repeated twice. Following the third wash, the 
samples were either used immediately or flash frozen in liquid nitrogen and stored at        
-80C. 
The cross-linked cells were resuspended in 7 mL swelling buffer (25 mM Hepes 
pH 7.9, 1.5 mM MgCl2, 10mM KCl, 0.1% NP-40) and incubated on ice for 10 minutes. 
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The cells were centrifuged at 3,500 rpm for 10 minutes at 4C and the supernatant 
aspirated. The cell pellets were resuspended in 1 mL sonication buffer (50 mM Hepes pH 
7.9, 140 mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% Sodium deoxycholate, 0.1% 
SDS) and 10 L protease inhibitors (Sigma P8340) and transferred to a 1.5 mL 
Eppendorf tube. The samples were sonicated for 5 minutes and the sonication was 
repeated twice. Following sonication, the samples were centrifuged for 15 minutes at 
maximum speed. The supernatant was collected and centrifuged again as above. The 
remaining supernatant was precleared by adding 75 L of the appropriate agarose beads 
(See Table B.4) and 10 L IgG antibody (Santa Cruz Biotechnology sc-2027) and 
incubated for at least 4 hours at 4C. The samples were then centrifuged at 1200 rpm for 
15 minutes. The supernatant was collected and the amount of chromatin was quantified 
by making a 1:10 dilution of chromatin (2 L) in 0.1M NaOH (18 L). The amount of 
chromatin lysate was quantified using a NanoDrop Spectrophotometer (ND-1000) 
measuring the nucleic acid concentration at 260 nm. The appropriate amount of 
chromatin (see Table B.4) was transferred to a clean Eppendorf tube and the appropriate 
amount of primary antibody was added (see Table B.4). The samples were incubated 
overnight at 4C. The remaining chromatin was saved as an input. 
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Table B.4: Antibodies used for chromatin immunoprecipitation assays 
Antigen Source Concentration Agarose Beads 
Foxd3 Millipore 7 g  antibody/100 g  chromatin Protein A 
H3K14ac Millipore 5 L  antibody/25 g  chromatin Protein A 
H3K27me3 Millipore 5 g antibody/25 g  chromatin Protein A 
H3K4me2 Millipore 5 L  antibody/25 g  chromatin Protein A 
H4ac Millipore 5 L  antibody/25 g  chromatin Protein A 
IgG Santa Cruz 5 L  antibody/25 g  chromatin Protein A or G 
RNA Pol II pSer5 Abcam 2 L  antibody/25 g  chromatin Protein A 
Sox2 Santa Cruz 7 L  antibody/100 g  chromatin Protein G 
 
The next morning, 60 L of the appropriate agarose beads (see Table B.4) were 
added to the samples and then the samples were incubated on a nutator at 4C for 4 
hours.  Following the incubation, samples were centrifuged at 1200 rpm for 5 minutes. 
The supernatant was removed by aspiration into a vacuum flask with a gel-loading tip 
(Fisherbrand 02707181). At this time, it was crucial to remove all of the supernatant from 
the agarose beads but not remove the agarose beads. The beads were washed by adding 1 
mL of sonication buffer, incubating the samples at 4C on the nutator for 5 minutes, 
centrifuging as above for 5 minutes, and removing the supernatant. This step was 
repeated for the following wash buffers Buffer A (50 mM Hepes pH 7.9, 500 mM NaCl, 
1mM EDTA, 1% Triton X-100, 0.1% Sodium deoxycholate, 0.1% SDS), Buffer B (20 
mM Tris pH 8.0, 1 mM EDTA, 250 mM LiCl, 0.5% NP-40, 0.5% Sodium deoxycholate), 
and TE (10 mM Tris pH 8.0, 1mM EDTA) twice. Elution buffer (50 mM Tris pH 8.0, 1 
mM EDTA, 1% SDS) was made fresh and 250 L elution buffer was added to each 
sample. The samples were incubated 5 minutes at 65C, 15 minutes on a nutator at room 
temperature, and then the samples were centrifuged at 1200 rpm for 5 minutes. The 
eluates were collected in a fresh Eppendorf tube and the elution was repeated. TE was 
164 
 
added to the input samples to give at total volume of 500 L. Following elution, 20 L of 
4M NaCl and 1 L of 10 mg/mL RNaseA (Clonetech Labs, Inc 740505) were added to 
each sample and the samples were incubated overnight at 65C. 
 The following morning, 4 L of 0.5 M EDTA pH 8.0 and 5 L 20 mg/mL 
Proteinase K (Research Products Incorporated 39450-01-6) were added to the samples 
and the samples incubated at 45C for 2 hours. After the incubation, 500 L of Phenol: 
Chloroform: Isoamyl Alcohol (Sigma P3808) was added to each sample. Samples were 
rocked on a nutator for 20 minutes at room temperature, then centrifuged for 10 minutes 
at maximum speed and 450 L of the aqueous (top) layer was collected. To precipitate 
the immunoprecipitated DNA, 900 L 100% ethanol, 45 L 3.5mM sodium acetate, and 
1 L Pellet Paint (Novagen 69049) were added and the samples were incubated at -20C 
for at least 1 hour. The samples were then centrifuged for 10 minutes at maximum speed 
and the supernatant was carefully removed. The pellet was washed with 100 L 70% 
ethanol and allowed to dry. The DNA was resuspended in 35 L TE. Following 
resuspension, the samples were prepared for qPCR. This protocol was provided by Niall 
Dillon, Imperial College London. 
 
Animal cap assays 
 Bacteria from the following glycerol stocks were grown overnight at 37C at 200 
rpm in 10 mL LB with 10 L Ampicillin: pCS2-mFoxd3, pCS2-Eng-mFoxd3, and pCS2-
VP16-mFoxd3. DNA was purified using the Wizard Plus SV Minipreps DNA 
165 
 
Purification System (Promega). Fifteen micrograms of DNA from each sample was 
digested with NsiI (NEB) in a total volume of 100 L for 3 hours at 37C. Two 
microliters of the sample were run on a 1% agarose gel to ensure proper digestion. DNA 
was purified from the remaining sample using phenol-chloroform extraction. One 
microgram of DNA was transcribed as directed using the mMessage mMachine Sp6 kit 
(Ambion AM1340).  Following transcription, the RNA was isolated using the NucAway 
Spin Columns (Ambion AM10070). One microliter of the RNA was run on a 2% 
phosphate gel to ensure a minimal amount of degradation. The RNA samples were 
diluted to 25 ng/uL (VP16-mFoxd3) or 10 ng/uL (Eng-mFoxd3 and mFoxd3).  
 Xenopus laevis injections were performed by Justin Wells in Dr. Christopher 
Wright’s laboratory (Cha et al., 2006). A sperm solution was prepared by dissecting 
testes from male Xenopus and then mincing the testes into small pieces to extract the 
sperm. The sperm solution was added to freshly isolated Xenopus eggs and incubated at 
room temperature for 45 minutes. Following the incubation, the embryos were dejellied 
and injected at the 1 cell stage with 10 nL of each RNA (0.25 ng of VP16-mFoxd3 and 
0.10 ng of Eng-mFoxd3 and mFoxd3 (Steiner et al., 2006). The embryos were incubated 
overnight at 17C. The following morning, a small cube was removed from the animal 
pole of the embryo and the animal caps were transferred to a new dish and allowed to 
develop for 6 hours. After 6 hours, the animal caps were imaged and analyzed for 
convergent extension.   
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Statistical analyses 
 For all quantitative assays, the mean and standard error of the mean (SEM) were 
calculated. One common computer program used to calculate these values is Microsoft 
Excel. The following prompts within Excel were used: (Mean: =avg (enter data points)) 
and (SEM: =stdev (enter data points)/sqrt (count (enter data points))). Additionally, for 
most statistical analyses here, a two-tailed Student’s t-test was used to determine 
significance. Again, Microsoft Excel can be used to determine p-values using a Student’s 
t-test. The following Excel prompt was used to determine p-values:  (=ttest(enter data 
points group 1, enter data points group 2, 2,2)). This calculation assumed that variances 
among both groups were equal. In the case of glucose tolerance tests, a Student’s t-test is 
inappropriate because repeated measures are taken from the same animal. In this instance, 
a “repeated measures ANOVA with Bonferoni post-tests” was used to determine 
statistical significance with Graph Pad Prism software. 
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